

# **Review of the efficacy and safety of propoxyphene**

**Pharmacy Benefits Management  
Strategic Healthcare Group  
and the Medical Advisory Panel  
Dept. of Veterans Affairs**

Status / version	Final
Date	16 August 2001
Prepared by	Francine Goodman, PharmD, BCPS
Reviewed by PBM and MAP	24 May 2001
Reviewed by Mark Willenbring, MD	30 April 2001

## Summary

A debate over the VA formulary status of *d*-propoxyphene (DPP) prompted this evidence-based review of the efficacy and safety of DPP. Recent discussions about removing DPP from the VISN 12 formulary have resulted in some centers defending the use of the drug on anecdotal grounds. Questions have been posed about the status of DPP in the VA patient population and about its place in the treatment of VA patients.

The concerns about the use of DPP in VAMCs have focused on the following issues:

- There are more effective alternatives; DPP is equivalent to extra-strength APAP or ASA.
- There are safer alternatives; DPP causes seizures, cardiac arrhythmias, pulmonary edema, and is addictive.
- DPP is subject to misuse; patients may be given duplicate opioid prescriptions (e.g., a Step 3 opioid and DPP) or be prescribed DPP as an “opioid placebo.”

Concerns about DPP use in elderly patients (age 65 years and older) have also been raised.

In order to determine whether the use of DPP in the veteran population is justified, this report evaluates the evidence addressing the following clinical questions:

1. In VA patients with acute or chronic pain, does the analgesic effect of DPP alone or in combination with co-analgesics exceed the risks of its adverse effects; and
2. Is DPP cost-effective in comparison with NSAIDs and other opioids?

The objective of this report is to evaluate the relative efficacy, safety, and economics of DPP alone and in combination with co-analgesics based on a review of published clinical literature and unpublished data on VA patient populations.

**Methods.** Published reports of systematic reviews, meta-analyses, reviews, and randomized controlled trials on the efficacy and safety of propoxyphene were retrieved by a computerized literature search of the Medline database (1966 to 2000). An attempt was made to obtain information about the effectiveness and safety of DPP use in VAMCs from contact persons for VA pain clinics and via members of the VA Pain Pharmacy Working Group. Two informal polls of all VISNs were taken to obtain information on the nature of adverse events (AEs) associated with propoxyphene in the veteran population. In addition, information was obtained from a report prepared by the Office of the Medical Inspector on adverse drug events or experiences (ADEs) reported by VA centers as part of the Food and Drug Administration (FDA) MedWatch program in FY 1999.

**Current usage patterns.** Although DPP is not on the VA National Formulary, the drug is on 11 of the 22 VISN formularies (as of October 2000). A substantial number of patients each month (median: 24,217) are treated with DPP-containing products in the 11 VISNs with DPP on formulary—about 1.6 times the number of patients per month (median: 15,156) treated with DPP products in the VISNs with nonformulary DPP. The most frequently prescribed DPP formulations were DPP napsylate (100 mg) in combination with APAP (650 mg), and DPP HCl (65 mg). In the VISNs with nonformulary DPP, the usage of five analgesics exceeded that of the VISNs with formulary DPP during the 20-month period: (1) codeine alone (4% of total codeine dosage units dispensed) or in combination with APAP (94%); (2) hydrocodone combinations (96% of which were APAP combinations); (3) tramadol; (4) extra-strength APAP (500 or 650 mg); and (5) extra-strength ASA (500 to 975 mg).

**Pharmacologic and pharmacokinetic considerations.** The absorption of DPP from the gastrointestinal tract is rapid. The fast rate of absorption is believed to contribute to the rapid deterioration seen in DPP overdoses. DPP undergoes extensive dose-dependent first-pass metabolism and is quickly converted to an active metabolite, norpropoxyphene (NPP), which has very weak

analgesic properties. After single doses of DPP, both DPP and NPP may have long elimination half-lives, about 12 and 36 hours, respectively. In elderly (65- to 90-year old) hospitalized patients, the mean half-lives have been reported to be even longer, 35.7 and 53.3 hours, respectively. The recommended dosing interval, however, is every 4 hours. Because of the long biologic half-lives, accumulation of DPP and NPP may occur when the drug is dosed at the recommended dosing interval. Marked interindividual variation in plasma concentrations of DPP have been observed after standard doses due to differences in absorption and biotransformation.

Animal studies have demonstrated that NPP has less neurotoxic effects than DPP but greater cardiotoxic effects due to membrane-stabilizing properties. The local anesthetic properties of DPP and NPP are similar to those of tricyclic antidepressants and Type I antiarrhythmics. Recent *in vivo* data showed that, at high concentrations of drug similar to those observed in fatal DPP overdoses, DPP and NPP block HERG (human ether-a-go-go-related gene) potassium channels, which have been implicated in the mechanism of the long QT syndrome.

About 15% of acute overdose cases have had blood concentrations (0.1 to 1.0 µg/ml) that overlap with the range of concentrations achieved from single therapeutic doses or those from multiple therapeutic doses of DPP.

**Efficacy and effectiveness.** In patients with acute pain, *single-dose* DPP 65 mg + APAP 650 mg is inferior to diclofenac 50 to 100 mg, naproxen 440 mg, ASA 1200 mg, and ketorolac 10 mg in terms of analgesic efficacy. [QE: I] The analgesic efficacy of DPP 65 mg + APAP 650 mg is also inferior to codeine 60 mg + APAP 1000 mg and to oxycodone 10 mg + APAP 650 mg, but similar in efficacy to combinations of codeine 30 to 60 mg and smaller doses of APAP (300 to 650 mg).[QE: I] In turn, the same dose of combination DPP + APAP is more efficacious than codeine 60 mg or tramadol 50 mg.[QE: I]

The analgesic efficacy of *multiple* doses of DPP alone or in combination with APAP is inferior to [4 QE: I] or not statistically different from [9 I, 1 II-1] that of NSAIDs or high-dose APAP (3900 to 4000 mg/day) in the treatment of acute pain. Results varied depending on the type of NSAID used.<sup>1</sup>[QE: I]

Six RCTs comparing DPP(N) ± APAP to opioids found DPP(N) ± APAP to be similar to or less effective than the opioid preparation in the treatment of acute pain.

Well-designed RCTs evaluating the efficacy of DPP in the treatment of chronic pain or under steady-state conditions are lacking. Limited data suggest that the analgesic efficacy of DPP(N) ± APAP in patients with chronic pain is similar to that observed in the treatment of acute pain: DPP(N) ± APAP is no better than NSAIDs or other opioids.[3 QE: I], [QE: II-1] DPP may be better tolerated than low-dose morphine and may provide adequate pain relief in some opioid-naïve individuals. In addition, contrary to single-dose, acute pain trial results, further benefit was gained from the addition of DPP to an NSAID (diclofenac) in this patient population. These results need to be confirmed in additional chronic pain trials.

Systematically collected VA data on the effectiveness of DPP relative to other opioids is lacking.

**Safety.** Standard therapeutic doses of DPP are generally well tolerated and seem to be associated with few SAEs [3 QE: I], [QE: 23 I, 3 II-1]. Based on limited data, DPP may be less tolerated than NSAIDs or APAP [QE: I], and more tolerated than codeine + APAP [QE: I]. As a WHO Step 2 agent in the treatment of opioid-naïve cancer patients, DPP may be better tolerated than low-dose morphine in some patients [QE: II-1]. There was no convincing evidence suggesting that single or multiple doses of DPP ± APAP was associated with a higher frequency of NSAEs than codeine ± APAP. In veterans, the most commonly reported NSAEs associated with DPP ± APAP and other “weak” opioids were allergic or allergic-like in nature.

Elderly patients (aged 65 years or older) treated with DPP may be at higher risk of developing hip fractures [QE: II-2]. A similar increase in risk was also associated with codeine [QE: II-2]. The results of these two studies contradict those of a more recent systematic review and meta-analysis (which did not include the two former studies) that found no increased risk of falls in older patients (> 60 years old) in association with narcotic analgesics [QE: I]. The differences in results may be due to differences in inclusion criteria and targeted outcomes (hip fractures vs. falls).

Serious toxicity, including coma, respiratory depression, pulmonary edema, seizures, cardiac arrhythmias, and death, primarily occurred in patients with certain characteristics associated with intentional or unintentional overdose. The complications often occurred in patients who had a history of misuse (overuse) of DPP or other prescription drugs, who had psychiatric or emotional problems, and who co-ingested alcohol or other CNS depressants with moderate (6 to 20 capsules or tablets) or larger (suicidal) overdoses of DPP(N) ± APAP. The danger of the additive or potentiating effects on the toxicity of the combination of CNS depressants and DPP cannot be overemphasized. The development of SAEs is probably partly dependent on the individual's level of opioid tolerance. [QE: III]

In the case of poisonings, based on 1999 AAPCC TESS data, exposures to DPP alone and to any DPP-containing analgesics were associated with higher rates of major medical outcomes (5.9% and 4.0%, respectively) and of death (2.1% and 0.5%, respectively) relative to other, selected opioid and non-opioid analgesic drug or drug class exposures. [QE: III]

Drug abuse-related deaths, however, seem to be more likely with codeine than with DPP or other opioids based on the most recent (1998) DAWN data. [QE: III]

There is no convincing data that DPP is more addicting than other opioids. Based on drug abuse-related episodes reported by EDs participating in DAWN in 1999, the rate of DPP abuse mentions (2.6) per 100,000 population was relatively low compared with that of cocaine (80.7) and heroin/morphine (34.7), and was lower than that of hydrocodone (6.0). [QE: III]

The problem of DPP misuse that may be considered to be a form of addictive behavior among patients with acute or chronic pain has not been well reported, and recent U.S. studies comparing DPP with other opioids are lacking. Furthermore, data on the frequency of opioid addiction in veterans is limited. At one VA pain center, the rate of opioid addiction among patients with chronic nonmalignant pain was about 20% after at least one year of follow-up.

Long-term trials of DPP for chronic pain are lacking; therefore, the long-term safety of therapeutic doses of DPP in comparison to other agents is unclear.

Overall, there is little safety data on DPP ± APAP use in veterans. It is unclear whether serious adverse events are not occurring in VA patients or are under-reported or under-recognized.

**Cost-efficacy value.** No pharmacoeconomic studies were found by the literature search. If single-dose efficacy is assumed to predict relative multiple-dose efficacy of the analgesics in acute pain (5-day) treatment, then standard daily doses of diclofenac 50 to 100 mg, ibuprofen 200 to 400 mg, piroxicam 20 mg, ASA 600 to 1200 mg, or APAP 500 to 1500 mg would be less or similar in cost than either DPP 130 mg or DPP 65 mg + APAP 650 mg while providing similar or superior analgesic efficacy. Codeine 60 mg + APAP 1000 mg or oxycodone 10 mg + APAP 650 mg would be more expensive than DPP 130 mg with similar efficacy, and more costly than and superior to DPP 65 mg + APAP 650 mg or DPP 65 mg. Codeine 60 mg has the poorest value (high cost with lowest efficacy).

**Conclusion.** In the majority of VA patients with mild to moderate acute pain and who do not have certain characteristics associated with intentional or unintentional overdose, single-dose or short-term therapy with DPP ± APAP probably provides adequate analgesia with an acceptable safety profile.

The efficacy and safety of long-term therapy with DPP ± APAP for treatment of chronic pain has not been adequately studied.

In patients with certain characteristics associated with intentional or unintentional overdose, the potential for DPP toxicity probably outweighs the drug's potential analgesic benefit. Important safety issues that remain unclear are what is the frequency and risk of serious DPP toxicity among veterans with risk factors, and how does that risk compare with the risk associated with other opioids. Until these questions are answered, it seems prudent to restrict the use of DPP ± APAP to those veterans who do not have the particular characteristics associated with intentional or unintentional overdose and in whom NSAIDs, extra-strength or high-dose APAP, and other opioids are inadequate, intolerable, or contraindicated.

Based on single doses with similar analgesic efficacy in the treatment of postoperative pain, a number of NSAIDs offer better cost-efficacy value than DPP ± APAP. Codeine or oxycodone in combination with APAP are more expensive alternatives to DPP 130 mg alone and DPP 65 mg + APAP 650 mg.

## Table of Contents

List of tables.....	vii
List of figures.....	viii
List of appendices.....	ix
List of appendix tables.....	x
Abbreviations.....	xi
1 Background.....	1
2 Introduction.....	1
3 Clinical questions and objectives.....	2
4 Methods.....	2
5 Current usage pattern of DPP and alternative analgesics.....	3
6 Duplicate prescriptions for DPP and more potent opioids.....	6
7 Pharmacologic and Pharmacokinetic Considerations.....	6
8 Efficacy.....	9
8.1 Results of Published Randomized Trials.....	9
8.1.1 Single-dose trials.....	9
8.1.2 Multiple-dose trials.....	13
8.1.3 Patient Characteristics: Applicability of published results to VA patients.....	16
8.2 Unpublished findings from VA data (Effectiveness of DPP).....	16
8.3 Summary of Efficacy and Effectiveness.....	17
9 Safety.....	18
9.1 Published trials.....	18
9.1.1 Serious adverse events.....	18
9.1.2 Tolerability.....	29
9.2 Unpublished safety findings from VA data.....	30
9.2.1 Adverse event data from VISN Polls.....	30
9.2.2 MedWatch adverse drug experience data.....	32
9.2.3 Prevalence of opioid addiction among veterans.....	32
9.3 Summary of Safety.....	34
9.4 Drug Interactions.....	35
10 Cost-efficacy value.....	35
11 Discussion.....	37
12 Therapeutic role of DPP.....	39
13 Conclusion.....	40
References.....	41
Appendices.....	50

## List of tables

Table 1	DPP usage per 1000 patients (Jan. 1999 to Aug. 2000).....	3
Table 2	Total quantity (%) of DPP and other selected analgesics dispensed during 20-month period by VISN formulary status per 1000 patients (Jan. 1999 to Aug. 2000).....	5
Table 3	Pharmacokinetic and pharmacologic properties of selected oral opioids.....	7
Table 4	Number-needed-to-treat to achieve 50% pain relief over 4 to 6 hours with single-dose DPP alone and with APAP for post-operative pain in comparison with placebo.....	9
Table 5	Number-needed-to-treat for at least 50% pain relief over 8 hours with single doses of analgesics in dental and post-surgical pain in comparison with placebo control.....	10
Table 6	Efficacy of single-doses of selected oral analgesics in patients with moderate to severe acute postoperative pain in increasing order of NNT.....	11
Table 7	Relative analgesic efficacy of DPP preparations based on 95% CIs of NNTs for at least 50% pain relief.....	12
Table 8	Frequency of opioid prescriptions and pain scores associated with opioids at admission.....	17
Table 9	Major medical outcomes and deaths associated with selected analgesic exposures by drug class in decreasing order of major outcome frequency (%): 1999 AAPCC TESS data.....	25
Table 10	Number (%) of drug abuse deaths for narcotic and non-narcotic analgesic drugs mentioned most frequently by medical examiners: 1998.....	27
Table 11	Number of adverse drug reactions reported by poison centers by analgesic class in decreasing order of frequency (%): 1999 AAPCC TESS data.....	29
Table 12	Summary of adverse events reported by VISNs (January 1999 to September 2000)....	31
Table 13	Causality and intensity of AEs reported by VISNs.....	32
Table 14	Number (%) of patients prescribed opioid analgesics in decreasing order of pre-treatment frequency (N = 117).....	33
Table 15	Lowest FSS costs of selected analgesics.....	36

**List of figures**

Figure 1	Total quantity of DPP formulations dispensed from Jan. 1999 to Aug. 2000.....	4
Figure 2	Monthly proportion of selected opioids dispensed as percentages of total quantity of selected opioids dispensed (January 1999 to August 2000).....	6



**List of appendices**

Appendix 1	Methods.....	51
Appendix 2	Validity criteria and evidence rating scale.....	53
Appendix 3	Summary of trials.....	54
Appendix 4	Summary of a national assessment of propoxyphene in postmortem medicolegal investigation (1972–1975).....	80
Appendix 5	Prevalence of mental disorders including alcohol abuse among veterans.....	84

**List of appendix tables**

Appendix Table 1	Evidence Rating Scale.....	53
Appendix Table 2	RCTs comparing multiple doses of DPP ± APAP with NSAIDs or APAP in acute pain.....	58
Appendix Table 3	RCTs comparing multiple doses of DPP ± APAP with opioids in treatment of acute pain.....	68
Appendix Table 4	RCTs comparing multiple doses of DPP with NSAIDs or opioids in treatment of chronic pain.....	74
Appendix Table 5	Summary of safety RCTs.....	78
Appendix Table 6	Medical outcomes associated with exposure to selected analgesics by drug or drug combination class: 1999 AAPCC TESS data.....	82
Appendix Table 7	Prevalence of mental conditions among veterans.....	84

## Abbreviations

AAPCC	American Association of Poison Control Centers
ADDIS	Alcohol Drug Diagnos InStrument (Swe.)
ADE	Adverse drug event or experience (term used in MedWatch program)
ADR	Adverse [drug] reaction (term used in AAPCC TESS data)
AE	Adverse event
APAP	Acetaminophen
ASA	Aspirin
CI	Confidence interval
CNS	Central nervous system
DAWN	Drug Abuse Warning Network
DPP	<i>d</i> -propoxyphene
DPP + APAP	<i>d</i> -propoxyphene in combination with acetaminophen
DPP ± APAP	<i>d</i> -propoxyphene alone or in combination with acetaminophen
DPP HCl	<i>d</i> -propoxyphene hydrochloride
DPPN	<i>d</i> -propoxyphene napsylate
DSM	Diagnostic and Statistical Manual of Mental Disorders
ED	Emergency department
FDA	Food and Drug Administration
%maxTOTPAR	percentage of the maximum possible for the area under the curve of pain relief (categorical scale) against time; also percentage of maximal total pain relief
ME	Medical examiner
NMDA	N-methyl-D-aspartate
NNH	Number-needed-to-harm
NNT	Number-needed-to-treat
NPDB	National Pain Data Bank
NPP	Norpropoxyphene
NSAE	Nonserious adverse event
NSAID	Nonsteroidal anti-inflammatory drug
PBM-MAP	Pharmacy Benefits Management-Medical Advisory Panel
RCT	Randomized controlled trial
RR	Relative risk
SAE	Serious adverse event
SD	Standard deviation

SUDDS	Substance Use Disorder Diagnostic Schedule
TESS	Toxic Exposure Surveillance System
VAMC	Veterans Affairs Medical Center
VAS	Visual analogue scale
VISN	Veterans Integrated Service Network
WHO	World Health Organization

## 1 Background

A debate over the VA formulary status of *d*-propoxyphene (DPP) has recently arisen. Although DPP is not on the VA National Formulary, the drug is on 11 of the 22 VISN formularies (as of October 2000). Recent discussions about removing it from the VISN 12 formulary have resulted in some centers defending the use of the drug on anecdotal grounds. Questions have been posed about the status of DPP in the VA patient population and about its place in the treatment of VA patients.

## 2 Introduction

The therapeutic benefit-to-risk ratio of DPP has been a subject of debate since the 1970s. Based on a critical review of literature published on DPP up to 1969, Miller, *et al.* documented that the analgesic effect of DPP was not superior to that of codeine or aspirin, yet DPP was liable to abuse and physical dependence.<sup>2</sup>

Deaths due to propoxyphene overdose and poisoning have been reported in the toxicology or drug abuse literature since 1964.<sup>3</sup> In the US, there was a trend of increasing DPP-related deaths from 1972 to July 1975, primarily among a particular medical population who misused prescription drugs and alcohol, and who had psychiatric histories, but interestingly, not among illegal drug abusers.<sup>4</sup> In 1983 DPP intoxication and overdose were described as endemic in developed countries and it was estimated that 30% of drug abusers would develop a complication.<sup>5</sup>

A 1978–80 informational campaign by the FDA and the drug's manufacturers had little effect on DPP prescribing and overdose-related deaths.<sup>6</sup> The nationwide use of DPP *stabilized* after a pre-campaign decline of about 8% per year. Refill rates remained constant, as did the risk of death related to overdoses per DPP prescription from 1979 to 1983. Other efforts to restrict prescribing of DPP compounds have resulted in only partial reduction in their use, suggesting that physicians find DPP useful.<sup>7</sup> Furthermore, the restrictions led to unpredictable consequences where the alternate analgesics (e.g., compounds containing high-dose codeine) were not necessarily more desirable.

Despite controversies about its efficacy and safety, DPP seems to remain a popular analgesic. Based on interviews with a randomly selected representative cross-section of 1000 adults suffering from chronic pain (6 months' duration or longer) and a representative sample of 500 primary care physicians or specialists involved in chronic pain management, DPP-containing products were ranked the third (11% of patients) most likely prescription pain medications to be taken by chronic pain sufferers in the 1999 National Pain Survey.<sup>8</sup> A survey of a national cross-section of 500 randomly selected Americans over age 60 years who regularly took analgesics for chronic pain (6 months' duration or longer) found that DPP was used by 10% of the survey respondents—the second most common type of prescription analgesic taken among the sample of older chronic pain sufferers.<sup>9</sup> Another survey of physician state medical board members revealed that 17% of the 304 evaluable respondents ranked DPP 1, 2, or 3 as an opioid analgesic that they would recommend for use in the management of prolonged moderate to severe cancer pain (and 33% would not recommend its use).<sup>10</sup> There is also evidence that DPP is commonly prescribed outside the U.S. on a long-term basis.<sup>11, 12</sup>

DPP is considered by pain clinicians<sup>13, 14</sup> to be a Step 2, “weak” opioid analgesic indicated for treatment of mild to moderate cancer pain not relieved by Step 1 (nonopioid) agents in the World Health Organization (WHO) analgesic ladder for management of cancer pain.<sup>15</sup> Pain or palliative medicine specialists from the U.S. and U.K. have supported the use of DPP for chronic pain in the published literature. One author suggested there was improved analgesic efficacy with DPP relative to “simple” analgesics for chronic pain.<sup>16</sup> Another author claimed that DPP + APAP “is recommended and has been extensively used at step 2 of the WHO analgesic ladder for managing chronic pain in cancer.”<sup>13</sup> It seems that DPP is considered by physicians to be a useful bridge between NSAIDs and strong opioid analgesics.

A survey of 141 physicians who were identified from state Medicaid prescribing records as moderate to high prescribers of DPP identified the reasons for such “misprescribing.” The most common

reasons were patient demand (46%, 51 of 110 statements), the prescriber's own clinical experience indicated that DPP was actually the drug of choice in the conditions presented (26%), and intentional use of placebo effect (24%).<sup>17</sup>

With this history of DPP as a background, the concerns about the use of DPP in VAMCs have focused on the following issues:

- There are more effective alternatives; DPP is equivalent to extra-strength APAP or ASA.
- There are safer alternatives; DPP causes seizures, cardiac arrhythmias, pulmonary edema, and is addictive.
- DPP is subject to misuse; patients may be given duplicate opioid prescriptions (e.g., a Step 3 opioid and DPP) or be prescribed DPP as a “opioid placebo.”

Concerns about DPP use in elderly patients (age 65 years and older) have also been raised. In the context of order text messages (alerts) for DPP, the Pharmacy Benefits Management-Medical Advisory Panel (PBM-MAP) addressed this as a separate issue. After an extensive review of the literature, it was felt that an order text message for prescribing DPP in elderly veterans was not warranted. Prescribing DPP in elderly veterans in the context of formulary considerations or criteria for drug use has not been specifically addressed.

### **3 Clinical questions and objectives**

In order to determine whether the use of DPP in the veteran population is justified, this report evaluates the evidence addressing the following clinical questions:

1. In VA patients with acute or chronic pain, does the analgesic effect of DPP alone or in combination with co-analgesics exceed the risks of its adverse effects; and
2. Is DPP cost-effective in comparison with NSAIDs and other opioids?

The objective of this report is to evaluate the relative efficacy, safety, and economics of DPP alone and in combination with co-analgesics based on a review of published clinical literature and unpublished data on VA patient populations.

### **4 Methods**

Published reports of systematic reviews, meta-analyses, reviews, and randomized controlled trials on the efficacy and safety of propoxyphene were retrieved by a computerized literature search of the Medline (1966 to 2000) database. Details of the methods used for the literature search and inclusion and exclusion criteria are described in Appendix 1. The validity criteria and evidence rating scale used to evaluate trial reports are presented in Appendix 2.

An attempt was made to obtain information about the effectiveness and safety of DPP use in VAMCs from contact persons for VA pain clinics and via members of the VA Pain Pharmacy Working Group.

Two informal polls of all VISNs were taken to obtain information on the nature of adverse events (AEs) associated with propoxyphene in the veteran population. The first poll focused on DPP AEs reported between January 1999 and August 2000. The second poll covered AEs involving DPP, hydrocodone, codeine, and tramadol products for the period January 1999 to September 2000. Some VISNs voluntarily reported AE data on oxycodone as well. To increase response yield, unique AE data on DPP were combined for the two periods. The combined data (13 AEs reported by 14 VISNs in the first poll plus 13 AEs reported by 7 VISNs in the second poll) yielded a total of 26 unique AEs reported by 17 VISNs.

In addition, information was obtained from a report prepared by the Office of the Medical Inspector on adverse drug events or experiences (ADEs) reported by VA centers as part of the Food and Drug Administration (FDA) MedWatch program in FY 1999. It should be noted that the purposes of the FDA MedWatch program are to perform post-marketing safety surveillance and to identify signals of potential drug problems. The frequency of ADEs cannot be determined from MedWatch data because of the voluntary nature of the reporting system and the lack of a valid denominator. Serious adverse drug experiences (ones which result in death, hospitalization, disability, congenital anomaly/teratogenicity, are life threatening or require intervention), ADEs for new drugs, and unlabeled reactions for older drugs are required to be reported to the FDA according to VA policy.

For this report, 65 mg of DPP hydrochloride (HCl) was considered to be equivalent to 100 mg of DPP napsylate (DPPN).<sup>153</sup> Unless otherwise specified, the term DPP 65 mg in this report refers to DPP HCl 65 mg or its equivalent as DPPN 100 mg.

## 5 Current usage pattern of DPP and alternative analgesics

As mentioned previously, the informal poll of the 22 VISNs in September and October 2000 showed that 11 VISNs (50%) had DPP on the VISN formulary and 11 (50%) did not. Table 1 shows the number of unique patients who were prescribed DPP-containing products, the quantity prescribed, and the number of prescriptions for DPP-containing products processed per month per 1000 patients among the 22 VISNs during the period from January 1999 to August 2000.

**Table 1 DPP usage per 1000 patients (Jan. 1999 to Aug. 2000)**

	Statistic	VISN status of DPP		All VISNs
		Formulary	Nonformulary	
<b>Patients enrolled<sup>†</sup></b>	—	1,487,598	1,709,955	3,197,553
<b>Monthly usage</b>				
No. of unique patients	Median	16	9	12
	Min	14	8	11
	Max	18	10	13
Quantity dispensed	Median	1462	814	1120
	Min	1220	704	944
	Max	1645	910	1252
No. of prescriptions	Median	18	10	14
	Min	16	9	12
	Max	20	11	15
<b>Cumulative usage (20 months)</b>				
No. of unique patients	Total	(325) <sup>†</sup>	(177) <sup>†</sup>	(246) <sup>†</sup>
Quantity dispensed	Total	29196	16293	22296
No. of prescriptions	Total	369	201	279

<sup>†</sup> Patients may have been counted more than once from month to month since unique patients were determined on a monthly basis; the true cumulative number of unique patients over the entire 20-month period was not determined.


<sup>‡</sup> VISN patient enrollment from the 1999 Large Health Survey in Veterans.<sup>71</sup>

A fair number of patients each month (median: 24,217 or 16 per 1000 VISN patients enrolled) are treated with DPP-containing products in the 11 VISNs with DPP on formulary—about 1.6 times the number of patients per month (median: 15,156; 9 per 1000 patients) treated with DPP products in the VISNs with nonformulary DPP. The total number of prescriptions filled each month (median: 27,445; 18 per 1000 patients enrolled) over the 20-month period in VISNs with formulary DPP is about 37% greater than the number (median: 17,191; 10 per 1000 patients) filled in VISNs with nonformulary DPP. These prescriptions corresponded to over 2.2 million and 1.4 million (medians) dosage units

dispensed each month (1462 and 814 per 1000 patients) for VISNs with formulary and nonformulary DPP, respectively (a difference of about 0.8 million dosage units per month or 1120 per 1000 patients).

Each month an estimated (median) 1.1 prescriptions for DPP formulations were processed per unique patient with about 80 dosage units dispensed for each prescription. The most frequently prescribed DPP formulations were DPP napsylate (100 mg) in combination with APAP (650 mg), and DPP HCl (65 mg) (Figure 1).

**Figure 1 Total quantity of DPP formulations dispensed from Jan. 1999 to Aug. 2000**



DPP = *D*-propoxyphene; APAP = Acetaminophen.

DPP dosage strengths of 32 and 65 mg refer to DPP HCl; 50 and 100 mg refer to DPP napsylate.

The usage of DPP HCl preparation in the VISNs with nonformulary DPP exceeded that in the VISNs with formulary DPP mostly because of high usage in VISN 8. Notably, VISN 8 also had the highest number of dosage units prescribed in a single month (675,504, May 2000) despite having VISN-nonformulary DPP.

The prescription usages of six other analgesic products—hydrocodone combinations, oxycodone combinations, codeine alone or in combination with APAP (codeine ± APAP), tramadol, APAP extra-strength (500 and 650 mg), and ASA extra-strength (> 500 mg)—were evaluated to determine which agent(s) were used to a greater extent among VISNs with nonformulary DPP. These analgesics were selected based on feedback from VISN formulary leaders, relative qualitative potency of the opioids,<sup>18</sup> expected clinical use, and published reports of similar analgesic efficacy between DPP and either codeine, APAP, or ASA products.<sup>2, 19, 20</sup> Combinations of hydrocodone or oxycodone and non-opioid analgesics, and not the single agents alone, were assessed because the maximal dosage limitations of the non-opioid component made these agents “weaker” analgesics that were more likely to be used as alternatives to DPP relative to the opioid alone.

In the VISNs with nonformulary DPP, the usage of five analgesics exceeded that of the VISNs with formulary DPP during the 20-month period: (1) codeine alone (4% of total codeine dosage units dispensed) or in combination with APAP (94%); (2) hydrocodone combinations (96% of which were



APAP combinations); (3) tramadol; (4) extra-strength APAP (500 or 650 mg); and (5) extra-strength ASA (500 to 975 mg) (Table 2).

**Table 2 Total quantity (%) of DPP and other selected analgesics dispensed during 20-month period by VISN formulary status per 1000 patients (Jan. 1999 to Aug. 2000)**

	VISN status of <i>d</i> -propoxyphene				All VISNs	%	Difference <sup>†</sup>
	Formulary	%	Nonformulary	%			
<b>Patients enrolled<sup>‡</sup></b>	1,487,598		1,709,955		3,197,553		-222,357
<b>Opioids</b>							
<i>D</i> -propoxyphene	29,196	34.2%	16,293	20.9%	22,296	27.4%	12,904
Codeine	17,182	20.1%	20,304	26.0%	18,851	23.2%	-3,122
Hydrocodone	6,446	7.6%	14,485	18.6%	10,745	13.2%	-8,039
Oxycodone	23,663	27.7%	19,306	24.8%	21,333	26.2%	4,357
Tramadol	8,789	10.3%	7,565	9.7%	8,134	10.0%	1,223
Subtotal	85,276	100.0%	77,953	100.0%	81,360	100.0%	7,323
<b>Non-opioids</b>							
APAP	67,694	99.8%	122,768	99.7%	65,653	99.7%	-55,074
ASA	104	0.2%	383	0.3%	205	0.3%	-280
Subtotal	67,798	100.0%	123,152	100.0%	65,858	100.0%	-55,354
<b>Total</b>	153,073	100.0%	275,292	100.0%	147,218	100.0%	-122,218

Quantity dispensed in dosage units per 1000 patients.

*D*-propoxyphene = All oral formulations of *d*-propoxyphene HCl or napsylate alone or in combination with acetaminophen, aspirin, or aspirin and caffeine. Most common preparations dispensed were *d*-propoxyphene napsylate 100 mg with acetaminophen 650 mg (46,422,301; 65% of total *d*-propoxyphene dosage units), *d*-propoxyphene HCl alone 65 mg (21,680,547; 30%), and *d*-propoxyphene napsylate alone 100 mg (3,034,985; 4%).

Codeine = Oral formulations of codeine alone or in combination with acetaminophen; aspirin; acetaminophen and butalbital; aspirin and caffeine; acetaminophen, butalbital, and caffeine; or aspirin, butalbital, and caffeine. Most commonly dispensed formulations were codeine with acetaminophen 30 / 300 mg (53,123,391; 88% of total codeine dosage units), codeine with acetaminophen 60 / 300 mg (3,591,372; 6%), and codeine 30 mg (2,357,176; 4%).

Hydrocodone = Oral formulations of hydrocodone in combination with acetaminophen, ibuprofen, or phenyltoloxamine. Most common preparations dispensed were hydrocodone with acetaminophen 5 / 500 mg (30,204,789; 88% of total dosage units), 7.5 / 500 mg (2,325,151; 7%), and 10 / 650 mg (418,643; 1%).

Oxycodone = Oral formulations of oxycodone in combination with acetaminophen or aspirin. More oxycodone / acetaminophen 5 / 325 mg was dispensed (67,801,389; 98% of total oxycodone dosage units) than 5 / 500 mg (928,206; 1%).

Tramadol = Tramadol 50 mg.

APAP = Oral acetaminophen extra-strength (500 mg or 650 mg).

ASA = Oral aspirin extra-strength (500 to 975 mg).


<sup>†</sup> Difference = Formulary – Nonformulary dosage units dispensed.

<sup>‡</sup> VISN patient enrollment from the 1999 Large Health Survey in Veterans.<sup>71</sup>

The overall amount of tramadol dispensed for the 20-month period was greater in VISNs with formulary DPP than in VISNs with nonformulary DPP. The pattern of tramadol use over time showed that more tramadol was used in VISNs with formulary DPP during 1999, but from January 2000 and on, a greater quantity of tramadol was dispensed among VISNs with nonformulary DPP than among VISNs with formulary DPP. This change in tramadol use was not temporally related to any new price incentives.

Reductions were seen in the proportions (%) of DPP and codeine products dispensed of the total quantity of the five opioid products dispensed (DPP, codeine, hydrocodone, oxycodone, and tramadol). In contrast, the proportion for hydrocodone products increased over the 20-month period (Figure 2).

**Figure 2 Monthly proportion of selected opioids dispensed as percentages of total quantity of selected opioids dispensed (January 1999 to August 2000)**



DPP = *D*-propoxyphene or *d*-propoxyphene-containing products; COD = Codeine or codeine-containing products; HCOD = Hydrocodone-containing products; OCOD = Oxycodone-containing products; TRAM = Tramadol; APAP = Acetaminophen (extra-strength); ASA = Aspirin (extra-strength). For additional details, see footnote to Table 2.

The reason for the increase in hydrocodone use is unclear; however, this usage pattern suggests a growing preference for hydrocodone products over either DPP or codeine products.

## 6 Duplicate prescriptions for DPP and more potent opioids

Between January 1999 and December 2000, a total of 12,390 unique patients were prescribed DPP at the same time as a more potent opioid (e.g., morphine, hydromorphone) (median, range per VISN: 540, 8 to 1970 patients). The 12,390 patients represent 6% of the 206,402 unique patients prescribed any DPP product during the same period. The reasons for prescribing a WHO step 2 agent with a step 3 agent may deserve further evaluation.

## 7 Pharmacologic and Pharmacokinetic Considerations

DPP, the *αd*-isomer of propoxyphene, is a synthetic, diphenylheptane-derivative opiate agonist with moderate analgesic effects. DPP shares structural similarities with methadone, the isomers of which have been suggested to have at least weak N-methyl-D-aspartate (NMDA) antagonist activity in vivo.<sup>21, 22</sup> A recent study suggests that in addition to activity at opiate receptors, DPP also exhibits antagonist activity at the NMDA receptor.<sup>23</sup> DPP may have a theoretical beneficial effect in the treatment of hyperalgesia of chronic pain associated with nerve or soft tissue injury,<sup>24-27</sup> and in the development of opioid tolerance,<sup>24, 28</sup> both of which have been shown in animal experiments to be related to stimulation of the NMDA receptor.

A summary of the pharmacokinetic and pharmacologic properties of DPP is shown in Table 3. Other, selected opioids are also shown for reference.

**Table 3 Pharmacokinetic and pharmacologic properties of selected oral opioids**

	<b>D-propoxyphene</b>	<b>Codeine</b>	<b>Hydrocodone</b>	<b>Oxycodone<sup>†</sup></b>	<b>Tramadol</b>
Onset (min)	30 to 60	15 to 30	< 30	10 to 30	60
T <sub>max</sub> (h)	2 to 2.5	0.5 to 1	1.3	1	2
Duration (h)	4 to 6	4 to 6	4 to 6	3 to 6	3 to 6
t <sub>1/2</sub> of parent drug [active metabolite] (h)	6 to 12 [30 to 36]	3 [1.5 to 2]	3.3 to 4.5 [1.5 to 2]	3.2 [1.5 to 2]	5.5   [6.7]
Active metabolite	Norpropoxyphene	Morphine	Hydromorphone	Oxymorphone	M1
Elimination	Hepatic / Renal	Hepatic / Renal	Hepatic / Renal	Hepatic / Renal	Hepatic / Renal
Dosage reduction in elderly	Yes	Yes	Yes	Yes	Yes (max. dose 300 mg for age > 75 y)
Dosage reduction in renal failure	Yes	Yes	Yes	Yes	Yes (CrCl < 30 ml/min)
Dosage reduction in hepatic failure	Yes	Yes	Yes	Yes	Yes
Equivalent oral dose (mg, q 4 h) <sup>‡</sup>	65 <sup>§</sup>	22.5	3.75	2.5 <sup>  </sup>	ND <sup>††</sup>
Recommended dose	65 mg q 4 h <sup>§</sup>	30 mg q 4 h	5 to 10 mg q 4 to 6 h	5 mg q 6 h <sup>  </sup>	50 to 100 mg q 4 to 6 h
Maximum dose (mg/d)	390	[Limited by APAP content] <sup>††</sup>	[Limited by APAP content] <sup>††</sup>	[Limited by APAP content] <sup>††</sup>	400

Sources: <sup>29, 18, 30, 31</sup>

<sup>†</sup> Oxycodone immediate release

<sup>‡</sup> Based on Opioid Converter<sup>29</sup> Equivalent oral doses for conversion are shown WITH 30% reduction for incomplete cross-tolerance. Equivalent oral doses refer to 1 tablet of *d*-propoxyphene HCl 65 mg ± acetaminophen 650 mg; 1.5 tablets of codeine 15 mg ± acetaminophen 300 mg; 1.5 tablets of hydrocodone 2.5 mg + acetaminophen 500 mg; and 0.5 tablet of oxycodone 5 mg + acetaminophen 500 mg.

<sup>§</sup> Doses of *d*-propoxyphene expressed as HCl salt; 65 mg of HCl is equivalent to 100 mg of napsylate salt.

<sup>||</sup> Dose of oxycodone expressed as HCl salt; 5 mg HCl is equivalent to 4.88 mg combination HCl / terephthalate salts

<sup>††</sup> ND = No data<sup>29</sup>

<sup>††</sup> Maximum dose of APAP (acetaminophen): 4 g/d

The absorption of DPP from the gastrointestinal tract is rapid. The fast rate of absorption is believed to contribute to the rapid deterioration seen in DPP overdoses where collapse and death of the subject often occurs within 1 hour, and in some cases in 15 minutes (see Section 9.1.1.5).

DPP undergoes extensive dose-dependent first-pass metabolism and is quickly converted to an active metabolite, norpropoxyphene (NPP), which has very weak analgesic properties. Blood concentrations of NPP resemble those of DPP with a dramatic increase of the metabolite concentrations to the maximum at 2 to 4 hours.

After single doses of DPP, both DPP and NPP may have long elimination half-lives, about 12 and 36 hours, respectively (N = 4).<sup>32</sup> There seems to be considerable interpatient variability, however, as Inturrisi, *et al.* observed much shorter half-lives of about 3 and 10 hours, respectively, after single doses (N = 6).<sup>33</sup> The pharmacokinetic study by Inturrisi, *et al.* suggested that DPP and NPP inhibit the hepatic metabolism of DPP. After single doses, 50% to 80% of DPP in the hepatoportal system was converted to NPP but only 5% was biotransformed after multiple doses. In elderly (65- to 90-year old) hospitalized patients, the mean half-lives have been reported to be even longer, 35.7 and 53.3 hours, respectively.<sup>34</sup>

Because of the self-inhibition of metabolism, plasma concentrations of DPP and NPP after multiple doses were 3 to 5 times higher and 7 times higher, respectively, than after single doses.<sup>33</sup> Likewise, half-lives of DPP and NPP increased 4- to 6-fold to 11.8 and 39.2 hours, respectively, with repeated dosing. In the same study, plasma concentrations of NPP increased to 13 times the plasma concentration of DPP in tolerant patients taking large doses (900 to 1200 mg) of DPP on a long-term basis (4 to 16 weeks) for heroin withdrawal (DPP maintenance).<sup>33</sup>

The recommended dosing interval for DPP, however, is every 4 hours. Because of the long biologic half-lives, accumulation of DPP and NPP may occur when the drug is dosed at the recommended dosing interval. The majority of RCTs that involved multiple doses of DPP for the treatment of acute or chronic pain and that were reviewed for this report, however, used longer dosing intervals of every 6 to 8 hours or 3 to 4 daily doses (see Section 8.1.2). The literature search found no trials that documented the duration of analgesia resulting from DPP therapy under steady-state conditions.

Marked interindividual variation in plasma concentrations of DPP have been observed after standard doses due to differences in absorption and biotransformation.<sup>33, 35</sup> Results of studies evaluating the relationship between dosage size (or plasma DPP concentration) and number of AEs have been variable with studies finding no relationship<sup>35, 36</sup> or a linear relationship.<sup>37</sup>

The absorption of the napsylate salt tends to be delayed (time to peak, 2 h) in comparison with the HCl salt (1 to 2 h) at equivalent doses.<sup>35</sup> Toxicologic studies in animals have demonstrated less or delayed toxicity with the napsylate salt due to decreased or delayed absorption.<sup>38</sup> However, in humans the extent of absorption for the two salts at supratherapeutic doses (equivalent to 130 to 195 mg of the HCl salt) has been shown to be similar.<sup>35</sup> A toxicologic advantage with the napsylate salt has not been confirmed in man.

Animal studies have demonstrated that NPP has less neurotoxic effects than DPP but greater cardiotoxic effects due to membrane-stabilizing properties.<sup>39</sup> The local anesthetic properties of DPP and NPP are similar to those of tricyclic antidepressants such as amitriptyline and Type I antiarrhythmics such as lidocaine and quinidine.<sup>18, 39-41</sup> Recent in vivo data showed that, at high concentrations of drug similar to those observed in fatal DPP overdoses, DPP and NPP block HERG (human ether-a-go-go-related gene) potassium channels, which have been found to be the main mechanism of the long QT syndrome associated with non-sedating antihistamines, haloperidol, and thioridazine.<sup>42</sup> Ulens, *et al.* suggested that the cardiotoxic effects of DPP and NPP may be partly due to their interaction with HERG cardiac potassium channels.

As with other opioids, tolerance to the analgesic and adverse effects of DPP may develop. Plasma concentrations of DPP associated with therapeutic use<sup>33, 43</sup> may be similar to those seen in acute fatal overdoses<sup>4</sup> but without manifestations of toxicity, even with high doses such as those used for maintenance treatment of heroin addiction.<sup>33, 44</sup>

About 15% of acute overdose cases have had blood concentrations (0.1 to 1.0 µg/ml) that overlap with the range of concentrations (0.2 to 0.3 µg/ml)<sup>32</sup> achieved from single therapeutic doses or those (0.13 to 0.15 µg/ml)<sup>43</sup> from multiple therapeutic doses of DPP (also see Section 9.1.1.5).<sup>4</sup> Inturrisi, *et al.* proposed that ingestion of a single, larger than usual dose may saturate first-pass metabolic processes, causing a higher systemic concentration of DPP and a lower NPP to DPP ratio than those observed with therapeutic use of DPP.<sup>33</sup>

## 8 Efficacy

### 8.1 Results of Published Randomized Trials

#### 8.1.1 Single-dose trials

Three systematic reviews or meta-analyses, in which a total of 7087 patients were randomized to DPP (alone or in combination with APAP) or to placebo, tramadol, or APAP in single doses, were identified by the literature search.<sup>19, 20, 45</sup> In addition, the Oxford League Table of Analgesic Efficacy was located on the Web. This table is based on ongoing systematic reviews of randomized, double-blind, single-dose studies of analgesics in patients with postoperative pain.<sup>46</sup>

DPP alone was shown to have a weak analgesic effect in a systematic review of RCTs comparing single doses of DPP 65 mg alone to placebo (6 trials, 440 patients) and DPP 65 mg + APAP 650 mg to placebo (5 trials, 963 patients) for moderate to severe post-operative pain.<sup>20</sup> The number-needed-to-treat (NNT) for one more patient to achieve at least 50% pain relief was found to be 7.7 (95% CI: 4.6 to 22) when compared with placebo over 4 to 6 hours (Table 4).

**Table 4** Number-needed-to-treat to achieve 50% pain relief over 4 to 6 hours with single-dose DPP alone and with APAP for post-operative pain in comparison with placebo

Active Treatment	N	Control Event Rate	Treatment Event Rate	Relative Benefit (95% CI)	NNT (95% CI)
<b>Current systematic review</b>					
DPP 65 mg	440	85/214	60/226	1.5 (1.2 to 1.9)	7.7 (4.6 to 22)
DPP 130 mg	50	10/25	1/25	10.0 (1.4 to 72)	2.8 (1.8 to 6.5)
DPP + APAP 65 + 650 mg	963	184/478	74/485	2.5 (2.0 to 3.2)	4.4 (3.5 to 5.6)
<b>Previous systematic review</b>					
Ibuprofen 400 mg	NR	NR	NR	NR	2.7 (2.5 to 3.0) *
Codeine+A 60 +650 mg	NR	NR	NR	NR	3.6 (2.9 to 4.5) **
Tramadol 100 mg	NR	NR	NR	NR	4.8 (3.8 to 6.1)

From Collins, *et al.* 2000<sup>20</sup>. Previous, equivalent systematic review by Collins, *et al.* 1998<sup>47</sup>

NNT = Number-needed-to-treat in order to achieve at least 50% pain relief (as measured by 50% maximum total pain relief, 50%maxTOTPAR) over 4 to 6 hours in one more patient relative to placebo for post-operative pain of moderate to severe intensity.

Includes DPP HCl 65 mg or napsylate 100 mg

\* Ibuprofen was the only analgesic previously evaluated in an equivalent systematic review<sup>47</sup> whose 95% CI for NNT did not overlap that of DPP + APAP; the 95% CI also does not overlap with that of DPP 65 mg.

\*\* 95% CI does not overlap with that of DPP 65 mg

The combination of DPP and APAP was more effective than DPP alone (NNT; 95% CI: 4.4; 3.5 to 5.6) and was found to be similar in efficacy to codeine 60 mg + APAP 650 mg or tramadol 100 mg based on data from a previous, equivalent systematic review. In these indirect comparisons, ibuprofen 400 mg seemed to be more effective (lower NNT of 2.7; 95% CI: 2.5 to 3.0) than both the DPP 65 mg + APAP 650 mg combination and tramadol 100 mg, and was the only agent of a wide range of analgesics tested in postoperative pain whose 95% CI did not overlap the CI of DPP + APAP. Although a higher dose (130 mg) of DPP seemed to be more effective (lower NNT) than the 65 mg dose, the small sample size and overlapping confidence intervals prevent a definite conclusion.

A single-patient data meta-analysis in 3453 patients with moderate or severe pain after surgery or dental extraction support the results of the indirect comparison between combination DPP + APAP and tramadol.<sup>45</sup> The meta-analysis found similar efficacy (i.e., 95% CIs overlap) between a combination of DPP 100 mg (salt form unspecified; probably napsylate salt based on dose) and APAP 650 mg (NNT compared with placebo; 95% CI: 4.0; 3.0 to 5.7) and tramadol 50 mg (7.1; 4.6 to 18), 100 mg (4.8; 3.4 to 8.2), or 150 mg (2.4; 2.0 to 3.1) for post-operative pain (Table 5).

**Table 5** Number-needed-to-treat for at least 50% pain relief over 8 hours with single doses of analgesics in dental and post-surgical pain in comparison with placebo control

Active Treatment	Control Event Rate	Treatment Event Rate	Relative benefit (95% CI)	NNT (95% CI)
<b>Post-surgical pain</b>				
Codeine 60 mg	35/283	63/275	1.9 (1.3 to 2.7)	9.1 (6 to 23.4)
Tramadol 50 mg	13/136	38/163	2.4 (1.4 to 4.4)	7.1 (4.6 to 17.9)
Tramadol 75 mg	31/187	74/186	2.4 (1.7 to 3.5)	4.4 (3.1 to 7.0)
Tramadol 100 mg	13/136	51/168	3.2 (1.8 to 5.6)	4.8 (3.4 to 8.2)
Tramadol 150 mg	31/187	106/184	3.5 (2.5 to 4.9)	2.4 (2.0 to 3.1) *
DPP[N] 100 mg + APAP 650 mg	34/227	91/225	2.7 (1.9 to 3.8)	4.0 (3.0 to 5.7)
Codeine 60 mg + ASA 650 mg	4/68	24/70	5.8 (2.1 to 15.9)	3.6 (2.5 to 6.3)
<b>Dental pain</b>				
Codeine 60 mg	28/373	36/374	1.3 (0.8 to 2.1)	50 (16.3 to ∞)
Tramadol 50 mg	13/225	41/246	2.9 (1.6 to 5.2)	9.1 (6.1 to 18.8)
Tramadol 75 mg	6/95	16/95	2.7 (1.1 to 6.5)	9.1 (5.1 to 64.5)
Tramadol 100 mg	22/278	89/300	3.8 (2.4 to 5.8)	4.6 (3.6 to 6.4) **
Tramadol 150 mg	6/95	29/95	4.8 (2.1 to 11.1)	4.2 (2.9 to 7.3) **
DPP[N] 100 mg + APAP 650 mg	6/95	23/91	4.0 (1.7 to 9.4)	5.3 (3.4 to 11.4) **
Codeine 60 mg + ASA 650 mg	13/225	52/235	3.8 (2.2 to 6.8)	6.3 (4.5 to 9.8) **

From Moore, *et al.*<sup>45</sup>

At least 50% pain relief was measured as >50% of %maxTOTPAR (50%maxTOTPAR). %maxTOTPAR is percentage of the maximum possible for the area under the curve of pain relief (categorical scale) against time.

NNT = Number-needed-to-treat (for 8 hours) in order to achieve at least 50% pain relief in one more patient.

NR = Not reported.

\* NNT 95% CI does not overlap with that of tramadol 100 mg, and just overlaps with that of tramadol 75 mg for post-surgical pain.

\*\* NNT 95% CI does not overlap with that of codeine 60 mg for dental pain.

There was a similar pattern for DPP + APAP treatment comparisons but with slightly higher NNT values for dental pain. This meta-analysis also found comparable analgesic efficacy between DPP + APAP and codeine 60 mg + aspirin 650 mg for both post-operative pain (NNT; 95% CI: 4.0; 3.0 to 5.7 vs. 3.6; 2.5 to 6.3, respectively) and dental pain (5.3; 3.4 to 11.4 vs. 6.3; 4.5 to 9.8, respectively). DPP + APAP was more efficacious than codeine 60 mg for both post-operative pain (NNT, 95% CI for codeine: 9.1; 6 to 23.4) and dental extraction pain (50; 16.3 to ∞). Of note, the NNTs were lower for post-surgical pain than dental pain, indicating that the analgesics were more efficacious in post-surgical pain than in dental pain despite significantly more patients having severe pain intensity at baseline in post-surgical pain; however, the NNT 95% CIs associated with each agent for post-surgical and dental pain overlapped.

While there is a widely held view that the combination of DPP and APAP has additive effects, a systematic review of 24 single-dose RCTs involving 2231 patients found that the combination was no more effective than APAP alone in the treatment of dental, postpartum, post-operative, arthritis, and musculoskeletal pain.<sup>19</sup> The difference in pain intensity between DPP HCl 65 mg + APAP 650 mg and APAP 650 mg alone was 7.3% (95% CI: -0.2 to 14.9). In direct comparisons, the difference in response rate ratio was 1.05 (95% CI: 0.8 to 1.3) for the combination therapy and APAP monotherapy, where response was defined as moderate to excellent pain relief.

The Oxford League Table of Analgesic Efficacy presents a summary of the analgesic efficacy of single doses of analgesics in patients with moderate to severe acute postoperative pain (Table 6).<sup>46</sup> Analgesic efficacy (NNT) was based on the proportion of patients achieving at least 50% pain relief over 4 to 6 hours compared with placebo in randomized, double-blind trials.

**Table 6 Efficacy of single-doses of selected oral analgesics in patients with moderate to severe acute postoperative pain in increasing order of NNT**

Drug	N (active drug)	Percent (%) with ≥ 50% pain relief	NNT	95% CI
Diclofenac 100 mg	308	65	1.8	1.5 to 2.1
Codeine 60 mg + APAP 1000 mg	197 <sup>†</sup>	57	2.2	1.7 to 2.9
Diclofenac 50 mg	636	63	2.3	2.0 to 2.7
Naproxen 440 mg	257	50	2.3	2.0 to 2.9
Aspirin 1200 mg	279	61	2.4	1.9 to 3.2
Oxycodone 10 mg + APAP 650 mg	315	66	2.6	2.0 to 3.5
Ketorolac 10 mg	790	50	2.6	2.3 to 3.1
Piroxicam 20 mg	280	63	2.7	2.1 to 3.8
Ibuprofen 400 mg	2898	53	2.7	2.5 to 3.0
<b>DPP 130 mg</b>	<b>50<sup>†</sup></b>	<b>40</b>	<b>2.8</b>	<b>1.8 to 6.5</b>
Tramadol 150 mg	561	48	2.9	2.4 to 3.6
Codeine 60 mg + APAP 600 / 650 mg	816	50	3.1	2.6 to 3.9
Ibuprofen 200 mg	726	37	3.3	2.8 to 4.0
Aspirin 1000 mg	716	43	4.0	3.2 to 5.4
<b>DPP 65 mg + APAP 650 mg</b>	<b>963</b>	<b>38</b>	<b>4.4</b>	<b>3.5 to 5.6</b>
Aspirin 600 / 650 mg	5061	38	4.4	4.0 to 4.9
APAP 1000 mg	2283	45	4.6	3.9 to 5.4
Tramadol 100 mg	882	30	4.8	3.8 to 6.1
APAP 1500 mg	348	64	5.0	3.3 to 11.0
Codeine 30 mg + APAP 300 mg	442	28	5.3	3.8 to 8.0
Tramadol 75 mg	563	32	5.3	3.9 to 8.2
APAP 600 mg / 650 mg	1167	41	5.3	4.1 to 7.2
Codeine 60 mg + ASA 650 mg	598	25	5.3	4.1 to 7.4
APAP 500 mg	649	55	5.6	3.9 to 9.5
<b>DPP 65 mg</b>	<b>440</b>	<b>40</b>	<b>7.7</b>	<b>4.6 to ∞</b>
Tramadol 50 mg	770	19	8.3	6.0 to 13.0
Codeine 60 mg	1305	15	16.7	11.0 to 48.0
Aspirin 500 mg	250	33	18.0	5.9 to -17.0

Adapted from the Oxford League Table of Analgesic Efficacy (1999).<sup>46</sup> Selection of agents for this table was based on the role of the agent as a WHO step 2 agent and data set (N) ≥ 250 (see footnote [†] below). For reference, morphine 10 mg i.m. has an analgesic efficacy rate of 50% and an NNT of 2.9 (95% CI: 2.6 to 3.6; N = 946).

DPP = Propoxyphene hydrochloride or equivalent dose of napsylate salt (65 mg hydrochloride ≅ 100 mg napsylate).

NNT = Number needed to treat for one more patient with moderate or severe pain to achieve at least 50% pain relief compared with placebo over a treatment period of 4 to 6 hours.

95% CI = 95% Confidence interval

† A data set consisting of less than about 250 patients is considered to be probably inadequate for accurate estimation of the magnitude of the analgesic effect. NNT point estimates and 95% CIs based on data sets smaller than 250 patients should be interpreted with caution.

Table 7 summarizes the relative analgesic efficacy of DPP preparations in comparison with NSAIDs, APAP, or other opioids based on the information in Table 6.

**Table 7 Relative analgesic efficacy of DPP preparations based on 95% CIs of NNTs for at least 50% pain relief**

	<b>Superior to</b>	<b>Similar to</b>	<b>Inferior to</b>
DPP 130 mg	<u>NSAIDs / APAP</u> ASA 500 mg  <u>Opioids</u> Codeine 60 mg Tramadol 50 to 150 mg	<u>NSAIDs / APAP</u> Diclofenac 50 to 100 mg Naproxen 440 mg Ketorolac 10 mg Piroxicam 20 mg Ibuprofen 200 to 400 mg APAP 500 to 1500 mg ASA 600 to 1200 mg  <u>Opioids</u> Codeine 60 mg + APAP 1000 mg Oxycodone 10 mg + APAP 650 mg	—
DPP 65 mg + APAP 650 mg	<u>NSAIDs / APAP</u> ASA 500 mg  <u>Opioids</u> Tramadol 50 mg Codeine 60 mg	<u>NSAIDs / APAP</u> APAP 1000 mg ASA 600 to 1000 mg  <u>Opioids</u> Codeine 30 to 60 mg + APAP 300 to 650 mg Codeine 60 mg + ASA 650 mg Tramadol 75 to 150 mg	<u>NSAIDs / APAP</u> Diclofenac 50 to 100 mg Naproxen 440 mg Ketorolac 10 mg ASA 1200 mg  <u>Opioids</u> Codeine 60 mg + APAP 1000 mg Oxycodone 10 mg + APAP 650 mg
DPP 65 mg	—	<u>NSAIDs / APAP</u> APAP 600 to 1000 mg  <u>Opioids</u> Codeine 30 to 60 mg + APAP 300 to 650 mg Codeine 60 mg + ASA 650 mg Tramadol 50 to 100 mg	<u>NSAIDs / APAP</u> Diclofenac 50 to 100 mg Naproxen 440 mg Ketorolac 10 mg Piroxicam 20 mg Ibuprofen 200 to 400 mg ASA 1200 mg  <u>Opioids</u> Codeine 60 mg + APAP 1000 mg Oxycodone 10 mg + APAP 650 mg Tramadol 150 mg

Source: Table 6, based on the Oxford League Table of Analgesic Efficacy.<sup>46</sup>

APAP = Acetaminophen; ASA = Aspirin; DPP = Dextropropoxyphene; NSAID = Nonsteroidal anti-inflammatory drug

For different types of surgical procedures, single doses of the NSAIDs or high-dose (1200 mg) ASA perform the best. ASA 500 mg is inferior to DPP 65 mg + APAP 650 mg and DPP 130 mg but the size of its data set is borderline (N = 250). Even slightly higher doses of ASA (600 to 1200 mg) are similar or superior in efficacy to DPP 65 mg + APAP 650 mg or DPP 130 mg. Of the NSAIDs evaluated, diclofenac 50 to 100 mg, naproxen 440 mg, ASA 1200 mg, and ketorolac 10 mg were superior to DPP



65 mg + APAP 650 mg. DPP 130 mg was similar in efficacy to these NSAIDs; however, the NNT data set was small.

Codeine 60 mg in combination with high-dose (1000 mg) APAP and oxycodone 10 mg + APAP 650 mg appear to be slightly more effective than DPP 130 mg but the 95% CIs overlap. They are significantly more effective than DPP 65 mg + APAP 650 mg. Caution should be used in interpreting the NNTs, however, as the data sets for codeine 60 mg + APAP 1000 mg and DPP 130 mg are small ( $N < 250$ ). DPP 65 mg + APAP 650 mg is similar in efficacy to codeine 30 to 60 mg in combination with either APAP 300 to 650 mg or ASA 650 mg, and to tramadol 75 to 150 mg. DPP 65 mg and codeine 60 mg are significantly less effective than the NSAIDs. Codeine alone (60 mg) performs the worst of the opioid agents evaluated. Adding extra-strength APAP to either DPP or codeine improves the analgesic efficacy. DPP 130 mg appears to have greater efficacy than DPP 65 mg + APAP 650 mg, followed by DPP 65 mg; however, the 95% CIs overlap.

Although the use of 50%maxTOTPAR is useful for comparison of analgesics across different trials, this measurement should not be over-interpreted. It is possible for patients with less than 50%maxTOTPAR to obtain useful pain relief. Conversely, it is also possible for patients with at least 50%maxTOTPAR to obtain near maximal pain relief.

The usual practice in pain management, however, is to prescribe multiple doses of analgesics. Young, *et al.* found that a statistically significantly smaller proportion of patients obtained at least 50% maximal pain relief following a single dose as compared with two doses of either DPPN 100 mg (7 of 30 patients, 23%, vs. 21 of 30 patients, 70.0%;  $p = 0.001$ ) or codeine 60 mg (7 of 31 patients, 22.5%, vs. 23 of 30 patients, 76.7%;  $p < 0.001$ ) given 4 hours apart.<sup>48</sup> Therefore, the results of single-dose trials may not be applicable to repeated doses of analgesics.

## 8.1.2 Multiple-dose trials

### 8.1.2.1 Acute pain

For the purposes of this report, acute pain was defined as pain of less than 3 months' duration, pain immediately following tissue injury, or pain of undisclosed duration but that was described as acute by the author. One trial involving acute exacerbation of chronic pain was considered under acute pain.<sup>49</sup> One trial included patients with acute exacerbation of low back pain of undisclosed duration.<sup>1</sup> A summary of the multiple dose, acute pain trials is presented in Appendix 3, Appendix Table 2 and Appendix Table 3.

A total of 19 efficacy-safety RCTs were included in the multiple-dose efficacy evaluation of this report. In these trials, 1395 patients with acute pain were included in the analgesic efficacy analyses. An accurate account of the number of randomized patients was not possible because of incomplete information (1406 patients were recruited, randomized, or analyzed). The acute pain trials differed in study design, patient characteristics, pain severity, type of pain, sample size, and treatment regimens. For an overview of the study designs of these trials, see Appendix 3.

#### 8.1.2.1.1 Trials comparing DPP with NSAIDs or APAP

Thirteen RCTs, in which 698 analyzed patients had been randomized to DPP(N) (alone or in combination with APAP) or to NSAIDs or APAP (alone or in combination with non-analgesics), examined the efficacy of DPP in comparison with non-opioid agents (see Appendix 3, Appendix Table 2). Three trials found DPP + APAP less efficacious ( $p < 0.05$ ) than NSAIDs in relieving pain<sup>1, 50, 51</sup> and one trial found DPP to be less efficacious ( $p < 0.05$ ) than a combination APAP product (Percogesic).<sup>52</sup> The results of 10 trials showed no difference in analgesic efficacy between DPP products and either NSAIDs or APAP.<sup>1, 53-63</sup> None of these 10 trials performed a priori power calculations or presented results using 95% confidence intervals (which reflect sample size). Therefore, the results of these 10

trials may be inconclusive because of Type II error (no significant difference was found when a true difference existed).

The results of the trial by Evans, *et al.* demonstrated that differences in analgesic efficacy between DPP + APAP and NSAIDs may depend on the type of NSAID.<sup>1</sup> DPP + APAP was compared with four NSAIDs and APAP alone in this single-blind, three-period crossover study involving 60 patients (aged 47.0 ± 9.2 years; 20 men, 40 women) suffering from acute exacerbations of low back pain primarily of moderate intensity. The treatment regimens were DPP + APAP (Distalgesic, 65/650 mg QID), aspirin (900 mg QID), indomethacin (Indocid, 50 mg TID), mefenamic acid (Ponstan, 500 mg TID), phenylbutazone (Butazolidin, 100 mg TID), and APAP (1000 mg QID). Each treatment was given for 1 week. There was no statistically significant difference in spinal anterior flexion between treatment groups. A statistically significant difference was found between mefenamic acid (mean ± standard error, SE: 1.38 ± 0.09) and APAP (1.66 ± 0.09) or DPP + APAP (1.71 ± 0.09) (in favor of mefenamic acid), and between ASA (1.42 ± 0.09) and DPP + APAP (in favor of ASA) in terms of the daily pain index as measured by a 4-point pain intensity scale (0 = nil, 1 = mid, 2 = moderate, and 3 = severe). Notably, there was no statistically significant difference between DPP + APAP and either APAP, indomethacin, or phenylbutazone in terms of pain intensity. The percentage of the recommended dose taken by patients was lowest with DPP + APAP (71.7%), and treatment differences in this regard were significant between DPP + APAP and phenylbutazone (96.5%;  $p < 0.01$ ), mefenamic acid (91.8%;  $p < 0.01$ ), and APAP (89.8%;  $p < 0.05$ ) (also see Section 0). Patient's preference, ranked on a scale of 1 (best) to 3 (worst), favored phenylbutazone (mean rank: 1.68) and mefenamic acid (1.75). Significant differences ( $p < 0.05$ ) were found between each of these two agents and aspirin (2.37). DPP + APAP was rated fourth (mean rank: 2.07) among the six agents.

#### 8.1.2.1.2 Trials comparing DPP with opioids

A total of 697 analyzed patients had been randomized in six trials to DPP(N) ± APAP or opioids ± APAP for the treatment of acute pain (see Appendix 3, Appendix Table 3). Codeine-containing combination analgesics or tramadol were shown to have greater analgesic efficacy than DPP + APAP in one study<sup>64</sup> and to produce analgesia that was not statistically different from either DPP alone<sup>48</sup> or DPP(N) + APAP<sup>49, 54, 55, 65</sup> in five trials.

Of the five trials that found no statistically significant difference in pain intensity between DPP(N)+A and another opioid agent, two showed adequate power (at least 0.80) to detect a statistically significant difference if a true difference existed based on a priori<sup>54</sup> or post hoc<sup>49</sup> power calculations. The results of the remaining three trials were not presented using 95% confidence intervals (which reflect sample size) and, therefore, were inconclusive.<sup>48, 55, 65</sup>

One RCT also evaluated treatment based on a measure of clinical outcome.<sup>62</sup> Beveridge, *et al.* found that football players with soft tissue injuries treated with naproxen returned to training about 1 day sooner than those treated with DPP (mean: 7.0 vs. 7.8 days; no statistical analysis reported). The numbers of days for patients to be available for selection were also lower for naproxen than DPP patients (8.3 vs. 9.6 days; no statistical analysis reported). However, a greater proportion of patients randomized to naproxen had been prescribed rehabilitation exercises.

#### 8.1.2.1.3 Validity of acute pain trial results

The major and minor validity criteria are described in Appendix 2. The results of all the RCTs were considered to be of doubtful validity because of one or more of the major, minor, or other validity issues outlined in Appendix 3.

In total, eight trials<sup>1, 48, 49, 51-54, 61</sup> met major validity criteria and six trials<sup>48, 50, 53, 56, 57, 65</sup> met minor validity criteria. Only the trials by Buck, *et al.* (preliminary results) and Young, *et al.* met both major and minor (excluding other) validity criteria.

### 8.1.2.2 Chronic pain

For the purposes of this report, chronic pain was considered to be pain of 3 months' duration or longer, persistent pain related to an incurable disease (e.g., cancer), or pain described by the author as being associated with deterioration in quality of life (a characteristic more typical of chronic pain than acute pain).<sup>66</sup> Four RCTs involved patients with chronic pain as defined for this report (see Appendix 3, Appendix Table 4).

Two of the four RCTs compared DPP ± APAP to NSAIDs<sup>67, 68</sup> and two compared DPP to opioids (either dihydrocodeine<sup>69</sup> or morphine<sup>14</sup>). A total of 864 patients were included in the analgesic efficacy analyses. One trial found DPP to be inferior to diclofenac sustained release,<sup>67</sup> and the remaining three trials found no difference between DPP ± APAP and either indomethacin<sup>68</sup> or opioids (dihydrocodeine or morphine sustained release).<sup>14, 69</sup>

As with the acute pain, multiple-dose RCTs, the chronic pain trials varied in study design, patient populations, pain characteristics, and treatment regimens. For an overview of the study designs of the chronic pain trials, see Appendix 3.

One of the three studies that found no statistically significant difference between DPP + APAP and comparator agents performed an a priori power calculation.<sup>69</sup> The other trials did not perform power calculations or did not present results using 95% confidence intervals (which reflects sample size) and, therefore, their results are inconclusive.

The study by Mercadante, *et al.* was an open-label RCT that assessed the long-term use of DPP for the treatment of pain in terminally ill patients with cancer.<sup>14</sup> Daily doses of DPP 120 to 240 mg (N=16) were compared with low-dose morphine SR 20 mg (N=16) in opioid-naive cancer patients with moderate pain. This study was unique in that it was the only study that compared DPP as a WHO step 2 with a step 3 opioid analgesic. The objective of the study was not to compare equianalgesic doses of the two drugs, but to compare the analgesia and adverse effects of DPP with morphine SR as the second step in the WHO analgesic ladder (i.e., a step 2 opioid vs. a step 3 opioid, skipping a step 2 agent). The step 1 agents (mainly diclofenac 100 mg orally or 75 mg intramuscularly twice daily) were continued upon addition of opioid treatment.

The overall mean duration of therapy was 46 days for DPP and 68 days for morphine. In the first 10 days of therapy, the mean equianalgesic dose of DPP (mean in morphine equivalents:  $14 \pm 5.2$  mg; calculated as being equivalent to greater than  $91 \pm 33.8$  mg of DPP) was statistically significantly lower than those of morphine ( $20.1 \pm 6$  mg;  $p < 0.01$ )<sup>a</sup> without a difference in pain intensity (median and range VAS score: 3 cm and 2 to 5 cm, respectively, in both treatment groups). Three patients maintained DPP therapy until death (mean: 38 days' therapy; range: 25 to 131 days). Three of the 16 morphine patients had to switch to DPP 5 to 7 days after starting treatment because of intolerable side effects (vomiting, drowsiness) and continued DPP with adequate pain relief until death.

A total of 13 patients were switched to morphine after reaching the ceiling dose (240 mg) of DPP. Two of these patients were able to continue DPP with adequate relief until 1 to 2 days before death when they became unable to swallow and were switched to subcutaneous morphine. Nausea, vomiting, drowsiness, and dry mouth were significantly more frequent and severe in the morphine group than the DPP group ( $p < 0.01$ ); however, the differences in each case were relatively small (median and mean symptom intensity: 0 and 0.5 to 0.6 for DPP; 1 and 1.2 for morphine, where 0 was not at all, 1 was slight, 2 a lot, and 3 awful).

---

<sup>a</sup> An equianalgesic ratio of 65 mg DPP (and APAP 650 mg [*sic*]) to < 10 mg morphine orally was suggested in the reference cited by the trial report.<sup>70</sup> Hanks GW, Justins DM. Cancer pain: management [see comments]. *Lancet* 1992; 339:1031-6.]

The study did not exclude the possibility that lower doses of morphine could have had fewer adverse effects. The results suggested that DPP produced a more favorable balance between analgesia and adverse effects than when a low dose of morphine was used to skip step 2 of the WHO analgesic ladder in opioid-naïve patients.

The authors concluded that the results stressed the role of "weak" opioids during initiation of opioid therapy in opioid-naïve cancer patients. In addition, the results of this long-term study demonstrated that some patients experience an improvement in analgesia when DPP is added to nonopioid analgesics.

#### 8.1.2.2.1 Validity of chronic pain trial results

The validity of results in all chronic pain trials was considered to be doubtful because of the major and minor validity issues outlined in Appendix 3 (for validity criteria, see Appendix 2).

None of the chronic pain trials met major validity criteria.

### 8.1.3 Patient Characteristics: Applicability of published results to VA patients

The 2298 patients recruited, randomized, or analyzed in the published RCTs consisted of mostly females (60%, 1372) with no or few co-morbid conditions. Patients were generally young with a mean or median age ranging from 19.2 to 55 years among 1613 patients (12 trials)<sup>62, 1, 48, 51, 54, 56, 59, 61, 63-65, 67</sup> and from 66 to 81 years among 299 patients (4 trials)<sup>14, 49, 58, 69</sup>. Age range was < 16 to 67 years in 4 trials reporting only age range (n = 281).<sup>50, 55, 57, 68</sup> Age was not stated in two trials (n = 272)<sup>53, 60</sup>.

The VA patient population is composed of mostly elderly men (95.2% men; age, mean ± SD: 59.9 ± 15.1 years) with co-morbidities.<sup>71</sup> A substantial proportion of the veteran population suffer from painful medical conditions (weighted percentages): 21.6% have osteoarthritis, 16.5% low back pain, and 10.7% cancer.

Because of these differences in characteristics between RCT and VA patients, the patients included in the RCTs were considered to have sociodemographic features or pathobiologic characteristics that may be sufficiently different from VA patients that the results were not completely applicable to the veteran population. Efficacy results should be particularized to veteran patients with caution, since sex differences in pain perception have been reported (with women more sensitive to pain than men).<sup>72-77</sup> Older persons may require lower opioid doses.<sup>78-80</sup> Furthermore, differences in analgesic (and toxic) effects might exist between young and elderly patients due to differences in renal function and blood concentrations of DPP or NPP.

## 8.2 Unpublished findings from VA data (Effectiveness of DPP)

VA data on the effectiveness of DPP in comparison with other opioids is lacking. Some indication of relative effectiveness of opioids in veterans was available from one center. The Chronic Pain Rehabilitation Unit of the Tampa VAMC (VISN 8) systematically collects pain-related outcome measures as part of a validation study of the National Pain Data Bank (NPDB), a multidisciplinary outcome system developed by the American Academy of Pain Management. Participants in the multidisciplinary, inpatient pain management program, which serves as a national referral center and as a VA Center of Excellence for pain treatment, suffer from chronic pain (duration of at least 3 months) from a variety of causes. Participants have had poor responses to prior conservative treatment efforts, are medically and emotionally stable, have no pending litigation or primary substance abuse, and are willing to discontinue opioid analgesics and muscle relaxants for pain. Narcotics are discontinued in all patients admitted to the program.

Of 248 consecutive admissions to the pain rehabilitation unit, 104 patients (43.9%) (mean age 50.3 years [range: 24 to 81 years]; 87.5% male) were taking daily opioid analgesics at admission,

including 29 (27.9%) who were taking DPP (ME Clark, E-mail [[Michael.Clark2@med.va.gov](mailto:Michael.Clark2@med.va.gov)], 31 October, 2 November 2000) The mean duration of pain was 14.6 years (range: 1 to more than 20 years). More than 20 different types of opioids were used, most by 6 or fewer patients. A total of 149 opioid prescriptions were taken by the 104 patients with about 40% of these patients taking 2 (or in a few cases, 3) different opioids. Doses and frequency of administration were not recorded. Upon admission, patients rated their average pain during the previous week from 0 to 10 using a numerical pain scale.

The frequency of opioid prescriptions and admission pain scores associated with the most commonly used opioids (those taken at least once daily on a continuing basis) and all other opioids are shown in Table 8.

**Table 8 Frequency of opioid prescriptions and pain scores associated with opioids at admission**

Opioid	No. of prescriptions	% of all opioid prescriptions	Pain Score (mean) <sup>†</sup>
Oxycodone	41	27.5	7.2
Propoxyphene	29	19.5	7.0
Codeine	26	17.4	7.1
Hydrocodone	17	11.4	6.9
Morphine	10	6.7	6.7
Other	26	17.4	7.7
<b>Total</b>	<b>149</b>	<b>99.9</b>	—

N = 104

<sup>†</sup> Pain score for average pain during the last week based on a numerical scale from 0 to 10.

A comparison of the pain scores, age, and gender across the different opioid groups revealed no significant differences ( $p > 0.05$ , ANOVA) (ME Clark, E-mail [[Michael.Clark2@med.va.gov](mailto:Michael.Clark2@med.va.gov)], 2 November 2000). Although these results suggest the type of opioid was not related to pain severity at admission, little can be concluded about the relative effectiveness of DPP without dosing information and repeated pain scores.

### 8.3 Summary of Efficacy and Effectiveness

In patients with acute pain, *single*-dose DPP 65 mg + APAP 650 mg is inferior to diclofenac 50 to 100 mg, naproxen 440 mg, ASA 1200 mg, and ketorolac 10 mg in terms of analgesic efficacy.<sup>46</sup>[QE: I] The analgesic efficacy of DPP 65 mg + APAP 650 mg is also inferior to codeine 60 mg + APAP 1000 mg and to oxycodone 10 mg + APAP 650 mg, but similar in efficacy to combinations of codeine 30 to 60 mg and smaller doses of APAP (300 to 650 mg).<sup>46</sup>[QE: I] In turn, the same dose of combination DPP + APAP is more efficacious than codeine 60 mg or tramadol 50 mg.<sup>46</sup>[QE: I]

The analgesic efficacy of *multiple* doses of DPP alone or in combination with APAP is inferior to [4 QE: I] or not statistically different from [9 I, 1 II-1] that of NSAIDs or high-dose APAP (3900 to 4000 mg/day) in the treatment of acute pain. Results varied depending on the type of NSAID used.<sup>1</sup>[QE: I]

Six RCTs comparing DPP(N) ± APAP to opioids found DPP(N) ± APAP to be similar to<sup>49, 55 48, 54</sup> [4 QE: I],<sup>65</sup>[1 QE: II-1] or less effective than<sup>64</sup>[QE: I] the opioid preparation in the treatment of acute pain.

Well-designed RCTs evaluating the efficacy of DPP in the treatment of chronic pain or under steady-state conditions are lacking. Limited data suggest that the analgesic efficacy of DPP(N) ± APAP in patients with chronic pain is similar to that observed in the treatment of acute pain: DPP(N) ± APAP is no better than NSAIDs or other opioids.<sup>67-69</sup>[3 QE: I],<sup>81</sup> [QE: II-1] The analgesic efficacy of titrated DPP (mean dose: 60 ± 22.5 mg/day) was not statistically different from low-dose morphine

SR ( $20.1 \pm 6.0$  mg/day) in the first 10 days' treatment of cancer pain in opioid-naïve patients.<sup>81</sup> [QE: II-1] However, DPP may be better tolerated than low-dose morphine and may provide adequate pain relief in some opioid-naïve individuals. In addition, contrary to single-dose, acute pain trial results, further benefit was gained from the addition of DPP to an NSAID (diclofenac) in this patient population. These results need to be confirmed in additional chronic pain trials.

Systematically collected VA data on the effectiveness of DPP relative to other opioids is lacking. Limited information from one center suggests that the effectiveness of DPP is similar to that of other opioids in patients with recalcitrant, chronic pain.

There was no evidence to justify the practices of prescribing DPP  $\pm$  APAP in addition to Step 3 analgesics or as an analgesic placebo.

## 9 Safety

### 9.1 Published trials

Safety data included frequencies of serious adverse events (SAEs), risks of drug dependency and abuse as an SAE, risks associated with dependency and abuse, non-serious adverse events (NSAEs), and tolerability. To address the safety concerns regarding DPP use in veterans, the discussion here focuses on SAEs. NSAE and other safety data from published trials are summarized in Appendix 3.

Clinical safety data was obtained from the results of 3 meta-analyses or systematic reviews, 23 efficacy/safety RCTs, 3 safety RCTs, 1 retrospective case-control study, 1 follow-up study, 6 large retrospective reporting programs, 9 retrospective surveys or case reviews, 3 large case series, and 4 small case series or case reports.

A total of 25 efficacy-safety or safety RCTs evaluated the safety of standard therapeutic doses of DPP(N)  $\pm$  APAP in comparison with NSAIDs or opioids (codeine  $\pm$  APAP, tramadol, or morphine). The numbers of patients with known exposures to the different treatments were 1160 for DPP-containing products, 701 for NSAIDs, 355 for codeine  $\pm$  APAP or dihydrocodeine, 26 for morphine, and 21 for tramadol (total for opioids: 406; the treatment assignments of 3 patients who were withdrawn were not reported in one study and are therefore unaccounted for in the overall patient population exposed to treatment<sup>65</sup>). Based on reported information, a total of 2306 patients were evaluated for safety in the RCTs reviewed in this report.

#### 9.1.1 Serious adverse events

Serious adverse events in this report were defined according to the FDA regulations on postmarketing reporting of adverse events (or experiences) (21 CFR 314.80). These regulations define a serious adverse event as any adverse event occurring at any dose that results in any of the following outcomes:

- death
- a life-threatening adverse event
- inpatient hospitalization or prolongation of existing hospitalization
- a persistent or significant disability/incapacity
- congenital anomaly or birth defect
- important medical events that may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed above (e.g., seizures that do not result in inpatient hospitalization, development of drug dependency or abuse).

### 9.1.1.1 SAEs observed at standard therapeutic doses

#### 9.1.1.1.1 Deaths

No deaths were reported in meta-analyses and systematic analyses of RCTs evaluating single doses of DPP alone or in combination with APAP.<sup>19, 20, 45</sup>

A death due to the ingestion of large quantities of alcohol after taking therapeutic doses of DPP has been reported in a retrospective review of DPP-related deaths.<sup>82</sup> In this “well documented” case, a subject lost consciousness 4 hours after taking only two Distalgesic tablets (equivalent to 65 mg of DPP and 650 mg of APAP; blood DPP concentration: 0.2 µg/ml) in combination with half a bottle each of champagne and martini (blood alcohol concentration, BAC: 168 mg%).

#### 9.1.1.1.2 Other SAEs

No SAEs were reported in meta-analyses and systematic analyses of RCTs evaluating single doses of DPP alone or in combination with APAP.

No SAEs were reported among the 1160 patients exposed to DPP ± APAP in the RCTs reviewed in this report. Two SAEs associated with codeine preparations were observed among 163 patients exposed to codeine + APAP and 62 patients exposed to codeine + APAP + caffeine (Solpadeine). The first SAE was acute pulmonary edema possibly related to codeine + APAP treatment; the patient was also taking a beta-blocker.<sup>49</sup> The second SAE, postoperative hemorrhage, was reported in a patient who received codeine + APAP + caffeine (Solpadeine) after tonsillectomy.<sup>65</sup>

No seizures, cardiac arrhythmias, or pulmonary edema related to standard doses of DPP alone or in combination with APAP were reported in controlled clinical trials.

Furthermore, the literature search did not identify any case reports of such SAEs in association with therapeutic doses of DPP-containing products in the absence of other CNS depressants (cases were found when DPP-containing products were misused, abused, or overdosed with or without other CNS depressants; see Section 9.1.1.5).

#### 9.1.1.1.3 SAEs in older patients

No relationship between the use of opioid analgesic (mainly DPP, codeine, and oxycodone) and increased risk of falls in older patients (> 60 years old) was found in a recent systematic review and meta-analysis of 29 nonrandomized, cohort (with at least 6 months’ follow-up), case-control, or cross-sectional studies.<sup>83</sup> Based on the results of 13 studies involving 4537 patients (of whom 442 were taking drug), the pooled odds ratio (OR) for associations between use of opioid analgesics and occurrence of one or more falls was 0.97 (95% CI: 0.78 to 1.20).

In a recent follow-up study conducted in Sweden, Guo *et al.* assessed the effects of cognitive function and drug use on the incidence of **hip fracture** in a community-based population of 1,608 patients aged 75 years or older.<sup>12</sup> A total of 134 first hip fractures were identified during the 7,124 person-year follow-up. Of 109 patients using opioid analgesics, 106 (97%) took DPP. Opioid analgesic use was associated with an 80% increased risk of developing hip fracture (relative risk [RR] of 2.01 [95% CI: 1.19 to 3.40]). The major limitation of this study was that drug use was not monitored after the initial baseline assessment and, therefore, the temporal relationship between DPP use and the occurrence of hip fracture is uncertain.

The results of this recent study support those of a previous retrospective case-control study that also found an increased risk of **hip fracture** among elderly patients (aged 65 years or older) who were current users of DPP (RR 1.6; 95% CI: 1.2 to 2.2) or codeine (1.6; 1.3 to 1.9) in comparison to nonusers.<sup>84</sup> There was no difference in the relative risks of developing hip fracture between the two opioid analgesics (95% CIs overlap).

Neither of the latter two studies were reviewed in the meta-analysis by Leipzig, *et al.* which focused on associations between the use of opioid analgesics and falls as opposed to hip fractures.

#### **9.1.1.2 SAEs observed at high doses in the treatment of heroin maintenance**

In a double-blind RCT in which 125 patients with heroin addiction took high doses (mean, 1000 mg/d) of DPPN (equivalent to 650 mg/d of the HCl salt), two SAEs were reported.<sup>44</sup> In the first case, a 52 year old man with diabetes developed a transient cerebral ischemic attack and required hospitalization. In the second case, the patient, who had a history of alcohol, sedative, benzodiazepine, and narcotic abuse, became obtunded apparently because of concomitant ingestion of DPPN 300 mg b.i.d. and other sedatives (two 30-mg flurazepam capsules and five “pills” of unknown content). None of the patients developed cardiac arrhythmias or seizures. The total daily doses taken for treatment of heroin dependence in this study are within the range of single doses taken in fatal acute overdoses. The relative lack of significant respiratory or CNS depressant effects in this population of narcotic addicts was believed to be due to tolerance to the opiate agonist effects.

#### **9.1.1.3 Risks of dependency, misuse, or abuse as SAEs**

Although DPP was first marketed in the U.S. in 1957 with initial claims that it lacked risk of dependency, its liability for dependence, addiction, and abuse typical of opioid narcotics was recognized by the late 1960s. DPP’s abuse potential was considered to be relatively low based on several observations: (1) its transient opioid effects (in daily doses of 390 to 1625 mg) as a substitute for heroin or morphine among narcotic abusers; (2) its weaker abstinence-suppressing effects in comparison with codeine in patients physically dependent on morphine; and (3) its reportedly low use as a drug of primary abuse among abusers seeking euphoric effects.<sup>85</sup> The low abuse liability of DPP has also been reviewed by Miller, *et al.*<sup>2</sup>

Among US Army soldiers stationed in West Germany between 1969 and 1971, however, the nonmedical use of DPP reached epidemic proportions.<sup>86</sup> In 1974 the U.S. DAWN found DPP to rank eighth among the most abused drugs. It was suggested that DPP was a likely target for abuse and addiction because of its relative ease of availability by prescription and lower cost compared with illicit opiates.<sup>87</sup> Despite the reports of DPP abuse, in discussion comments to Lader’s review on the abuse of weak opioid analgesics, Finkle noted that information that had been presented at hearings in the U.S. and supported by the Law Enforcement Agency, the National Institute on Drug Abuse, and the Drug Early Warning Network, showed that the overall rate of DPP abuse during the 1960s and 1970s was very low.<sup>85</sup>

In a review of DPP as a drug of medical misuse, Lader cited many published cases of high-dose dependence on the drug, both psychological and physical.<sup>85</sup>

Although the likelihood of developing dependency on DPP is rated to be less than that with morphine, hydromorphone, oxycodone, and oxymorphone,<sup>18</sup> the literature search found no systematic analyses, controlled trials, cohort or case-control studies on the absolute or relative risk of DPP dependency or abuse.

The year-end 1999 emergency department (ED) data from the Drug Abuse Warning Network (DAWN) provided recent information on the frequency of DPP abuse-related visits among the participating EDs.<sup>88</sup> DPP was mentioned as a licit drug whose non-medical use resulted in or was related to an ED visit in 6252 (1%) of 554,932 episodes (DAWN estimate of total ED visits: 91.1 million).<sup>a</sup> Among the narcotic analgesics, hydrocodone was mentioned most often (3%, 14,639), and

---

<sup>a</sup> The annual survey of hospital emergency departments participating in the Drug Abuse Warning Network (DAWN) is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). Eligible hospitals are non-Federal, short-stay facilities located in the coterminous U.S. and that have emergency departments (EDs) open 24 hours a



the frequency of mentions of oxycodone (1%, 6429) and codeine + APAP (1%, 3721) were similar to that of DPP (codeine alone was not one of the selected drugs reported).

The estimated rate of drug mentions per 100,000 population was highest for hydrocodone (6.0), followed by DPP and oxycodone (each with 2.6), and then codeine + APAP (1.5). In comparison, the rates for cocaine and heroin/morphine were 80.7 and 34.7. (Note: These estimates were based on a representative sample of non-Federal, short-stay hospitals with 24-hour EDs in the coterminous U.S.)

The problem of DPP misuse that may be considered to be a form of addictive behavior among patients treated with opioids for acute or chronic pain has not been well studied. In one study of 144 consecutive patients referred to a treatment program for chronic nonmalignant pain, 35 (24%) were found to be drug-dependent, 59 (41%) drug abusers, and 50 (35%) nonabusers.<sup>89</sup> The definitions of drug abuse and drug dependence were based on modified criteria of the WHO, Feighner and associates', and DSM III. DPP was misused in 8 (14%) of 59 drug abusers and 6 (17%) of 35 drug-dependent patients. Codeine (23, 39% and 15, 43%, respectively) and oxycodone (12, 20% and 11, 31%, respectively) were most frequently misused. The findings are outdated, however, and may not necessarily reflect current opioid prescribing or usage patterns.

The prevalence of DPP and codeine use disorders was assessed in a single retrospective survey involving patients with orthopedic and chronic pain who were admitted to a Swedish hospital orthopedic ward for rehabilitation.<sup>11</sup>[QE = III] All 265 patients referred to the ward were interviewed using ADDIS (Alcohol Drug Diagnos Instrument) (Swe.), a Swedish version of SUDDS (Substance Use Disorder Diagnostic Schedule). The ADDIS/SUDDS instrument allowed the diagnosis of substance use disorders based on DSM-III-R criteria. ADDIS assessments were recoded into DSM-IV criteria (7 criteria of dependence) for comparisons with DSM-III-R (9 criteria of dependence). Of 243 patients who completed the survey, a total of 58 patients (22%) met DSM-III-R criteria for analgesic use disorders, and 49 patients (18.5%) met DSM-IV criteria. DPP was the most frequently prescribed analgesic in the study population (32% of 243) and was taken by 25 of 54 (47%) of the patients who met DSM-III-R criteria for analgesic use disorders as compared with 49 of 189 (26%) of patients with no analgesic use disorder ( $p = 0.003$  for the difference, Chi-square). [The reason for not using DSM-IV criteria for this assessment was not explained by the authors.] The corresponding figures for codeine were 10 (18%) and 17 (9%) ( $p = 0.06$  for the difference, Chi-square).

The interpretation of results on DPP abuse, dependency, and misuse are hampered by varying definitions for each of the drug use disorders among the studies.

#### ***9.1.1.4 SAEs associated with DPP dependency, misuse, or abuse***

Toxicologic and drug abuse data have identified a number of notable adverse reactions associated with DPP misuse. A random questionnaire survey of 5300 soldiers revealed that about 15% to 20% of the 180,000 American soldiers stationed in West Germany in the fall of 1970 (prior to instituting restrictions on DPP use as a narcotic in that country) used DPP orally, subcutaneously, or intravenously at least once for nonmedical reasons.<sup>86</sup> There were 13 reported deaths, each of which was preceded by seizures and occurred within 30 to 45 minutes after oral ingestion of DPP HCl in doses ranging from 1300 to 1950 mg (24 to 32 mg/kg of body weight). Other important medical complications were seizures, respiratory depression or arrest, phlebitis (with intravenous use), and

---

day. The survey does not measure prevalence of drug use in the population, but is intended to collect data on ED episodes that are induced by or related to the use of an illegal drug or the nonmedical use of a legal drug. Drug Abuse is defined as the nonmedical use of a drug for any of the following reasons: psychic effect, dependence, or suicide attempt/gesture. A Drug-Related Episode, or drug episode, is an ED visit that was induced by or related to the use of an illegal drug(s) or the nonmedical use of a legal drug for patients age 6 years and older. A Drug Mention refers to a substance that was mentioned during a drug-related ED episode (up to 4 drugs can be reported for each drug abuse episode).

withdrawal symptoms. Psychiatric complications, including disorientation, delusions, hallucinations, and extreme confusion were also noted. Further information on DPP misuse and abuse in the context of overdose and poisoning can be found in Section 9.1.1.5.

The frequency of seizures associated with DPP abuse can be high. In a retrospective, noncontrolled review of the records of patients admitted to the Detoxification Unit in the Mental Health Institute in Mexicali, Mexico from March to December 1988, 53% of 73 patients (median age: 26 years, 97% males) had confirmed, generalized seizures while intoxicated from oral DPP abuse.<sup>90</sup> All except one of these patients had no history of seizures prior to DPP abuse. The average daily dose of DPP was 1365 mg (range: 195 to 3575 mg) and most patients had abused DPP for at least 4 continuous years. All patients had a diagnosis of DPP dependence according to DSM-III-R criteria. Note that the lower end of the dosage range among the abusers was only slightly greater than a standard therapeutic dose of DPP (195 mg, equivalent to three 65-mg capsules). The dosage range of DPP among the patients who developed seizures was not reported and, therefore, it is not known whether the 195-mg dose was associated with seizures. A similar, high frequency of seizures among DPP abusers has not been reported elsewhere.

#### **9.1.1.5 Overdose and Poisoning**

The symptoms characteristic of overdoses involving DPP, alone or in combination with alcohol or other central nervous system (CNS) depressants, are similar to those of other opioids. They include respiratory depression, central nervous system depression, and miosis, all of which are reversible by naloxone. Psychotic reactions have also been reported.<sup>86</sup> The symptomatology and time course of codeine, hydrocodone, and oxycodone overdoses have not been documented as extensively as they have been for DPP.

In addition to the typical signs of opioid toxicity, however, DPP may cause seizures, wide QRS complexes, bradycardia, and cardiac arrhythmias.<sup>4, 86, 91, 92</sup> These complications are probably at least partly due to the neurotoxic effects of DPP and the membrane-stabilizing, quinidine-like<sup>39-41</sup> or possibly non-sedating histamine-like<sup>42</sup> cardiotoxic effects of DPP and NPP. The cardiotoxic effects are not reversible with naloxone.

Pulmonary edema has been reported to occur after DPP overdose.<sup>93-97</sup> Other opioids have also been associated with pulmonary edema following overdose, including codeine<sup>98</sup>, morphine<sup>99</sup>, heroin<sup>97, 100-104</sup>, fentanyl<sup>105</sup>, oxycodone<sup>106</sup>, and methadone<sup>107-114</sup>.

The mechanism of pulmonary edema is unclear. Typically, physical findings are consistent with a noncardiogenic etiology. Hypoxia, additive negative inotropic effects of DPP and NPP,<sup>40</sup> and pulmonary venoconstriction due to histamine release<sup>115</sup> may all be at least partly causally related. On autopsy, pulmonary edema is a frequent and nonspecific finding attributed to terminal hypoxia following overdose.<sup>4, 86, 96, 97</sup> The literature search did not identify any reports of pulmonary edema occurring with therapeutic use of DPP.

DPP overdoses are remarkable for the rapidity with which cardiopulmonary arrest, seizures, coma, or death can occur. Victims have collapsed within an hour, sometimes in as little as 15 minutes, after ingestion.<sup>86</sup> Therefore, profound pharmacologic effects occur during the absorption and distribution phases for the drug. In a U.K. study of deaths due to DPP over a 3-year period, 31 (91%) of 35 victims died before effective medical care could be given.<sup>82</sup> The co-ingestion of alcohol or other CNS depressants seems to be associated with rapid onset of DPP poisoning and death.<sup>116</sup>

Also remarkable is the observation that relatively small overdoses (6 to 20 tablets) may be lethal especially in combination with other CNS depressants.<sup>82, 92, 117</sup> Even a therapeutic dose (2 tablets) combined with alcohol has been fatal (also see Section 9.1.1.1.1).<sup>82</sup>

Finkle, *et al.*<sup>4</sup> noted there was an overlap between postmortem DPP blood concentrations (ranging from less than 0.1 to greater than 20 µg/ml; median: 3 to 4 µg/ml; mode: 1 to 2 µg/ml)<sup>a</sup> and plasma concentrations obtained by therapeutic doses (0.2 to 0.3 µg/ml) or doses only moderately above the usual recommended dose in healthy volunteers. Blood DPP concentrations have been reported to be 0.13 to 0.21 µg/ml after single doses of DPP 130 mg or 195 mg of the HCl salt (n = 8); and 0.8 µg/ml after 13 consecutive doses of DPP 130 mg every 8 hours (n = 1).<sup>33, 35</sup> The postmortem DPP concentrations also overlap with steady-state blood concentrations that have been observed in tolerant patients (0.42 to 0.57 µg/ml after ingestion of 900 to 1200 mg/d for 4 to 16 weeks [n = 3],<sup>33</sup> and 2 µg/ml after ingestion of 1200 mg daily for two weeks<sup>4</sup>. It has been suggested that tolerance to DPP may be overcome when DPP is ingested in large, single doses, resulting in toxicity or death.

Of 143 cases found to have postmortem DPP concentrations < 1 µg/ml, 14 (9.8%) were categorized as ingestions of DPP alone and 129 (90.2%) as ingestions of DPP plus another drug or alcohol. None of the cases categorized as ingestions of DPP alone had concentrations less than 0.2 µg/ml, and 3 cases (2%) had concentrations of 0.2 to 0.3 µg/ml, which overlap with blood drug concentrations observed after therapeutic doses of DPP. The number of cases involving DPP alone was too small to draw firm conclusions. The subpopulation of cases with low DPP concentrations (< 1 µg/ml) was considered to probably represent multiple-drug ingestions.

Fatal poisoning cases involving “low” concentrations of DPP resulting from ingestion of a DPP + APAP combination product in the U.K. were examined in more detail because of anecdotal reports that even small quantities of DPP may be fatal.<sup>116</sup> Nine of 1456 cases (0.6%) involved DPP concentrations < 1.0 µg/ml and no alcohol or other drugs. Results were inconclusive. Wide variability between DPP concentrations for particular APAP levels was noted.

The CNS and respiratory depressant effects of DPP are increased by alcohol and other CNS depressants.<sup>82, 118, 119</sup> Postmortem DPP blood concentrations have been found to be statistically significantly lower when alcohol was co-ingested with DPP + APAP (mean DPP concentration: 1.7 µg/ml; range: 0.2 to 8.5 µg/ml; n = 27) than in cases where DPP + APAP only were detected (mean: 6.2 µg/ml; range: 0.2 to 77 µg/ml; n = 48; p < 0.01, Mann-Whitney *U* test).<sup>82</sup> Finkle, *et al.* found that co-ingestion of alcohol or other drugs occurred in 90.2% of 143 cases in which fatal DPP blood concentrations were very low (1 µg/ml or less), and 50% of these cases involved BACs greater than 0.22% (mean: 0.20%).<sup>4</sup> In addition to additive or potentiated pharmacologic effects of DPP and alcohol, alcohol may increase DPP blood concentrations via a pharmacokinetic interaction (see Section 9.4).

Notably, DPP abuse (16 of 1022 cases, 1.6%) was rarely seen among the patients who died from DPP overdose in the U.S between 1972 and 1975.<sup>4</sup> On the contrary, there were “definite tendencies” to overuse DPP. Abuse or misuse of alcohol or drugs, alone or in combination, was common, occurring in 350 (34.2%) of the cases; a history of drug misuse was present in 175 cases (17.1%). The majority (82%) of the deceased had psychiatric or “emotional problems.” The manner of death was categorized as suicide in 468 cases (45.8%), but a substantial number (267 cases, 26.1%) was categorized as accidental. Additional information on this study is summarized in Appendix 4. These findings were confirmed in subsequent surveys covering the periods 1976 to 1978 and 1969 to mid-1983.<sup>120, 121</sup>

The characteristics of the deceased and method of overdose with DPP poisoning have been noted to differ from those of codeine poisoning, in which drug addiction, street drug abuse, and accidental deaths were more common among the deceased.<sup>122</sup>

---

<sup>a</sup> Postmortem blood concentrations of DPP were measured by gas chromatography (GC) and/or ultraviolet (UV) analysis with almost twice as many cases using GC as UV. The GC analysis detected DPP only (sensitivity, 0.1 µg/ml) The UV analyses measured both DPP and NPP concentrations (sensitivity, 0.5 to 1.0 µg/ml).

Early animal studies comparing the two salts of DPP found DPP napsylate to be markedly less toxic than the HCl salt.<sup>38</sup> These interesting results have not been confirmed in humans, and DPP-related fatalities have involved both salt types.

#### 9.1.1.5.1 Mortality rates in DPP overdoses

There is limited published information on the mortality rate associated with DPP overdoses relative to other opioids. The best comparative data on mortality comes from a retrospective, Danish study published 14 years ago. This study included 1423 consecutive patients admitted to an intensive care unit on 1558 occasions between 1975 and 1980 because of severe self-poisonings.<sup>123</sup> The main drug classes (and corresponding number of patients) were barbiturates (438), tricyclic antidepressants (302), DPP (212), tranquilizers (127), neuroleptics (116), salicylate (82), other hypnotics (61), strong analgesics (58), and others (162). The highest rates of death due to the acute self-poisoning were seen with salicylates (11%), DPP (9%), and strong analgesics (9%). These deaths reflect those of severe self-poisonings admitted to an intensive care unit and do not apply to all cases of self-poisoning for any individual agent, particularly given that many DPP-related fatalities occur prior to hospital admission.<sup>4, 82</sup>

##### 9.1.1.5.1.1 AAPCC TESS SAE data

The 1999 Toxic Exposure Surveillance System (TESS) data compiled by the American Association of Poison Control Centers (AAPCC) reflects over 2.2 million human exposure cases reported by 64 participating poison centers—an estimated 95.7% of human poison exposures that prompted poison center calls in 1999.<sup>124</sup> Most of the reported exposures occurred in children or adults less than 20 years old (66.8%). Of the 722,243 (32.8%) exposures in adults aged 20 to 99 years or of unknown adult age, more than half occurred in women (58.3%). A summary of the major and fatal medical outcomes from exposures to selected opioid and non-opioid analgesics is presented in Table 9. An expanded summary that also shows no, minor, and moderate outcomes is presented in Appendix Table 6.

A major medical outcome was defined as one where the patient exhibited signs or symptoms as a result of the exposure that were life-threatening or resulted in significant residual disability or disfigurement. Death as a medical outcome category included instances where the patient died as a result of the exposure or as a direct complication of the exposure. Only those deaths that were probably or undoubtedly related to the exposure were coded.

During 1999, exposures to DPP alone were associated with the second highest rate of major medical outcomes (33 of 560 exposures, 5.9%) and the highest rate of death (12, 2.1%) among 24 selected opioid and non-opioid analgesic drug or drug class exposures reported by the 64 participating poison control centers (Table 9). Among the 16 specified drug exposures (excluding “other/unknown” categories), DPP was associated with the highest death rate. These figures were similar to those for the previous year (1998, not presented in Table 9), which showed that DPP alone had the second highest rate of major medical outcomes (38 of 581 exposures, 6.5%) and the highest rate of death (10 of 581 exposures, 1.7%) among the narcotic exposures reported by 65 participating poison control centers.

As shown in Table 9, the rate of major outcomes for the combined total for all DPP-containing analgesics (DPP alone, DPP + APAP, and DPP + ASA) was 4.0%, the fourth highest of the opioids after methadone (with the highest rate, 11.2%), morphine (5.0%), and meperidine (4.2%). In comparison, the rates were 2.9% and 1.8% for oxycodone and codeine, respectively.

**Table 9 Major medical outcomes and deaths associated with selected analgesic exposures by drug class in decreasing order of major outcome frequency (%): 1999 AAPCC TESS data**

Agent implicated in exposure	No. of Exposures	% of all analgesic exposures (N = 214,066)	Outcome			
			Major		Death	
			No.	%	No.	%
<b>Opioids</b>						
Methadone	1047	0.5%	117	11.2%	17	1.6%
<b>D-propoxyphene</b>	560	0.3%	33	5.9%	12	2.1%
Morphine	1218	0.6%	61	5.0%	10	0.8%
Oxycodone	1632	0.8%	71	4.4%	12	0.7%
Meperidine	600	0.3%	25	4.2%	2	0.3%
Pentazocine	204	0.1%	7	3.4%	0	0.0%
Codeine	1258	0.6%	16	1.3%	3	0.2%
Other/unknown narcotic	3267	1.5%	159	4.9%	44	1.3%
<b>Acetaminophen + opioid combinations</b>						
Acetaminophen + <b>d-propoxyphene</b>	5120	2.4%	193	3.8%	18	0.4%
Acetaminophen + Oxycodone	3553	1.7%	81	2.3%	15	0.4%
Acetaminophen + Codeine	5741	2.7%	98	1.7%	3	0.1%
Acetaminophen + Other narcotics	11,626	5.4%	320	2.8%	40	0.3%
<b>Aspirin + opioid combinations</b>						
Aspirin + Codeine	353	0.2%	18	5.1%	1	0.3%
Aspirin + <b>d-propoxyphene</b>	41	0.0%	2	4.9%	0	0.0%
Aspirin + Oxycodone	234	0.1%	5	2.1%	2	0.9%
Aspirin + Other narcotics	33	0.0%	1	3.0%	1	3.0%
<b>NSAIDs / Acetaminophen</b>						
Acetaminophen alone, adult formulations	25,978	12.1%	457	1.8%	38	0.1%
Acetaminophen alone, unknown formulations	8963	4.2%	261	2.9%	47	0.5%
Aspirin alone, adult formulations	4022	1.9%	38	0.9%	7	0.2%
Aspirin alone, unknown formulations	9350	4.4%	213	2.3%	38	0.4%
Indomethacin	682	0.3%	4	0.6%	0	0.0%
Ibuprofen	54,643	25.5%	105	0.2%	3	0.0%
Nonaspirin salicylates	1065	0.5%	5	0.5%	0	0.0%
Other NSAID	18,181	8.5%	115	0.6%	3	0.0%
<b>Combined totals</b>						
All DPP-containing agents	5721	2.7%	228	4.0%	30	0.5%
All codeine-containing agents	7352	3.4%	132	1.8%	7	0.1%
All oxycodone-containing agents	5419	2.5%	157	2.9%	29	0.5%

Adapted from Litovitz, *et al.*<sup>124</sup>

AAPCC TESS = American Association of Poison Control Centers Toxic Exposure Surveillance System

Medical outcome categories were defined as follows: *Major*—The patient exhibited signs or symptoms as a result of the exposure that were life-threatening or resulted in significant residual disability or disfigurement. *Death*—The patient died as a result of the exposure or as a direct complication of the exposure. Only those deaths that were probably or undoubtedly related to the exposure were coded here.

The rates of deaths for the combined totals of DPP-containing analgesics and of oxycodone-containing analgesics were both 0.5%. In comparison, the rate of death was 0.1% for all codeine-containing analgesics.

Ibuprofen had the lowest rate of major outcomes (0.2%) and was associated with only 3 deaths while also having the highest number of exposures (54,643).

Overall, exposures to all DPP-containing agents comprised a small proportion of the total analgesic exposures reported (5721 of 214,066 exposures, 2.7%). This rate was somewhat lower than that of all codeine-containing agents (7352, 3.4%) and similar to that of all oxycodone-containing agents (5419, 2.5%). In comparison, 25.5% of all analgesic exposures involved ibuprofen and 12.1% involved adult formulations of acetaminophen alone.

The majority of the 1999 exposures to DPP alone (416 of 560 exposures, 74.3%), DPP in combination with APAP (3611 of 5120, 70.5%), or DPP + ASA (27 of 41, 65.8%) occurred in persons over 19 years of age (no further adult age classifications were provided). The reason for exposure was considered to be intentional (suicidal, misuse, abuse, or unknown motive) in most exposures to DPP alone (325 of 560 exposures, 58.0%) and DPP + APAP (3024 of 5120 exposures, 59.0%). Most exposures to DPP + ASA were classified as unintentional (includes, among others, general/not specified, therapeutic error, and unintentional misuse; 21 of 41 exposures, 51.2%) or intentional (17 exposures, 41.4%). *Unintentional misuse* was defined as unintentional (unplanned or unforeseen) improper or incorrect use of a nonpharmaceutical substance. *Intentional misuse* referred to the intentional improper or incorrect use of a substance for reasons other than to experience psychotropic effects. *Intentional abuse* included the intentional improper or incorrect use of a substance where the victim was likely to be pursuing euphoric or psychotropic effects.

The 1999 AAPCC TESS data suggests that exposures to DPP-containing agents is less common than exposures to ibuprofen or adult formulations of APAP alone. Most exposures to DPP-containing agents are intentional, due to suicide attempt, misuse, or abuse. Poison exposures to DPP-containing agents seem to be similar or slightly more toxic than those for oxycodone- and codeine-containing agents in terms of major and fatal outcomes, but DPP alone seems to be more toxic than most or all of the other opioids reported.

These results are difficult to particularize to the veteran population in the U.S. because of differences in patient age, and possibly other, unreported patient characteristics, prescribing patterns, and socioeconomic conditions.

#### 9.1.1.5.1.2 DAWN data

The most recent and extensive information on mortality comes from annual DAWN surveys. DAWN medical examiner reports probably include data from veterans as all forensic deaths and deaths due to therapeutic misadventures are reported to the county coroner's office [R. Lowe, Director of Autopsy Services, Denver VAMC; verbal communication, 17 December 2000]. Unfortunately, it is impossible to identify veterans from the DAWN data (J. Ball, [jball@samhsa.gov], E-mail, 17 December 2000). There is no centralized or national database that can identify deaths specifically in veterans [M. Stover, Coroner of Douglas County, Colorado; verbal communication, 17 December 2000].

The most recent (1998) DAWN annual medical examiner data showed that DPP (423 mentions, 4.2% of 10,123 medical examiner drug abuse deaths) ranked as the third most frequently mentioned prescription narcotic analgesic in drug abuse deaths reported by medical examiners participating in DAWN (Table 10).<sup>125</sup> Codeine (1240 mentions, 12.3%) ranked highest and methadone (560 mentions, 5.5%) was second. Based on data collected from a consistent panel of medical examiners between 1997 and 1998, large increases in mentions of oxycodone (93%) and methadone (13%) occurred, while a smaller increase was seen for DPP (5%) and a small decrease occurred with codeine (-3%).

**Table 10 Number (%) of drug abuse deaths for narcotic and non-narcotic analgesic drugs mentioned most frequently by medical examiners: 1998**

Drug name/category as reported	No. of weighted mentions, ME	Percentage (%) of total ME drug episodes <sup>†</sup>
Codeine	1240	12.3
Fentanyl	60	0.6
Meperidine HCl (Demerol)	66	0.7
Methadone	560	5.5
D-propoxyphene (Darvocet N, Darvon)	423	4.2
Heroin/morphine <sup>‡</sup>	4330	42.8
Hydromorphone (Dilaudid)	32	0.3
Oxycodone (Percocet 5, Percodan, Tylox)	169	1.7
Hydrocodone	339	3.4
Acetaminophen with codeine (Tylenol [sic]) <sup>§</sup>	80	0.8
Acetaminophen (Tylenol)	401	4.0
Aspirin	101	1.0
Ibuprofen	31	0.3
Naproxen (Naprosyn)	11	0.1
Dihydrocodeine	19	0.2
Oxymorphones	10	0.1

Adapted from Drug Abuse Warning Network Annual Medical Examiner Data 1998.<sup>126</sup>

Excludes adjunctive analgesic agents, such as antidepressants and antiepileptics, and local anesthetics. Excludes data on homicides, deaths in which AIDS was reported, and deaths in which "drug unknown" was the only substance.

ME = Medical examiner

<sup>†</sup> Percentages are based on a total raw medical examiner drug abuse case count of 10,123.

<sup>‡</sup> Heroin and morphine were treated as a single drug because heroin is metabolized to morphine.

<sup>§</sup> Represents mentions of acetaminophen (Tylenol) and codeine reported in combination in episodes involving 2 or more drugs.

The majority of drug abuse deaths reported by participating medical examiners in 1998 were drug-induced (overdoses, 65%) and involved more than one drug (75%). DPP (341, 4.8%) ranked as the eighth most frequently mentioned drug among 7071 decedents aged 35 years and older, and was among the top 12 drugs mentioned for either white (360, 5.8% of 6179) or Hispanic (19, 1.9% of 1004) decedents (DPP was not among the top 15 drugs mentioned among 2708 cases involving black decedents). DPP was mentioned in a greater proportion of drug abuse deaths involving women (195, 7.4% of 2644) than men (225, 3.0% of 7440). The three drugs most frequently mentioned in combination with DPP were alcohol (107 mentions), heroin/morphine (83 mentions), and APAP (78 mentions).

#### 9.1.1.6 AAPCC TESS adverse drug reaction data

The 1999 AAPCC TESS data included adverse [drug] reactions (ADRs) that had been reported to participating poison centers. An adverse [drug] reaction (ADR) was an AE that occurred with normal, prescribed, labeled, or recommended use of the product, as opposed to overdose, misuse, or abuse, and included unwanted effects due to an allergic, hypersensitive, or idiosyncratic response to the active ingredients, inactive ingredients, or excipients (excluding concomitant use of a contraindicated medication or food). The ADRs were not classified by seriousness and are presented in this report under SAEs because they resulted in a call to a poison center.

Interestingly, DPP alone or in combination with APAP had the lowest rate of reported ADRs among the opioids or APAP + opioid combinations, respectively (Table 11). Furthermore, all DPP-containing

agents had the lowest rate of ADRs (0.3%) of all the selected analgesics, opioid and non-opioid. ASA + DPP, however, had the highest rate of ADRs among the ASA + opioid combinations.

In contrast to the AAPCC TESS data on poison exposures to DPP-containing agents (which showed DPP to have a similar or slightly greater toxicity in comparison with oxycodone- and codeine-containing agents and less toxicity than stronger opioids in terms of major and fatal outcomes [see Section 9.1.1.5.1.1]), the therapeutic use of DPP-containing agents seems to be associated with a lower rate of ADRs reported by poison centers in comparison with all selected analgesics, opioid and non-opioid.



**Table 11 Number of adverse drug reactions reported by poison centers by analgesic class in decreasing order of frequency (%): 1999 AAPCC TESS data**

Substance implicated in exposure	No. of Exposures	No. of ADRs	%
<b>Opioids</b>			
Pentazocine	204	38	18.6%
Meperidine	600	82	13.7%
Oxycodone	1632	163	10.0%
Morphine	1218	100	8.2%
Methadone	1047	84	8.0%
Codeine	1258	89	7.1%
<i>D</i> -propoxyphene	560	35	6.3%
Other/unknown narcotic	3267	435	13.3%
<b>Acetaminophen + opioid combinations</b>			
Acetaminophen + oxycodone	3553	317	8.9%
Acetaminophen + codeine	5741	444	7.7%
Acetaminophen + <i>d</i> -propoxyphene	5120	223	4.4%
Acetaminophen + other narcotics	11,626	874	7.5%
<b>Aspirin + opioid combinations</b>			
Aspirin + <i>d</i> -propoxyphene	41	3	7.3%
Aspirin + oxycodone	234	15	6.4%
Aspirin + codeine	353	16	4.5%
Aspirin + other narcotics	33	1	3.0%
<b>NSAIDs / Acetaminophen</b>			
Acetaminophen only (adult formulations)	25,978	272	1.0%
Acetaminophen only, unknown formulations	8963	98	1.1%
Indomethacin	682	77	11.3%
Aspirin only (adult formulations)	4022	90	2.2%
Ibuprofen	54,643	854	1.6%
Nonaspirin salicylates	1065	41	3.8%
Other NSAIDs	18,181	1381	7.6%
<b>Combined totals</b>			
<b>All codeine</b>	<b>13,891</b>	<b>549</b>	<b>4.0%</b>
<b>All oxycodone</b>	<b>55,678</b>	<b>1559</b>	<b>2.8%</b>
<b>All <i>d</i>-propoxyphene</b>	<b>31,131</b>	<b>96</b>	<b>0.3%</b>

An adverse [drug] reaction (ADR) was an adverse event that occurred with normal, prescribed, labeled, or recommended use of the product, as opposed to overdose, misuse, or abuse, and included unwanted effects due to an allergic, hypersensitive, or idiosyncratic response to the active ingredients, inactive ingredients, or excipients (excluding concomitant use of a contraindicated medication or food).

### 9.1.2 Tolerability

In the acute pain, multiple-dose trial comparing DPP + APAP with NSAIDs or APAP by Evans, *et al.*, DPP + APAP was associated with the highest number of defaults (total of 17), where a default from the full regimen occurred if the patient took fewer than the prescribed number of tablets on any of the 6 non-clinic days for which that treatment was prescribed.<sup>1</sup> The second and third highest numbers of defaults were seen with indomethacin with 14 defaults and aspirin with 10 defaults. Most of the defaults with the three agents occurred because of adverse effects (13 of 17 with DPP + APAP; 14 of 14 with indomethacin; and 10 of 13 with aspirin). Phenylbutazone had the fewest defaults followed by mefenamic acid then APAP (6, 8, and 9 defaults, respectively).

Dropouts due to adverse events were three times higher with codeine + APAP (27 of 68 patients [39.7%]) than with DPP + APAP (9 of 68 patients [13.2%];  $p < 0.001$ ) in the RCT by Boissier, *et al.*<sup>49</sup>

## **9.2 Unpublished safety findings from VA data**

### **9.2.1 Adverse event data from VISN Polls**

A total of 17 VISNs reported AE data on DPP products while 7 VISNs provided AE data on products containing codeine, hydrocodone, or tramadol. In addition, 3 VISNs volunteered information on oxycodone products. There was a relatively high ratio of number of cases with at least one AE to number of VISNs reporting AEs (32:7) for codeine because of a large number of cases ( $n = 19$ ) reported by one VISN (#19).

The majority of the 66 reported AE cases involved codeine  $\pm$  APAP (32 cases) or DPP  $\pm$  APAP (26 cases) and were nonserious or of unclassified seriousness (Table 12).

One patient on DPP had a serious AE (increase in INR) apparently due to an interaction with warfarin. Another patient receiving codeine and penicillin developed anaphylaxis, which was suspected to be due to the penicillin.

Of the 55 AEs that were specified, the most common were allergic or allergic-like reactions such as rash, hives, itching, pruritus, welts, and watery eyes (Table 12). At least half of the nonserious or unclassified AEs specified in the reports for DPP- (8 of 13) or codeine- (6 of 12) containing products were allergic or allergic-like reactions. A total of 17 allergic or allergic-like AEs were reported in 11 cases with DPP, and 8 of the same type of AEs in 6 cases with codeine-containing products.

**Table 12 Summary of adverse events reported by VISNs (January 1999 to September 2000)**

Adverse events (AEs)	DPP	Codeine	Hydrocodone	Tramadol	Oxycodone <sup>†</sup>	Total
<b>No. of VISNs reporting</b>	<b>17</b>	<b>7</b>	<b>7</b>	<b>7</b>	<b>3</b>	<b>17</b>
<b>No. of cases with ≥ 1 AE</b>	<b>26</b>	<b>32</b>	<b>3</b>	<b>2</b>	<b>3</b>	<b>66</b>
Serious	1	1	—	—	—	2
Nonserious	14	19	2	1	—	36
Unclassified	11	12	1	1	3	28
<b>No. of AEs specified<sup>‡</sup> (No. of cases with ≥ 1 AE specified)</b>	<b>24 (22)</b>	<b>15 (12)</b>	<b>11 (3)</b>	<b>2 (2)</b>	<b>3 (2)</b>	<b>55 (41)</b>
<b>Serious AEs specified (n)</b>	<b>1 (1)</b>	<b>1 (1)</b>	<b>—</b>	<b>—</b>	<b>—</b>	<b>2 (2)</b>
Allergic / Allergic-like reaction	—	1 (1) <sup>§</sup>	—	—	—	1 (1)
Increased INR	1 (1) <sup>  </sup>	—	—	—	—	1 (1)
<b>Nonserious AEs specified (n)</b>	<b>15 (13)</b>	<b>3 (3)</b>	<b>7 (2)</b>	<b>1 (1)</b>	<b>—</b>	<b>26 (19)</b>
Allergic / Allergic-like reaction <sup>††</sup>	9 (7)	2 (2)	5 (2)	—	—	16 (11)
Nausea/vomiting, GI upset	1 (1)	—	1 (1)	—	—	2 (2)
Hallucinations	2 (2)	—	—	—	—	2 (2)
Dysphoria	1 (1)	—	—	—	—	1 (1)
Tachycardia	1 (1)	—	—	—	—	1 (1)
Urinary retention	1 (1)	—	—	—	—	1 (1)
Dysuria	—	1 (1)	—	—	—	1 (1)
Headache	—	—	1 (1)	—	—	1 (1)
Psychosis	—	—	—	1 (1)	—	1 (1)
<b>Unclassified AEs specified (n)</b>	<b>13 (8)</b>	<b>12 (9)</b>	<b>4 (1)</b>	<b>1 (1)</b>	<b>3 (2)</b>	<b>33 (21)</b>
Allergic / Allergic-like reaction <sup>††</sup>	8 (4)	6 (4)	4 (1)	—	2 (1)	20 (10)
Nausea/vomiting, GI upset	2 (1)	2 (1)	—	—	1 (1)	5 (3)
Constipation	1 (1)	2 (2)	—	1 (1)	—	4 (4)
Dizziness	1 (1)	—	—	—	—	1 (1)
Drowsiness	1 (1)	—	—	—	—	1 (1)
Dysuria	—	1 (1)	—	—	—	1 (1)
Hallucinations	—	1 (1)	—	—	—	1 (1)

<sup>†</sup> Oxycodone data was not requested; information shown was volunteered.

<sup>‡</sup> For any patient case, each event specified was counted as one AE, except for nausea / vomiting, which was counted as one AE.

<sup>§</sup> Anaphylaxis in patient on codeine and penicillin; reported by physician—suspected to be due to penicillin; patient was inpatient at the time.

<sup>||</sup> Patient appeared to have a drug-drug interaction between DPP and warfarin resulting in increased INR (international normalized ratio).

<sup>††</sup> Includes rash, hives, itching, pruritus, welts, watery eyes, or other allergic-like reactions. Other symptoms associated with allergic reaction such as nausea / vomiting and headache were categorized separately.

Causality and intensity of the AEs were available for 53 cases (Table 13).

**Table 13 Causality and intensity of AEs reported by VISNs**

	DPP	Codeine	Hydrocodone	Tramadol	Oxycodone	Total
<b>No. of cases</b>	<b>13</b>	<b>32</b>	<b>3</b>	<b>2</b>	<b>3</b>	<b>53</b>
<b>Causality</b>						
Unlikely	0	0	0	0	0	0
Possible	5	3	1	1	0	10
Probable	3	19	2	0	1	25
Not stated	5	10	0	1	2	18
<b>Intensity</b>						
Mild	7	22	2	0	0	31
Moderate	3	5	1	0	1	10
Severe	0	0	0	1 <sup>†</sup>	0	1
Not stated	3	5	0	1	2	11

<sup>†</sup> Psychosis (possible serotonin syndrome) of moderate to severe intensity; possible drug interaction as tramadol was added to fluoxetine therapy; nonserious.

All of the 53 cases with reported causality involved AEs possibly or probably related to treatment, and most were of mild (31 cases) or moderate (10 cases) intensity. Almost one-half (n = 25) of the cases had AEs considered to be probably related to the opioid, including 19 of 32 cases with AEs considered to be probably related to codeine. The majority (n = 31) of the cases had AEs rated as mild in intensity. One patient experienced an NSAE (psychosis, possible serotonin syndrome) that was rated as moderate to severe in intensity (shown as severe in Table 13). This NSAE was attributed to a possible drug interaction between tramadol and fluoxetine.

Comparisons between the rates of AEs associated with the different opioid agents were difficult because of the differences in number of VISNs providing data; variable, incomplete, or under-reporting; and the lack of valid denominators. It was unknown whether some patients were reported in more than one AE case.

### 9.2.2 MedWatch adverse drug experience data

Data on ADEs reported in 1999 by VA centers to MedWatch, the FDA's spontaneous postmarketing surveillance program, showed that DPP was the suspect drug associated with medication error and with noncompliance each in 1 of 2771 records (B. Bulinski, verbal communication, November 2000). In contrast, the number of reports in which morphine (28, 0.9%), fentanyl (19, 0.6%), codeine (14, 0.4%) or oxycodone (10, 0.3%) was a suspect drug in an ADE was higher. Details of the nature of the ADEs were not available.

Although the VA MedWatch data did not identify notable problems with DPP use, this type of data is subject to a number of limitations. The program was intended to identify unexpected problems with a drug, and not to register all adverse events related to drug products. It is estimated that only about 1% of all SAEs are reported to the FDA.<sup>127</sup> The number of ADEs reported to MedWatch are probably underestimated because of under-reporting by health professionals, and are subject to reporting bias. The data did not indicate whether there is or isn't a safety problem with DPP use in veterans.

### 9.2.3 Prevalence of opioid addiction among veterans

Confidential, unpublished, preliminary data was obtained on the rate of opioid addiction among veterans who were referred to the pain clinic of the Madison VAMC by primary care providers for failed treatment trials. Addiction was defined as increased pain and decreased function with opioid [dosage] escalation (GD Greany-Hudson [Geraldine.Greany-Hudson@med.va.gov], E-mail,

30 October 2000). Pain and function were measured before pain clinic evaluation and every 1 to 6 months at each pain clinic visit using the Multidimensional Pain Inventory and Brief Pain Inventory (BPI). Therapeutic interventions by the pain clinic (referred to here as “treatment”) included discontinuation or modification of analgesic drug therapy.

A total of 117 patients (109 males, 8 females; median age range: 40 to 50 years) who had mild to severe pain for periods ranging from less than 1 year to more than 50 years (median range: 10 to 20 years) were followed for 22 months (January 1999 to October 2000). The median score for average pain pre-treatment (N = 96) was 6 on a BPI scale of 0 (no pain) to 10 (pain as bad as you can imagine). Of the 117 patients followed, 4 (3.4%) had a mental health diagnosis of opioid addiction/dependence based on the single pre-treatment assessment (GD Greany-Hudson, written communication, November 2000). After a year, with repeated assessments, a specific pattern of drug-seeking behavior consistent with addiction was identified in 24 patients (20.5%). The drug seeking behavior seemed to be related mainly to patients’ attempts to mute emotions, to cope with depression, anxiety, or stress, and to escape from the fear of dealing with their pain—not to experience psychotropic effects (GD Greany-Hudson [Geraldine.Greany-Hudson@med.va.gov], E-mail, 30 October and 28 November 2000).

The opioids prescribed to the patients before and after drug therapy interventions by the pain clinic are shown in Table 14.

**Table 14 Number (%) of patients prescribed opioid analgesics in decreasing order of pre-treatment frequency (N = 117)**

Opioid	Pre-treatment		Post-treatment	
	n	%	n	%
Oxycodone	25	21.4	9	7.7
Oxycontin	18	15.4	26	22.2
Percocet	18	15.4	11	9.4
Morphine Contin	14	12.0	15	13.7
Fentanyl	10	8.6	9	7.7
Tylenol w/Codeine No. 3	9	7.7	6	5.1
Morphine Immediate Release	5	4.3	4	3.4
Propoxyphene	5	4.3	3	2.6
Tramadol	5	4.3	4	3.4
Vicodin	3	2.6	1	0.8
Hydromorphone	2	1.7	0	0.0
Methadone	1	0.8	5	4.3
Codeine	0	0.0	1	0.8

From GD Greany-Hudson, written communication, November 2000

Pre- and post-treatment refer to evaluations before and after pain clinic intervention(s), respectively; interventions included discontinuation or modification of analgesic drug therapy.

A patient may have been prescribed more than one type of opioid.

DPP was discontinued in 2 patients (opioids are usually discontinued because of ineffectiveness or adverse effects [GD Greany-Hudson, verbal communication, 30 November 2000]). Comparisons of addiction rates between DPP and the other opioid agents were not possible because of the small number of patients prescribed DPP. No patients took excessive doses of DPP and none of the patients on DPP had SAEs such as seizures or cardiac arrhythmias.

The present results are preliminary; further study is needed before definite conclusions can be made. Also, since this data reflects the population of patients referred to the pain clinic of the Madison VAMC from Wisconsin, Illinois, Iowa, and Minnesota, the findings may not be generalizable to veterans nationwide.

Supplementary information on the prevalence of mental conditions among veterans is presented in Appendix 5.

### 9.3 Summary of Safety

Based on published study results, standard therapeutic doses of DPP are generally well tolerated and seem to be associated with few SAEs<sup>19, 20, 45</sup>[3 QE: I], [26 RCTs, QE: 23 I, 3 II-1]. Based on limited data, DPP may be less tolerated than NSAIDs or APAP<sup>1</sup>[I], and more tolerated than codeine + APAP<sup>49</sup>[QE: I]. As a WHO Step 2 agent in the treatment of opioid-naïve cancer patients, DPP may be better tolerated than low-dose morphine in some patients<sup>14</sup>[QE: II-1]. There was no convincing evidence suggesting that single or multiple doses of DPP ± APAP was associated with a higher frequency of NSAEs than codeine ± APAP. Single doses of DPP + APAP cause dizziness less often than tramadol 100 mg<sup>20</sup>[QE: I].

Based on unpublished data on veterans, the most commonly reported NSAEs associated with DPP ± APAP and other “weak” opioids were allergic or allergic-like in nature.

Elderly patients (aged 65 years or older) treated with DPP may be at higher risk of developing hip fractures<sup>12</sup>[QE: II-2]. A similar increase in risk was also associated with codeine<sup>84</sup>[QE: II-2]. The results of these two studies contradict those of a more recent systematic review and meta-analysis (which did not include the two former studies) that found no increased risk of falls in older patients (> 60 years old) in association with narcotic analgesics<sup>83</sup>[QE: I]. The differences in results may be due to differences in inclusion criteria and targeted outcomes (hip fractures vs. falls).

Serious toxicity, including coma, respiratory depression, pulmonary edema, seizures, cardiac arrhythmias, and death, primarily occurred in patients with certain characteristics associated with intentional or unintentional overdose. The complications often occurred in patients who had a history of misuse (overuse) of DPP or other prescription drugs, who had psychiatric or emotional problems, and who co-ingested alcohol or other CNS depressants with moderate (6 to 20 capsules or tablets) or larger (suicidal) overdoses of DPP(N) ± APAP. The danger of the additive or potentiating effects on the toxicity of the combination of CNS depressants and DPP cannot be overemphasized. In an isolated case, co-ingestion of a sub-lethal quantity of alcohol with just 2 capsules of DPP resulted in death.<sup>82</sup>[QE: III] In a few cases, postmortem drug concentrations < 1 µg/ml suggested that deaths could have occurred after ingestion of therapeutic doses of propoxyphene alone, without co-ingestion of other CNS depressants or alcohol.<sup>4</sup>[QE: III] Because post-mortem DPP concentrations are highly variable, no conclusions can be made merely because therapeutic DPP concentrations are found in post-mortem blood. The development of SAEs is probably partly dependent on the individual’s level of opioid tolerance.<sup>44</sup>[QE: III]

In the case of poisonings, based on 1999 AAPCC TESS data, exposures to DPP alone and to any DPP-containing analgesics were associated with higher rates of major medical outcomes (5.9% and 4.0%, respectively) and of death (2.1% and 0.5%, respectively) relative to other, selected opioid and non-opioid analgesic drug or drug class exposures.<sup>124</sup>[QE: III]

Drug abuse-related deaths, however, seem to be more likely with codeine than with DPP or other opioids based on the most recent (1998) data on ME drug abuse deaths reported to DAWN.<sup>126</sup>[QE: III]

There is no convincing data that DPP is more addicting than other opioids. On the contrary, there is evidence suggesting that the addictive potential of DPP as a drug of abuse is less than that of codeine and other opioids<sup>2, 85</sup>[2 QE: III (reviews)]. Based on drug abuse-related episodes reported by EDs participating in DAWN in 1999, the rate of DPP abuse mentions (2.6) per 100,000 population was relatively low compared with that of cocaine (80.7) and heroin/morphine (34.7), and was lower than that of hydrocodone (6.0).<sup>88</sup>[QE: III]

The problem of DPP misuse that may be considered to be a form of addictive behavior among patients with acute or chronic pain has not been well reported, and recent U.S. studies comparing DPP with other opioids are lacking. Furthermore, data on the frequency of opioid addiction in veterans is limited.

Long-term trials of DPP for chronic pain are lacking; therefore, the long-term safety of therapeutic doses of DPP in comparison to other agents is unclear.

Overall, there is little safety data on DPP ± APAP use in veterans. It is unclear whether SAEs are not occurring in VA patients or are under-reported or under-recognized.

#### **9.4 Drug Interactions**

In healthy volunteers, **alcohol** has been shown to have no pharmacokinetic interaction or to increase the bioavailability of DPP by 25% to 31%, probably by decreasing its first-pass hepatic metabolism.<sup>128, 129</sup> Although the combination of DPP and alcohol has not been shown to potentiate the psychomotor depressant effects of either agent alone,<sup>128</sup> reductions in ventilatory function have been noted.<sup>130</sup>

Concomitant administration of DPP and **carbamazepine** has been found in a retrospective case-control study in elderly patients (mean age among four treatment groups: 75.3 to 76.9 years; N = 84) to result in statistically significant increases in serum concentrations of carbamazepine ( $p < 0.05$ ) and frequency of symptoms indicative of carbamazepine toxicity ( $p < 0.005$ ).<sup>131</sup> A number of case reports have also described carbamazepine toxicity resulting from an interaction with DPP.<sup>132-135</sup>

A drug interaction between DPP + APAP and **warfarin** has been reported to result in increased hypoprothrombinemia.<sup>136, 137</sup>

**Ritonavir**, a potent inhibitor of the CYP2D6 isoenzyme, is predicted to have a potential drug interaction with DPP,<sup>138</sup> however, the literature search found no clinical documentation of such an interaction in either pharmacokinetic studies or case reports. A similar interaction may also occur with hydrocodone, fentanyl, meperidine, methadone, oxycodone, and tramadol.<sup>138</sup>

**Tobacco** smoking has been shown to decrease the analgesic effects of DPP.<sup>139</sup>

#### **10 Cost-efficacy value**

No pharmacoeconomic study of DPP was found by the literature search.

The FSS drug costs of selected analgesics are shown in Table 15.

**Table 15 Lowest FSS costs of selected analgesics**

Product	FSS Cost / 100 <sup>†</sup>	5-d quantity	FSS Cost / 5 d
<b>Opioids</b>			
Codeine 30 mg + APAP 300 mg tab	\$5.14	15	\$0.77
Codeine 60 mg + APAP 300 mg tab	\$10.67	15	\$1.60
Codeine 60 mg + ASA 325 mg tab	\$11.93	15	\$1.79
Codeine sulfate 60 mg tab	\$37.45	15	\$5.62
Hydrocodone 5 mg + APAP 500 mg tab	\$1.54	15	\$0.23
Hydrocodone 7.5 mg + APAP 650 mg tab	\$3.84	15	\$0.58
Hydrocodone 7.5 mg + APAP 750 mg tab	\$5.00	15	\$0.75
Hydrocodone 5 mg + APAP 500 mg cap	\$5.78	15	\$0.87
Hydrocodone 7.5 mg + APAP 500 mg tab	\$4.97	15	\$0.75
Oxycodone 10 mg + APAP 650 mg	\$7.98	15	\$1.20
Propoxyphene HCl 65 mg cap	\$1.94	15	\$0.29
Propoxyphene N 100 mg + APAP 650 mg tab	\$3.79	15	\$0.57
Propoxyphene HCl 65 mg + APAP 650 mg tab	\$5.02	15	\$0.75
Propoxyphene N 100 mg tab	\$33.11	15	\$4.97
Tramadol HCl 50 mg tab	\$47.65	15	\$7.15
<b>Non-opioids</b>			
APAP 500 mg tab	\$0.47	15	\$0.07
APAP 650 mg tab	\$3.42	15	\$0.51
ASA 500 mg tab, EC	\$1.79	15	\$0.27
ASA 650 mg tab, EC	\$1.78	15	\$0.27
ASA 975 mg tab, EC	\$3.06	15	\$0.46
Diclofenac 50 mg tab, EC	\$2.73	15	\$0.41
Ibuprofen 200 mg tab	\$1.10	15	\$0.17
Ibuprofen 400 mg tab	\$1.18	15	\$0.18
Ketorolac 10 mg tab	\$19.00	15	\$2.85
Naproxen 500 mg tab	\$6.95	10	\$0.70
Piroxicam 20 mg cap	\$2.23	5	\$0.11

APAP = Acetaminophen; ASA = Aspirin; EC = Enteric coated; FSS = Federal supply schedule; N = Napsylate

<sup>†</sup> Lowest FSS price (as of 17 May 2001) was used when more than one product was available; non-unit dose formulations.

If single-dose efficacy is assumed to predict relative multiple-dose efficacy of the analgesics in acute pain (5-day) treatment, the following generalizations can be made about the cost-efficacy value of the analgesics (also refer to Table 6 and Table 7). Of the NSAIDs, standard daily doses of diclofenac 50 to 100 mg, ibuprofen 200 to 400 mg, piroxicam 20 mg, ASA 600 to 1200 mg, or APAP 500 to 1500 mg (cost range: \$0.11 to \$0.46) would be less or similar in cost than either DPP 130 mg (\$0.58) or DPP 65 mg + APAP 650 mg (\$0.75) while providing similar or superior analgesic efficacy. Of the opioids, codeine 60 mg + APAP 1000 (950) mg (\$1.60 + \$0.51 = \$2.11) or oxycodone 10 mg + APAP 650 mg (\$1.20) would be more expensive than DPP 130 mg (\$0.58) with similar efficacy, and more costly than and superior to DPP 65 mg + APAP 650 mg (\$0.75) or DPP 65 mg (\$0.29). Codeine 60 mg has the poorest value (high cost with lowest efficacy). DPP ± APAP preparations are less expensive and at least as effective as tramadol. Hydrocodone + APAP 5 + 500 mg and 7.5 + 650 mg tablets are similar in cost to DPP + APAP; however, the literature search found no clinical trials comparing the analgesic efficacy of these two agents. Therefore, switching to an NSAID, if possible, may decrease drug costs and provide similar or greater analgesic efficacy, while switching to another opioid may increase drug costs while providing similar efficacy.



## 11 Discussion

DPP ± APAP remains a relatively popular analgesic among non-veteran and veteran patients suffering from painful disorders despite more than a 30-year controversy about its therapeutic value. At least part of the reason for the ongoing controversy about the value of DPP as an analgesic may be due to differences among clinical trials in formulation; duration of therapy; pain intensity; cause or type of pain; trial design; method of pain assessment, and prescribed vs. actual dosing regimens (compliant vs. under- or over-compliant). Another issue to add to the controversy is that the results of the majority of the published RCTs were of doubtful validity and may not be completely applicable to the VA patient population because of differences in patient characteristics (see Section 8.1.3).

The majority of trials investigating the efficacy of DPP have involved single doses of drug. Single-dose trials are designed to demonstrate analgesic efficacy, but may not necessarily indicate how multiple doses of a drug will perform in terms of both efficacy and safety or tolerability. A similar disparity between single and repeated doses has been previously observed with oral morphine.<sup>140</sup> The pharmacokinetics of DPP (accumulation of DPP with multiple dosing due to its long half-life) may provide some rationale for claims of improved efficacy of multidose DPP in comparison with single-dose DPP.

The findings of this critical review of the published literature on DPP were generally supportive of the statement that DPP ± APAP was no better than NSAIDs or extra-strength APAP, with the exception of ASA 500 mg, which was significantly inferior. The best evidence addressing this issue was available from meta-analyses and systematic reviews of RCTs involving single-dose treatment with analgesics. DPP 65 mg (or DPPN 100 mg) in combination with APAP 650 mg was similar in efficacy to high-dose APAP (1000 mg) (see Table 6, Section 8.1.1).<sup>47</sup> DPP 65 mg alone had a higher NNT (indicating less efficacy) than DPP 65 mg + APAP 650 mg; however, a difference in efficacy was not detected (95% CIs overlapped).<sup>46</sup>

While the analgesic efficacy of DPP is often stated to be similar to that of extra-strength ASA or APAP, DPP differs from NSAIDs or APAP in pharmacologic and safety profiles. Depending on the patient's characteristics, these agents may not always be interchangeable. Comparisons between DPP ± APAP and other so-called weak opioid analgesics are probably more appropriate. In this respect, single doses of DPP ± APAP 65 mg + 650 mg are inferior to codeine 60 mg + APAP 1000 mg and to oxycodone 10 mg + APAP 650 mg (see Table 6, Section 8.1.1). The same dose of DPP + APAP is superior to codeine 60 mg alone and to tramadol 50 mg (95% CIs don't overlap).

As noted above, the results from single-dose trials may not apply to multiple doses of DPP in the treatment of either acute or chronic pain. Furthermore, the literature search did not find RCTs comparing multiple doses of DPP ± APAP with either APAP or aspirin in patients with chronic pain. Two RCTs found NSAIDs to be similar or superior to DPP ± APAP in analgesic efficacy.

In contrast to acute pain, the treatment of chronic pain may involve a trial of a number of different opioids alone or in combination with APAP or an NSAID before pain relief with acceptable tolerability is achieved. The three-step WHO analgesic ladder for treatment of cancer pain has been validated in a number of trials.<sup>141-144</sup> Although it has been suggested that there is no advantage in using weak opioids over strong opioids<sup>145, 146</sup>, adequate pain relief can be obtained in all three steps of the analgesic ladder.<sup>144</sup>

In combination with a step 1 agent (diclofenac), DPP may have a role as a WHO step 2 analgesic in opioid-naïve patients with chronic malignant pain; however, most patients eventually require a stronger opioid (morphine).<sup>14</sup>[II-1 B] The results of the RCT by Mercadante, *et al.* suggest that some opioid-naïve patients may tolerate DPP better than morphine CR and achieve adequate analgesia on the step 2 opioid. The practice of stepping down treatment from a step 3 agent (morphine) to a step 2 agent (DPP) instead of trying another step 3 agent in patients not tolerating the stronger opioid,

however, may benefit only a minority of patients. DPP has not been compared with other step 2 agents in studies evaluating the need for step 2 of the WHO analgesic ladder.

There have been no systematic studies evaluating the risk of developing serious complications from DPP in veterans. At standard therapeutic doses *in the majority of patients without certain characteristics associated with intentional or unintentional overdose*, DPP ± APAP seems to have an acceptable safety profile and has been seldom reported to be associated with SAEs. The more serious manifestations of toxicity, including coma, respiratory depression, pulmonary edema, seizures, cardiac arrhythmias, and death, have been reported to occur primarily after accidental or suicidal overdoses or in patients with certain characteristics. These characteristics are co-ingestion of alcohol or other CNS depressants, in particular benzodiazepines, tranquilizers, and other sedatives; DPP or other prescription drug misuse (overuse); alcohol or drug abuse or both; emotional problems; and self-destructive behavior (e.g., suicide attempts). “Emotional problems” is an undefined category that would be difficult to implement in a screening process to identify patients at risk for misusing DPP and consequently developing serious toxicity. It is unknown whether the use of another opioid agent in patients with these characteristics would be any safer than the use of DPP. Based on reports of overdose and poisoning, DPP appears to be more toxic than codeine and oxycodone, DPP toxicity is increased with the concomitant ingestion of alcohol or other CNS depressants, and even therapeutic misuse of DPP can be potentially fatal.

Of concern are Finkle’s documentation of a small number of postmortem blood DPP concentrations of 0.2 to 0.3 µg/ml that were taken from victims categorized as ingesting DPP alone.<sup>4</sup> These blood DPP concentrations overlap concentrations consistent with ingestion of therapeutic doses of DPP. More recent toxicokinetic studies of the postmortem redistribution of DPP in overdose victims have shown that blood concentrations of DPP may be highly variable, and site- and time-dependent.<sup>147</sup> Peripheral blood concentrations of DPP may be relatively low if absorption from the gastrointestinal tract was incomplete at the time of death. Since the site and timing of the blood samples in Finkle’s study were not specified, it remains speculative as to whether the postmortem blood concentrations reflected ingestion of therapeutic doses of DPP.

According to the findings of this literature review, elderly patients (≥ 65 years old) treated with DPP may be at higher risk of hip fractures. The risk was no different from that seen with codeine. Explicit criteria for inappropriate use of drugs in the elderly (> 65 years) have been reviewed by a panel of experts in geriatric care and pharmacology.<sup>148</sup> The concern regarding DPP was summarized as follows:

“Propoxyphene should generally be avoided in the elderly. It offers few analgesic advantages over acetaminophen, yet has the side effects of other narcotic drugs.”

Based on the panel’s review and consensus opinion, the concern was considered to be valid, independent of patient diagnoses. The use of DPP, however, was not believed to be associated with a high-severity adverse outcome, which was defined conceptually as a combination of both the likelihood that an adverse outcome would occur and the clinical significance of that outcome should it occur. As mentioned in the introduction (Section 2), the PBM-MAP felt that an order text message for prescribing DPP in elderly veterans was not warranted. Prescribing DPP in elderly veterans in the context of formulary considerations or criteria for drug use remains to be addressed.

The literature search found no studies evaluating DPP as a duplicate opioid prescription (e.g., a step 3 opioid and DPP) or the practice of prescribing DPP as a “narcotic placebo”. VA drug utilization records (January 1999 to December 2000) revealed that 6% of DPP prescriptions coincided with a second prescription for a more potent opioid analgesic.

The frequency of DPP dependency, misuse, or addiction among patients with chronic pain requires further study. Low frequencies of addiction have been found among morphine treated patients with cancer pain (1 of 550 patients, 0.2%)<sup>149</sup> and codeine or oxycodone treated patients with chronic

rheumatic disease pain (1 of 133 patients, 0.8%).<sup>150</sup> These figures are difficult to compare with those of Jonasson, *et al*, who reported the rate of analgesic use disorders in terms of the number of patients treated with DPP among patients who met DSM-III-R (22%) or DSM-IV (18.5%) criteria.

The lack of a standardized method of measuring pain treatment outcome hinders the comparison of different pain therapies. The National Pain Data Bank (NPDB), developed by the American Academy of Pain Management,<sup>151</sup> and the recent institution of a policy requiring systematic assessment of patients' pain intensity as a fifth vital sign among VA centers may provide valuable insight into the outcomes of pain interventions in the VA population.

## 12 Therapeutic role of DPP

Based on a critical review of the published literature, the therapeutic role of DPP can be summarized as follows:

- For treatment of acute post-operative pain of moderate to severe intensity, the NSAIDs (diclofenac, piroxicam, ibuprofen, or high-dose ASA) should be tried first.<sup>46</sup>[IA] Extra-strength or high-dose (600 to 1000 mg) APAP would be a reasonable alternative for patients in whom NSAIDs are contraindicated or not tolerated.<sup>19, 46</sup> [2 IA]. If APAP is ineffective, then codeine 60 + APAP 1000 mg or oxycodone 10 mg + APAP 650 mg could be used.<sup>46</sup>[IA] Patients who do not tolerate or have contraindications to codeine or oxycodone may be treated with DPP 130 mg or DPP 65 mg + APAP 650 mg.<sup>46</sup>[IA] If masking of fever is undesirable, then DPP 65 to 130 mg or codeine 60 mg alone may be used. If DPP ± APAP is ineffective, tramadol 75 to 150 mg may be tried.<sup>20, 46</sup> [2 IA]. It should be noted that these choices are based on single-dose studies.
- In multiple-dose studies of acute pain, NSAIDs seemed to have similar or greater efficacy in comparison with DPP ± APAP for mild to severe pain, and would be preferred for treatment of primary dysmenorrhea. Codeine ± APAP also seemed to have similar or greater efficacy relative to DPP ± APAP. The literature search found no RCTs comparing the efficacy of multiple-doses of DPP ± APAP with that of extra- or high-dose APAP alone in the treatment of acute pain. If the analgesic efficacy of single-dose analgesics is used as the basis for selecting multiple-dose analgesics, then it must be done with the understanding that the analgesic efficacy of the former may not accurately reflect that of the latter.
- There is insufficient data to make recommendations about choice of analgesic relative to DPP ± APAP for treatment of chronic pain. In the rare patient with mild to moderate chronic pain who has a documented allergy to codeine derivatives, or in whom masking fever is undesirable, DPP would be a reasonable alternative. In the treatment of patients with cancer pain, DPP may be considered in patients who are not tolerating other opioids. The decision to use DPP for management of chronic pain should be made after considering the expected low rate of successful long-term analgesia in the treatment of moderate to severe pain with a step 2 agent, and the lack of published data documenting long-term safety.
- In any case, the use of DPP ± APAP should be avoided or discontinued in patients with certain characteristics associated with intentional or unintentional overdose and development of serious DPP toxicity as described previously.
- Because the role of DPP is relegated to third- or fourth-line therapy, it is not recommended for inclusion on the VANF, and its nonformulary use should be restricted to patients who do not have the relevant characteristics associated with intentional or unintentional overdose, and who have failed or have contraindications to NSAIDs, APAP, or other opioids that have less favorable cost-efficacy.

### 13 Conclusion

In the majority of VA patients with mild to moderate acute pain and who do not have certain characteristics associated with intentional or unintentional overdose, single-dose or short-term therapy with DPP ± APAP probably provides adequate analgesia with an acceptable safety profile. The efficacy and safety of long-term therapy with DPP ± APAP for treatment of chronic pain has not been adequately studied.

In patients with certain characteristics associated with intentional or unintentional overdose, the potential for DPP toxicity probably outweighs the drug's potential analgesic benefit. Important safety issues that remain unclear are what is the frequency and risk of serious DPP toxicity among veterans with risk factors, and how does that risk compare with the risk associated with other opioids. Until these questions are answered, it seems prudent to restrict the use of DPP ± APAP to those veterans who do not have the particular characteristics associated with intentional or unintentional overdose and in whom NSAIDs, extra-strength or high-dose APAP, and other opioids are inadequate, intolerable, or contraindicated.

Based on single doses with similar analgesic efficacy in the treatment of postoperative pain, a number of NSAIDs offer better cost-efficacy value than DPP ± APAP. Codeine or oxycodone in combination with APAP are more expensive alternatives to DPP 130 mg alone and DPP 65 mg + APAP 650 mg.

## References

1. Evans DP, Burke MS, Newcombe RG. Medicines of choice in low back pain. *Curr Med Res Opin* 1980; 6:540-547.
2. Miller RR, Feingold A, Paxinos J. Propoxyphene hydrochloride. A critical review. *Jama* 1970; 213:996-1006.
3. McCarthy WH, Keenan RL. Propoxyphene hydrochloride poisoning: Report of the first fatality. *JAMA* 1964; 187:460-461.
4. Finkle BS, McCloskey KL, Kiplinger GF, Bennett IF. A national assessment of propoxyphene in postmortem medicolegal investigation, 1972-1975. *J Forensic Sci* 1976; 21:706-41.
5. Young RJ. Dextropropoxyphene overdose. Pharmacological considerations and clinical management. *Drugs* 1983; 26:70-9.
6. Soumerai SB, Avorn J, Gortmaker S, Hawley S. Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene. *Am J Public Health* 1987; 77:1518-23.
7. Shenfield GM, Jones AN, Paterson JW. Effect of restrictions on prescribing patterns for dextropropoxyphene. *Br Med J* 1980; 281:651-3.
8. 1999 National Pain Survey page. Ultram Web site. Available at: <http://www.ultram.com/painsurvey/introduction.htm>. Accessed 14 Sep 2000.
9. Pain and Older Americans Survey. O-M News Center page. Ortho-McNeil Web site. Available at: [http://www.ortho-mcneil.com/resources/reports/seniors\\_findings\\_bottom.html](http://www.ortho-mcneil.com/resources/reports/seniors_findings_bottom.html). Accessed 14 Sep 2000.
10. Joranson DE, Cleeland CS, Weissman DE, Gilson AM. Opioids for chronic cancer and non-cancer pain: A survey of state medical board members. Available at: <http://www.medsch.wisc.edu/painpolicy/publicat/92jmlido.htm>. Accessed 14 Sep 2000.
11. Jonasson U, Jonasson B, Wickstrom L, Andersson E, Saldeen T. Analgesic use disorders among orthopedic and chronic pain patients at a rehabilitation clinic. *Subst Use Misuse* 1998; 33:1375-85.
12. Guo Z, Wills P, Viitanen M, Fastbom J, Winblad B. Cognitive impairment, drug use, and the risk of hip fracture in persons over 75 years old: a community-based prospective study. *Am J Epidemiol* 1998; 148:887-92.
13. Hanks GW, Forbes K. Co-proxamol is effective in chronic pain [letter; comment]. *Bmj* 1998; 316:1980.
14. Mercadante S, Salvaggio L, Dardanoni G, Agnello A, Garofalo S. Dextropropoxyphene versus morphine in opioid-naive cancer patients with pain. *J Pain Symptom Manage* 1998; 15:76-81.
15. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation [see comments]. *JAMA* 1995; 274:1870-3.
16. Patt RB. Co-proxamol/propoxyphene: It is the wise doctor who listens to their patients (eLetter). *British Medical Journal* [serial online] 1998; 315:1565-1571. Available at: <http://www.bmj.com/cgi/eletters/315/7122/1565>. Accessed 24 July 2000.
17. Schwartz RK, Soumerai SB, Avorn J. Physician motivations for nonscientific drug prescribing. *Soc Sci Med* 1989; 28:577-82.

18. Anonymous. Drug Facts and Comparisons. In: TH B, ed. St. Louis: Facts and Comparisons® A Wolters Kluwer Co, 2000.
19. Po ALW, Zhang WY. Systematic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol. *BMJ* 1997; 315:1565-1571.
20. Collins SL, Edwards JE, Moore RA, McQuay HJ. Single-dose dextropropoxyphene, alone and with paracetamol (acetaminophen), for postoperative pain (Cochrane Review). The Cochrane Library. Vol. Issue 2. Oxford: Update Software, 2000.
21. Carpenter KJ, Chapman V, Dickenson AH. Neuronal inhibitory effects of methadone are predominantly opioid receptor mediated in the rat spinal cord in vivo. *Eur J Pain* 2000; 4:19-26.
22. Shimoyama N, Shimoyama M, Elliott KJ, Inturrisi CE. d-Methadone is antinociceptive in the rat formalin test. *J Pharmacol Exp Ther* 1997; 283:648-52.
23. Ebert B, Andersen S, Hjeds H, Dickenson AH. Dextropropoxyphene acts as a noncompetitive N-methyl-D-aspartate antagonist. *J Pain Symptom Manage* 1998; 15:269-74.
24. Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. *J Pharmacol Exp Ther* 1999; 289:1048-53.
25. Hewitt DJ. The use of NMDA-receptor antagonists in the treatment of chronic pain [In Process Citation]. *Clin J Pain* 2000; 16:S73-9.
26. Sang CN. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials [published erratum appears in *J Pain Symptom Manage* 2000 Mar;19(3):235]. *J Pain Symptom Manage* 2000; 19:S21-5.
27. Ebert B, Thorkildsen C, Andersen S, Christrup LL, Hjeds H. Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists. *Biochem Pharmacol* 1998; 56:553-9.
28. Gorman AL, Elliott KJ, Inturrisi CE. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. *Neurosci Lett* 1997; 223:5-8.
29. Du Pen S, DeRidder M, Du Pen A, Stanley K, Kim D. Cynergy Group Opioid Conversion Calculator; Cynergy Group Web site. Available at: <http://www.cynergygroup.com/cgi-bin/calc/Convert.asp>; December 2000, version 1.0M. Accessed 15 Dec 2000. 2000.
30. Forbes JA, Bates JA, Edquist IA, et al. Evaluation of two opioid-acetaminophen combinations and placebo in postoperative oral surgery pain. *Pharmacotherapy* 1994; 14:139-46.
31. Scott LJ, Perry CM. Tramadol: a review of its use in perioperative pain [In Process Citation]. *Drugs* 2000; 60:139-76.
32. Wolen RL, Ziege EA, Gruber CM, Jr. Determination of propoxyphene and norpropoxyphene by chemical ionization mass fragmentography. *Clin Pharmacol Ther* 1975; 17:15-20.
33. Inturrisi CE, Colburn WA, Verebey K, Dayton HE, Woody GE, O'Brien CP. Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene. *Clin Pharmacol Ther* 1982; 31:157-67.
34. Crome P, Gain R, Ghurye R, Flanagan RJ. Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in elderly hospital patients after single and multiple doses of distalgesic. Preliminary analysis of results. *Hum Toxicol* 1984; 3 Suppl:41S-48S.

35. Wolen RL, Gruber CM, Jr., Kiplinger GF, Scholz NE. Concentration of propoxyphene in human plasma following oral, intramuscular, and intravenous administration. *Toxicol Appl Pharmacol* 1971; 19:480-92.
36. Wolen RL, Gruber CM, Jr., Baptisti A, Jr., Scholz NE. The concentration of propoxyphene in the plasma and analgesia scores in postpartum patients. *Toxicol Appl Pharmacol* 1971; 19:498-503.
37. Baptisti A, Jr., Gruber CM, Jr., Santos EL. The effectiveness and side-effect liability of propoxyphene hydrochloride and propoxyphene napsylate in patients with postpartum uterine cramping. *Toxicol Appl Pharmacol* 1971; 19:519-27.
38. Emmerson JL, Gibson WR, Anderson RC. Acute toxicity of propoxyphene salts. *Toxicol Appl Pharmacol* 1971; 19:445-51.
39. Lund-Jacobsen H. Cardio-respiratory toxicity of propoxyphene and norpropoxyphene in conscious rabbits. *Acta Pharmacol Toxicol (Copenh)* 1978; 42:171-8.
40. Amsterdam EA, Rendig SV, Henderson GL, Mason DT. Depression of myocardial contractile function by propoxyphene and norpropoxyphene. *J Cardiovasc Pharmacol* 1981; 3:129-38.
41. Whitcomb DC, Gilliam FRd, Starmer CF, Grant AO. Marked QRS complex abnormalities and sodium channel blockade by propoxyphene reversed with lidocaine. *J Clin Invest* 1989; 84:1629-36.
42. Ulens C, Daenens P, Tytgat J. Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. *Cardiovasc Res* 1999; 44:568-78.
43. Wolen RL, Gruber CM, Jr., Kiplinger GF, Scholz NE. Concentration of propoxyphene in human plasma following repeated oral doses. *Toxicol Appl Pharmacol* 1971; 19:493-7.
44. Woody GE, McLellan AT, O'Brien CP, Tennant FS, Mintz J. Lack of toxicity of high dose propoxyphene napsylate when used for maintenance treatment of addiction. *Clin Toxicol* 1980; 16:473-8.
45. Moore RA, McQuay HJ. Single-patient data meta-analysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics. *Pain* 1997; 69:287-94.
46. Anonymous. The Oxford League Table of Analgesic Efficacy. The University of Oxford, Oxford Pain Internet Web site. Available at: [www.jr2.ox.ac.uk/bandolier/booth/painpag/Acutrev/Analgesics/lftab.html](http://www.jr2.ox.ac.uk/bandolier/booth/painpag/Acutrev/Analgesics/lftab.html). Accessed 1 May 2001, 1999.
47. Collins SL, Edwards JE, Moore RA, McQuay HJ. Single-dose dextropropoxyphene in post-operative pain: a quantitative systematic review. *Eur J Clin Pharmacol* 1998; 54:107-12.
48. Young RES. A two-dose evaluation of propoxyphene napsylate and codeine in postoperative pain. *Curr Ther Res* 1978; 24:495-502.
49. Boissier C, Perpoint B, Laporte-Simitsidis S, et al. Acceptability and efficacy of two associations of paracetamol with a central analgesic (dextropropoxyphene or codeine): Comparison in osteoarthritis. *J Clin Pharmacol* 1992; 32:990-995.
50. Anderson AB, Haynes PJ, Fraser IS, Turnbull AC. Trial of prostaglandin-synthetase inhibitors in primary dysmenorrhoea. *Lancet* 1978; 1:345-8.
51. Langrick AF, Gunn AD. A comparison of naproxen sodium and a dextropropoxyphene/paracetamol combination in the treatment of primary dysmenorrhoea in University Health Centres. *Br J Clin Pract* 1982; 36:181-4.

52. Cantor M. A comparison of propoxyphene HCl (Darvon) and an analgesic mixture (Percogesic) in pain relief after gingivectomy. *J Oral Ther Pharmacol* 1968; 4:224-228.
53. Buck ME, Paintin DB. Diflunisal in post-episiotomy pain: a preliminary report of a double-blind comparative study. *Curr Med Res Opin* 1978; 5:548-9.
54. Crighton IM, Hobbs GJ, Wrench IJ. Analgesia after day case laparoscopic sterilisation. A comparison of tramadol with paracetamol/dextropropoxyphene and paracetamol/codeine combinations. *Anaesthesia* 1997; 52:649-52.
55. Edmondson HD, Bradshaw AJ. Analgesia following oral surgery: a comparative study of Solpadeine and a soluble form of dextropropoxyphene napsylate and paracetamol. *J Int Med Res* 1983; 11:228-31.
56. Giles AD. Analgesia following dental surgery: a comparison of brufen and distalgesic. *Br J Oral Surg* 1981; 19:105-11.
57. Jaffé GV, Roylance PJ, Grimshaw JJ. A controlled study of diflunisal in sprains and strains. *Curr Med Res Opin* 1978; 5:584-588.
58. Rao SK, Sharma SK. The efficacy and safety of dolobid and distalgesic in post-traumatic pain and immobility. *Br J Clin Pract* 1982; 36:266-9, 285.
59. Sleet RA, Khan MA. Comparative study of mefenamic acid and dextropropoxyphene plus paracetamol in an accident and emergency department. *Curr Med Res Opin* 1980; 7:77-84.
60. Stableforth PG. Mefenamic acid and dextropropoxyphene with paracetamol as analgesics in the accident department. *Curr Med Res Opin* 1977; 5:189-191.
61. Williams AA, Backhouse CI. A general practice study of naproxen sodium and a dextropropoxyphene- paracetamol combination in primary dysmenorrhoea. *Br J Clin Pract* 1982; 36:383-5.
62. Beveridge K. Treatment of sports injuries with naproxen sodium and dextropropoxyphene napsylate. *Pharmatherapeutica* 1985; 4:393-8.
63. Jokl P, Warman M. A comparison of the efficacy and tolerability of diflunisal and dextropropoxyphene napsylate with acetaminophen in the management of mild to moderate pain after arthroscopy of the knee. *Clin Ther* 1989; 11:841-5.
64. Sagne S, Henrikson PA, Kahnberg KE, Thilander H, Bertilson SO. Analgesic efficacy and side-effect profile of paracetamol/codeine and paracetamol/dextropropoxyphene after surgical removal of a lower wisdom tooth. *J Int Med Res* 1987; 15:83-8.
65. MacKay IS, Ananian V. Analgesia following adult tonsillectomy: a comparative study of solpadeine and a soluble form of dextropropoxyphene napsylate and paracetamol. *J Int Med Res* 1982; 10:109-12.
66. Koo PJS. Pain. In: Young LY, Koda-Kimble MA, eds. *Applied Therapeutics: The Clinical Use of Drugs*. Vancouver: Applied Therapeutics, Inc., 1995:7-1 to 7-28.
67. Parr G, Darekar B, Fletcher A, Bulpitt C. Joint pain and quality of life: results of a randomised trial. *J Clin Pharmacol* 1989; 27:235-242.
68. Saarialho-Kere U, Julkunen H, Mattila MJ, Seppala T. Psychomotor performance of patients with rheumatoid arthritis: cross- over comparison of dextropropoxyphene, dextropropoxyphene plus amitriptyline, indomethacin, and placebo. *Pharmacol Toxicol* 1988; 63:286-92.



69. Lloyd RS, Costello F, Eves MJ, James IG, Miller AJ. The efficacy and tolerability of controlled-release dihydrocodeine tablets and combination dextropropoxyphene/paracetamol tablets in patients with severe osteoarthritis of the hips. *Curr Med Res Opin* 1992; 13:37-48.
70. Hanks GW, Justins DM. Cancer pain: management [see comments]. *Lancet* 1992; 339:1031-6.
71. Anonymous. Large Health Survey of Veterans: VHA, 1999:2-3 to 2-14.
72. Taenzer AH, Clark C, Curry CS. Gender affects report of pain and function after arthroscopic anterior cruciate ligament reconstruction. *Anesthesiology* 2000; 93:670-5.
73. Fillingim RB. Sex, Gender, and Pain: Women and Men Really Are Different. *Curr Rev Pain* 2000; 4:24-30.
74. Keefe FJ, Lefebvre JC, Egert JR, Affleck G, Sullivan MJ, Caldwell DS. The relationship of gender to pain, pain behavior, and disability in osteoarthritis patients: the role of catastrophizing. *Pain* 2000; 87:325-34.
75. Walker JS, Carmody JJ. Experimental pain in healthy human subjects: gender differences in nociception and in response to ibuprofen. *Anesth Analg* 1998; 86:1257-62.
76. Affleck G, Tennen H, Keefe FJ, et al. Everyday life with osteoarthritis or rheumatoid arthritis: independent effects of disease and gender on daily pain, mood, and coping. *Pain* 1999; 83:601-9.
77. Raftery KA, Smith-Coggins R, Chen AH. Gender-associated differences in emergency department pain management. *Ann Emerg Med* 1995; 26:414-21.
78. Vigano A, Bruera E, Suarez-Almazor ME. Age, pain intensity, and opioid dose in patients with advanced cancer. *Cancer* 1998; 83:1244-50.
79. Honari S, Patterson DR, Gibbons J, et al. Comparison of pain control medication in three age groups of elderly patients. *J Burn Care Rehabil* 1997; 18:500-4.
80. Kaiko RF. Age and morphine analgesia in cancer patients with postoperative pain. *Clin Pharmacol Ther* 1980; 28:823-6.
81. Mercadante S, Casuccio A, Genovese G. Ineffectiveness of dextromethorphan in cancer pain. *J Pain Symptom Manage* 1998; 16:317-22.
82. Whittington RM. Dextropropoxyphene deaths: coroner's report. *Hum Toxicol* 1984; 3 Suppl:175S-185S.
83. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. *J Am Geriatr Soc* 1999; 47:40-50.
84. Shorr RI, Griffin MR, Daugherty JR, Ray WA. Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene. *J Gerontol* 1992; 47:M111-5.
85. Lader M. Abuse of weak opioid analgesics. *Hum Toxicol* 1984; 3 Suppl:229S-236S.
86. Tennant FS, Jr. Complications of propoxyphene abuse. *Arch Intern Med* 1973; 132:191-4.
87. Collins GB, Kiefer KS. Propoxyphene dependence: an update. *Postgrad Med* 1981; 70:57-61.
88. Garfield T, Kissin W, Ball J. Year-end 1999 emergency department data from the Drug Abuse Warning Network. DAWN Series D-15, DHHS Publication No. (SMA) 00-3462, Published 8/2000 [publication online, SAMHSA Web site]. Available at: <http://www.samhsa.gov>. Accessed 14 Sep 2000. 2000.

89. Maruta T, Swanson DW, Finlayson RE. Drug abuse and dependency in patients with chronic pain. *Mayo Clin Proc* 1979; 54:241-4.
90. Ng B, Alvear M. Dextropropoxyphene addiction--a drug of primary abuse. *Am J Drug Alcohol Abuse* 1993; 19:153-8.
91. Sloth Madsen P, Strom J, Reiz S, Bredgaard Sorensen M. Acute propoxyphene self-poisoning in 222 consecutive patients. *Acta Anaesthesiol Scand* 1984; 28:661-5.
92. Young RJ, Lawson AA. Distalgesic poisoning--cause for concern. *Br Med J* 1980; 280:1045-7.
93. Bogartz LJ, Miller WC. Pulmonary edema associated with propoxyphene intoxication. *JAMA* 1971; 215:259-62.
94. Fisch HP, Wands J, Yeung J, Davis PJ. Pulmonary edema and disseminated intravascular coagulation after intravenous abuse of d-propoxyphene (darvon). *South Med J* 1972; 65:493-5.
95. Young DJ. Propoxyphene suicides. Report of nine cases. *Arch Intern Med* 1972; 129:62-6.
96. Henry LD, DiMaio VJ. Pulmonary edema and propoxyphene. *JAMA* 1971; 215:2115.
97. Hine CH, Wright JA, Allison DJ, Stephens BG, Pasi A. Analysis of fatalities from acute narcotism in a major urban area. *J Forensic Sci* 1982; 27:372-84.
98. Sklar J, Timms RM. Codeine-induced pulmonary edema. *Chest* 1977; 72:230-1.
99. Grellner W, Madea B, Sticht G. Pulmonary histopathology and survival period in morphine-involved deaths [see comments]. *J Forensic Sci* 1996; 41:433-7.
100. Chan P, Lin TH, Luo JP, Deng JF. Acute heroin intoxication with complications of acute pulmonary edema, acute renal failure, rhabdomyolysis and lumbosacral plexitis: a case report. *Chung Hua I Hsueh Tsa Chih (Taipei)* 1995; 55:397-400.
101. Paranthaman SK, Khan F. Acute cardiomyopathy with recurrent pulmonary edema and hypotension following heroin overdose. *Chest* 1976; 69:117-9.
102. Wang ML, Lin JL, Liaw SJ, Bullard MJ. Heroin lung: report of two cases. *J Formos Med Assoc* 1994; 93:170-2.
103. Webb DI. Heroin-induced pulmonary edema: a case report. *Mil Med* 1971; 136:292.
104. Lynch K, Greenbaum E, O'Loughlin BJ. Pulmonary edema in heroin overdose. *Radiology* 1970; 94:377-8.
105. Henderson GL. Fentanyl-related deaths: demographics, circumstances, and toxicology of 112 cases. *J Forensic Sci* 1991; 36:422-33.
106. Turturro MA, O'Toole KS. Oxycodone-induced pulmonary edema [letter]. *Am J Emerg Med* 1991; 9:201-3.
107. Karch SB, Stephens BG. Toxicology and pathology of deaths related to methadone: retrospective review [see comments]. *West J Med* 2000; 172:11-4.
108. Persky VW, Goldfrank LR. Methadone overdoses in a New York City hospital. *Jacep* 1976; 5:111-3.
109. Presant S, Knight L, Klassen G. Methadone-induced pulmonary edema. *Can Med Assoc J* 1975; 113:966-7.
110. Wilen SB, Ulreich S, Rabinowitz JG. Roentgenographic manifestations of methadone-induced pulmonary edema. *Radiology* 1975; 114:51-5.

111. Zyroff J, Slovis TL, Nagler J. Pulmonary edema induced by oral methadone. *Radiology* 1974; 112:567-8.
112. Johnson BA, James AE, Jr., Levey MS, Campbell HJ. Pulmonary edema caused by methadone. *Va Med Mon* 1974; 101:640-4.
113. Sokolowski JW, Jr. Case report. Methadone-induced pulmonary edema. *Clin Notes Respir Dis* 1974; 13:15-6.
114. Goldman AL, Enquist RW. Methadone pulmonary edema. *Chest* 1973; 63:275-6.
115. Hakim TS, Grunstein MM, Michel RP. Opiate action in the pulmonary circulation. *Pulm Pharmacol* 1992; 5:159-65.
116. Dwyer PS, Jones IF. Fatal self-poisoning in the UK and the paracetamol/dextropropoxyphene combination. *Hum Toxicol* 1984; 3 Suppl:145S-174S.
117. Whittington RM, Barclay AD. The epidemiology of dextropropoxyphene (Distalgesic) overdose fatalities in Birmingham and the West Midlands. *J Clin Hosp Pharm* 1981; 6:251-7.
118. Jonasson U, Jonasson B, Saldeen T. Middle-aged men--a risk category regarding fatal poisoning due to dextropropoxyphene and alcohol in combination. *Prev Med* 2000; 31:103-6.
119. Carson DJ. Fatal dextropropoxyphene poisoning in Northern Ireland. Review of 30 cases. *Lancet* 1977; 1:894-7.
120. Finkle BS. Self-poisoning with dextropropoxyphene and dextropropoxyphene compounds: the USA experience. *Hum Toxicol* 1984; 3 Suppl:115S-134S.
121. Finkle BS, Caplan YH, Garriott JC, Monforte JR, Shaw RF, Sonsalla PK. Propoxyphene in postmortem toxicology 1976-1978. *J Forensic Sci* 1981; 26:739-57.
122. Litman RE, Diller J, Nelson F. Deaths related to propoxyphene or codeine or both. *J Forensic Sci* 1983; 28:128-38.
123. Strom J, Thisted B, Krantz T, Bredgaard Sorensen M. Self-poisoning treated in an ICU: drug pattern, acute mortality and short-term survival. *Acta Anaesthesiol Scand* 1986; 30:148-53.
124. Litovitz TL, Klein-Schwartz W, White S, et al. 1999 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. *Am J Emerg Med* 2000; 18:517-74.
125. Golieb A. Drug Abuse Warning Network Annual Medical Examiner Data 1996. DAWN Series D-4, DHHS Publication No. (SMA) 98-3228, Published 7/1998[publication online, SAMHSA Web site]. Available at: <http://www.samhsa.gov/oas/DAWN>. Accessed 17 Dec 2000. 1998.
126. Kissin W, Garfield T, Ball J. Drug Abuse Warning Network annual medical examiner data 1998. SAMHSA Web site Available at: [www.samhsa.gov/oas/DAWN/98me\\_annualpdf](http://www.samhsa.gov/oas/DAWN/98me_annualpdf) Accessed 14 Sep 2000. 2000.
127. Kessler DA, et al. Introducing MedWatch. *J Clin Res Drug Dev* 1993; 269:183-190.
128. Girre C, Hirschhorn M, Bertaux L, et al. Enhancement of propoxyphene bioavailability by ethanol. Relation to psychomotor and cognitive function in healthy volunteers. *Eur J Clin Pharmacol* 1991; 41:147-52.
129. Sellers EM, Hamilton CA, Kaplan HL, Degani NC, Foltz RL. Pharmacokinetic interaction of propoxyphene with ethanol. *Br J Clin Pharmacol* 1985; 19:398-401.

130. Ali NA, Marshall RW, Allen EM, Graham DF, Richens A. Comparison of the effects of therapeutic doses of meptazinol and a dextropropoxyphene/paracetamol mixture alone and in combination with ethanol on ventilatory function and saccadic eye movements. *Br J Clin Pharmacol* 1985; 20:631-7.
131. Bergendal L, Friberg A, Schaffrath AM, Holmdahl M, Landahl S. The clinical relevance of the interaction between carbamazepine and dextropropoxyphene in elderly patients in Gothenburg, Sweden. *Eur J Clin Pharmacol* 1997; 53:203-6.
132. Oles KS, Mirza W, Penry JK. Catastrophic neurologic signs due to drug interaction: Tegretol and Darvon. *Surg Neurol* 1989; 32:144-51.
133. Yu YL, Huang CY, Chin D, Woo E, Chang CM. Interaction between carbamazepine and dextropropoxyphene. *Postgrad Med J* 1986; 62:231-3.
134. Kubacka RT, Ferrante JA. Carbamazepine-propoxyphene interaction [letter]. *Clin Pharm* 1983; 2:104.
135. Dam M, Kristensen CB, Hansen BS, Christiansen J. Interaction between carbamazepine and propoxyphene in man. *Acta Neurol Scand* 1977; 56:603-7.
136. Smith R, Prudden D, Hawkes C. Propoxyphene and warfarin interaction [letter]. *Drug Intell Clin Pharm* 1984; 18:822.
137. Jones RV. Letter: Warfarin and distalgesic interaction. *Br Med J* 1976; 1:460.
138. Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. *Pharmacotherapy* 1998; 18:84-112.
139. D'Arcy PF. Tobacco smoking and drugs: a clinically important interaction? *Drug Intell Clin Pharm* 1984; 18:302-7.
140. Hanks GW, Hoskin PJ, Aherne GW, Turner P, Poulain P. Explanation for potency of repeated oral doses of morphine? *Lancet* 1987; 2:723-5.
141. Grond S, Zech D, Schug SA, Lynch J, Lehmann KA. Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. *J Pain Symptom Manage* 1991; 6:411-22.
142. Grond S, Zech D, Lynch J, Diefenbach C, Schug SA, Lehmann KA. Validation of World Health Organization guidelines for pain relief in head and neck cancer. A prospective study. *Ann Otol Rhinol Laryngol* 1993; 102:342-8.
143. Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. *Cancer* 1987; 59:850-6.
144. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. *Pain* 1995; 63:65-76.
145. Ashby MA, Fleming BG, Brooksbank M, et al. Description of a mechanistic approach to pain management in advanced cancer. Preliminary report. *Pain* 1992; 51:153-61.
146. Regnard CF. Control of bleeding in advanced cancer [letter; comment]. *Lancet* 1991; 337:974.
147. Yonemitsu K, Pounder DJ. Postmortem toxico-kinetics of co-proxamol. *Int J Legal Med* 1992; 104:347-53.
148. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. *Arch Intern Med* 1997; 157:1531-6.

149. Schug SA, Zech D, Grond S, Jung H, Meuser T, Stobbe B. A long-term survey of morphine in cancer pain patients. *J Pain Symptom Manage* 1992; 7:259-66.
150. Ytterberg SR, Mahowald ML, Woods SR. Codeine and oxycodone use in patients with chronic rheumatic disease pain [see comments]. *Arthritis Rheum* 1998; 41:1603-12.
151. Clark ME, Gironda RJ. Concurrent Validity of the National Pain Data Bank: Preliminary Results. *American Journal of Pain Management* January 2000. Available at: <http://www.aapainmanage.org/aapm/Articles/NPDB/NPDBAssess1.html>. Accessed 14 Sep 2000.
152. How to find current best evidence. In: Parkinson M, ed. *Evidence-based Medicine*. Edinburgh: Churchill Livingstone, 2000.
153. AHFS. AHFS Drug Information. In: McEvoy GK, ed. Bethesda: American Society of Health-System Pharmacists, Inc., 2000.
154. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Therapy. In: Parkinson M, ed. *Evidence-based medicine*. Edinburgh: Churchill Livingstone, 2000:105-153.
155. O'Neill WM, Hanks GW, White L, Simpson P, Wesnes K. The cognitive and psychomotor effects of opioid analgesics. I. A randomized controlled trial of single doses of dextropropoxyphene, lorazepam and placebo in healthy subjects. *Eur J Clin Pharmacol* 1995; 48:447-53.
156. Edwards C, Gard PR, Handley SL, Hunter M, Whittington RM. Distalgesic and ethanol-impaired function [letter]. *Lancet* 1982; 2:384.
157. O'Neill WM, Hanks GW, Simpson P, Fallon MT, Jenkins E, Wesnes K. The cognitive and psychomotor effects of morphine in healthy subjects: a randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo. *Pain* 2000; 85:209-15.

## **Appendices**

## Appendix 1 Methods

Published reports of systematic reviews, meta-analyses, reviews, and randomized controlled trials on the efficacy and safety of propoxyphene were retrieved by a computerized literature search of the Medline (1966 to 2000) database. The search terms were *propoxyphene/\*therapeutic use* and *propoxyphene/\*administration and dosage*. These Medline articles were limited to English language, human subjects, meta-analyses, randomized controlled trials, and clinical trials.

The safety of propoxyphene was also searched on Medline (1966–2000) in all report types using the search terms *propoxyphene/\*adverse effects; propoxyphene; substance-related disorders; substance abuse, intravenous; substance abuse detection ; drug and narcotic control; substance withdrawal syndrome, drug interactions*, and *Drug Abuse Warning Network (DAWN)*, and the limiters English language and human subjects. For studies of prognosis, the search terms included *cohort studies, mortality, follow-up studies, prognosis, predict, and course*.<sup>152</sup> All subfiles on the Toxline database (1985–present) were searched using the search terms *propoxyphene* and *human* and excluded overlapping Medline articles. A search of the abstracts of the Cochrane Database of Systematic Reviews relating to propoxyphene was also performed. Additional articles were found from the reference list of articles found by the literature search.

Studies with active controls were preferred over those with only placebo controls. In order to make clinically feasible recommendations about possible alternative analgesic treatments, this evaluation included trials that compared propoxyphene to U.S. drug products. Reports that compared propoxyphene to only agents unavailable in the U.S. were excluded from this evaluation; however, articles involving foreign brand products that contained drug entities available in the U.S. were included.

In this report, the primary efficacy variable and primary efficacy evaluation were based on the efficacy variable used for a priori or retrospective power calculations or the first statistically analyzed evaluation of the patient's (not clinician's) assessment of analgesic efficacy that was presented in the results section.

For supplemental information, the Web sites of the Agency for Healthcare Research and Quality (AHRQ), National Institute for Clinical Excellence (NICE), Food and Drug Administration (FDA), European Medicines Evaluation Agency (EMA), DAWN, and World Health Organization (WHO) were also checked for pertinent reports, pharmacovigilance documents, or clinical guidelines regarding the use of DPP.

### Inclusion and exclusion criteria

Reports fulfilling the following criteria were **included**:

- Article published in a journal in hard copy or electronically in English language.
- Treatments consisted of drugs available in the U.S.
- For efficacy evaluations, randomized trials or meta-analyses and systematic reviews of randomized trials involving an active comparator treatment group. (Note: RCTs were included based on the best available evidence; i.e., for a given topic, individual RCTs were excluded if meta-analyses or systematic reviews were available). A randomized trial was considered to be one that was reported to be randomized by the author(s) even if the randomization technique was not specified.
- For safety evaluations, any reports providing safety data were included based on the best available evidence.

Reports fulfilling the following criteria were **excluded**:

- A non-random method was definitely used for treatment allocation. (No trials involving U.S. drugs met this exclusion criterion.)
- All comparator treatments consisted of drugs not available in the U.S. regardless of dosage formulation.
- Trial included children or teenagers (age less than 18 years).
- None of the treatment differences for analgesic efficacy were statistically analyzed.



## Appendix 2 Validity criteria and evidence rating scale

The validity of the results of the RCTs reviewed in this report were assessed using major and minor criteria as suggested by Sacket, *et al.*<sup>154</sup> Major criteria for validity were (1) randomization (and concealment) of treatment assignment; (2) complete and sufficient follow-up of patients; and (3) intent-to-treat (ITT) analysis (all patients were analyzed in the groups to which they were randomized). Minor validity criteria were (4) blinding to treatment; (5) equally treated groups (except in regards to experimental therapy); and (6) similar treatment groups at the start of the trial.

The quality of evidence and strength of recommendations were assessed using a rating scale based on the evidence rating system used by the U.S. Preventative Services Task Force<sup>a</sup> and adapted from the Canadian Task Force on the Periodic Health Examination (see Appendix Table 1).

**Appendix Table 1 Evidence Rating Scale**

---

<b>Quality of Evidence</b>	
I	Evidence obtained from at least one properly designed, randomized controlled trial.
II-1	Evidence obtained from well-designed controlled trials without randomization.
II-2	Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group.
II-3	Evidence obtained from multiple time series studies with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence.
III	Opinions of respected authorities, based on clinical experience; descriptive studies and case reports; or reports of expert committees.
<b>Strength of Recommendation</b>	
A	There is good evidence to support that the intervention be adopted.
B	There is fair evidence to support that the intervention be adopted.
C	There is insufficient evidence to recommend for or against the intervention, but recommendations may be made on other grounds.
D	There is fair evidence to support that the intervention be excluded.
E	There is good evidence to support that the intervention be excluded.

---

<sup>a</sup> (<http://text.nlm.nih.gov/cps/www/cps.3.html>)

### Appendix 3 Summary of trials

Overviews of study designs for both acute pain and chronic pain trials as well as nonserious adverse events are provided in this section. Summaries of the multiple-dose, acute pain trials evaluated in this review are presented in Appendix Table 2 and Appendix Table 3. A summary of the multiple-dose, chronic pain trials is provided in Appendix Table 4.

#### Overview of study designs: RCTs evaluating multiple-dose DPP ± APAP in acute pain

The acute pain trials differed in study design, patient characteristics, pain severity, type of pain, sample size, and treatment regimens. Fourteen of the multiple-dose, acute pain trials evaluated DPP HCl in combination with APAP (DPP + APAP),<sup>1, 49-51, 53-61, 64</sup> and two trials used DPPN+A.<sup>63, 65</sup> Three trials used either DPP<sup>52</sup> or DPPN alone.<sup>48, 62</sup> There was one open-label trial<sup>61</sup>; all others were single- or double-blinded investigations. Two trials used placebo controls in addition to active comparators.<sup>48, 53</sup>

Of the 19 RCTs, 14 used two treatment arms,<sup>49, 51, 52, 55-65</sup> 3 trials had 3 treatment arms,<sup>50, 53, 54</sup> 1 trial had 5 treatment arms,<sup>48</sup> and 1 study had 6 treatment arms<sup>1</sup>. Results for the six-arm trial are presented by the comparative efficacy of the NSAID relative to DPP (superior or no difference) and, therefore, the Evans, *et al.* reference appears twice in Appendix Table 2.

Patient populations consisted of only women in five trials,<sup>50, 51, 53, 54, 61</sup> only men in one trial,<sup>62</sup> and elderly patients (aged 70 to 93 years) in one trial<sup>58</sup>; the remaining 10 trials included men and women.

The DPP dosing interval was longer than the recommended interval of every 4 hours in 14 of the multiple-dose trials. Drug was dosed every 6 hours<sup>56, 59, 65</sup> or 4 times daily<sup>1, 55, 58, 62</sup> in seven trials; and every 8 hours<sup>50</sup> or 3 times daily<sup>49, 51, 53, 57, 60, 61</sup> in seven trials. Four of the multiple-dose trials dosed DPP every 4 hours<sup>48, 52, 63</sup> or every 4 to 6 hours.<sup>54</sup>

Two of the trials specified the primary efficacy variable used to determine analgesic efficacy.<sup>49, 64</sup> The majority of the trials did not declare the primary efficacy variable. As noted in Appendix 1, for these trials, the assumption about the primary efficacy variable was based on the first statistically analyzed evaluation of the patient's assessment of analgesic efficacy that was presented in the results section.

All except two of the trials used pain intensity, assessed by pain intensity rating scales, visual analogue scales (VASs), or categorical, non-numerical verbal pain scales, as the primary analgesic efficacy variable. The exceptions were one trial that rated treatment based on pain relief<sup>62</sup> and another trial that evaluated analgesia by a dichotomous (most/least effective), subjective general assessment of efficacy by the patient.<sup>50</sup> Although most of the trials used pain intensity as the primary efficacy variable, the methods and frequencies of assessing pain intensity differed. Eleven trials used either 4-point,<sup>1, 53, 57, 60, 62</sup> 5-point,<sup>48, 51, 56, 58, 61</sup> or 11-point<sup>63</sup> pain intensity or verbal pain scales. Four trials used the more sensitive tests, visual analogue scales (VASs),<sup>55, 59, 64, 65</sup> and two trials used visual analogue and verbal pain scales<sup>49, 54</sup>. Frequencies of assessments varied between trials from one final assessment<sup>50</sup> to hourly assessments for 12 hours.<sup>61</sup>

#### Validity of acute pain trial results

The major and minor validity criteria are described in Appendix 2. The results of all the RCTs were considered to be of doubtful validity because of one or more of the following major, minor, or other validity issues:

##### Major validity issues

- Properly performed but ineffective randomization resulted in mismatched treatment groups, and the discrepancy between groups may have affected the results. Baseline characteristics of treatment groups differed in age ( $p < 0.05$ )<sup>65</sup> or proportion of patients prescribed rehabilitation exercises.<sup>62</sup> For these reasons, the quality of evidence (QE) for these trials was rated

category II-1. The QE for each of the remaining trials was rated category I (based on proper randomization). (Also see Appendix 1 for assumptions about randomization technique.)

- High rate of patients lost to follow-up (23.2%, 13 of 56 enrolled patients).<sup>50</sup>
- An intent-to-treat analysis was not used (i.e., such analysis was not described in the methods, or treated patients who were excluded or withdrawn were clearly or apparently not analyzed in the group to which they were randomized).<sup>55-60, 63-65</sup>

#### Minor validity issues

- The assessor of analgesia was not blinded to treatment (in all<sup>1, 51, 55, 58, 61, 62</sup> except one<sup>65</sup> of the single-blinded trials).
- Treatment regimens were designed to be dissimilar between groups and the difference may have affected efficacy results, such as different doses of APAP<sup>49</sup>; different dosing frequencies<sup>51</sup>; or use of a loading dose in only one of the treatment groups.<sup>63</sup>
- Dosage regimens within treatment groups may have been different because variable (as-needed) dosing of study analgesics was allowed<sup>52, 54, 59, 60, 63, 64</sup> (furthermore, since the use of an as-needed dosing schedule has been reported to be inadequate at least 34% of the time<sup>66</sup> it may have affected the trial results).

#### Other validity issues

- The actual duration of treatment was too short (less than 7.5 days or five times 36 hours, the maximum half-life of NPP<sup>153</sup>) to allow development of steady-state blood concentrations of DPP and NPP and, therefore, the results may not have reflected the full analgesic effects of DPP and NPP (only two trials evaluated drugs at steady-state<sup>62, 63</sup>).
- Results were inconclusive because of possible Type II error (a statistically significant difference was not found when a true difference existed).<sup>1, 48, 55, 56, 58-62, 65</sup>
- Results were based on preliminary data.<sup>53, 57</sup>
- General assessment of treatment efficacy at the final visit relied on patient recall, which may have influenced the patient's interpretation of pain intensity or relief.<sup>50</sup>

In total, eight trials met major<sup>1, 48, 49, 51-54, 61</sup> and six trials met minor<sup>48, 50, 53, 56, 57, 65</sup> validity criteria. Only the trials by Buck, *et al.* (preliminary results) and Young, *et al.* met both major and minor (excluding other) validity criteria.

### **Overview of study designs: RCTs evaluating multiple-dose DPP ± APAP in chronic pain**

As with the acute pain, multiple-dose RCTs, the chronic pain trials varied in study design, patient populations, pain characteristics, and treatment regimens (see Appendix Table 4). One of the trials focused on the psychomotor effects of the analgesics.<sup>68</sup> Another trial evaluated treatments based on health status as a clinical outcome measure.<sup>67</sup>

The dosing interval of DPP was longer than the recommended interval of every 4 hours in three of the chronic pain trials (3 times daily<sup>67, 68</sup>; or 3 to 4 times daily<sup>69</sup>). In one trial, the dosing interval was not stated.<sup>14</sup>

### **Validity of chronic pain trial results**

The validity of results in all chronic pain trials was considered to be doubtful because of the following major and minor validity issues (for validity criteria, see Appendix 2):

Major validity issues

- Bias in pain assessment due to open-label treatment.<sup>14</sup>
- Lack of intent-to-treat analysis.<sup>67-69</sup>

Minor validity issue

- Unequal treatments due to the use of different dosing methods (titrated DPP vs. fixed dose morphine).<sup>14</sup>

None of the chronic pain trials met major validity criteria.

**Nonserious adverse events**

Nonserious adverse events included here were those specified as nonserious, those described as minimal, minor, or in other similar terms, or those not reported by the author as being serious.

*Acute pain, single-dose trials (meta-analyses and systematic reviews)*

No statistically significant difference in the relative risk of reported nonserious AEs (NSAEs) (headache, nausea, dizziness, or drowsiness) was found between DPP + APAP (65 mg + 650 mg) and APAP (650 mg) when given in single doses for various types of pain<sup>19</sup>.

In the systematic analyses including data on single-dose DPP + APAP for post-operative pain by Collins, *et al.*<sup>20</sup> and Moore, *et al.*,<sup>45</sup> the main AEs evaluated were dizziness, drowsiness / somnolence, headache, nausea, and vomiting. The frequencies of dizziness and drowsiness / somnolence were lower for DPP + APAP (65 mg + 650 mg) than for codeine + APAP (60 mg + 650 mg); however, the 95% CIs for number-needed-to-harm (NNH) overlapped. The NNH was 50 (24 to ∞) and 14 (9.1 to 30) for the two AEs, respectively, for DPP + APAP, and 25 (7.7 to 257) and 10 (4.6 to 31), respectively, for codeine + APAP.<sup>20</sup> The same dose of combination DPP + APAP had a similar frequency (NNH 95% CIs overlap) of drowsiness / somnolence in comparison with tramadol 100 mg (NNH, 95% CI: 13, 9 to 20). Dizziness was the only AE that showed a statistically significant difference between treatments with the frequency lower for DPP + APAP than for tramadol 100 mg (9, 6 to 13).<sup>20</sup>

The frequencies of nausea and dizziness were lower with DPP + APAP (~5% and ~1%, respectively) than with tramadol 150 mg (~24% and ~25%) in the treatment of dental pain (no statistical data).<sup>45</sup>

The results of studies investigating the cognitive and psychomotor effects of single-dose DPP are conflicting. Impairment in critical flicker fusion threshold (CFFT) was noted in healthy volunteers,<sup>155</sup> while no significant impairment was found in CFFT and other measures in other studies.<sup>128, 156</sup> The impairment in cognitive or psychomotor function associated with DPP seems to be less pronounced than that of either alcohol<sup>128</sup> or lorazepam.<sup>155</sup>

*Acute pain, multiple-dose RCTs*

Only a few trials performed statistical analyses on safety evaluations. Boissier, *et al.* observed more NSAEs with codeine + APAP than with DPP + APAP on both an open questionnaire (51 of 71, 71.8% and 38 of 70, 54.3%, respectively; p=0.019), and on a closed questionnaire (60 of 71, 84.5% and 50 of 70, 71.4%, respectively; p=0.029). Significantly more gastrointestinal (p=0.010) and neurologic (p=0.048) intolerance was noted with codeine + APAP.

In the study of Evans, *et al.*, there were no statistically significant differences between DPP + APAP and NSAIDs or APAP in terms of adverse events. The results of the trial by Sleet, *et al.* showed that a substantially greater proportion of patients on DPP + APAP (21 of 46, 45.6%) than on mefenamic acid (6 of 41, 14.6%) developed NSAEs. A higher frequency of nausea or vomiting was seen with DPP + APAP than mefenamic acid (7 of 46 patients [15.2%] vs. none of 41 patients, respectively;

$p < 0.05$ ). These results differ from those of Evans, *et al.*, who found no difference between DPP + APAP and mefenamic acid.

A low frequency of AEs was seen in all treatment groups in each of the remaining acute pain, multiple-dose RCTs. No remarkable differences in AE rates were noted between treatment groups (no statistical analyses).

#### *Chronic pain, multiple-dose trials*

Parr, *et al.* found more patients on DPP + APAP than diclofenac SR experienced tiredness/sleep disturbance (50 vs. 21 patients [13.1% vs. 5.6%];  $p < 0.01$ ) and dizziness/lightheadedness (30 vs. 14 patients [7.8% vs. 3.8%];  $p < 0.05$ ), while fewer DPP + APAP patients than diclofenac SR patients suffered abdominal/epigastric pain or indigestion (18 vs. 40 [4.7% vs. 10.7%];  $p < 0.01$ ) and diarrhea (2 vs. 14 [0.5% vs. 3.8%];  $p < 0.01$ ).

When DPP was compared as a WHO Step 2 agent with morphine as a Step 3 agent in the treatment of opioid-naïve patients with cancer pain, 3 (18.7%) of the 16 morphine patients had to switch to DPP because of intolerable side effects.<sup>14</sup> Nausea and vomiting, drowsiness, and dry mouth were statistically significantly more severe in the group taking morphine SR 20 mg daily than the group taking DPP 120 to 240 mg daily ( $p < 0.01$ ); however, clinical differences were small (i.e., none vs. slight symptom intensity).

Saarialho-Kere, *et al.* observed that DPP (65 mg t.i.d.  $\times$  2 d then 130 mg  $\times$  1 dose) impaired body balance and critical flicker discrimination while not affecting coordination or reactive skills.<sup>68</sup> DPP in combination with amitriptyline (DPP 65 mg b.i.d. + amitriptyline 25 mg  $\times$  2 d then single dose of DPP 65 mg + amitriptyline 25 mg) also decreased critical flicker discrimination and body balance, as well as medial attention and symbol copying. In comparison, indomethacin (25 mg t.i.d.  $\times$  2 d then 50 mg  $\times$  1 dose) transiently affected flicker recognition and slightly improved lateral attention. Overall, all treatments caused mild alterations in psychomotor performance that corresponded with peak plasma concentrations of drug.

#### *Safety trials*

Two additional RCTs evaluated the psychomotor effects of DPP.<sup>155 157</sup> For details, see Appendix 3, Appendix Table 5.

#### *Maintenance treatment trials*

In the study by Woody, *et al.*, only 12% of the 227 opioid-tolerant heroin addicts who took high doses (400 to 1000 mg/d) of DPPN for more than 4 weeks developed NSAEs. The symptoms were consistent with CNS irritability (increased anxiety, restlessness, or confusion).<sup>44</sup> The AEs resolved after discontinuation of DPPN.

Appendix Table 2 RCTs comparing multiple doses of DPP ± APAP with NSAIDs or APAP in acute pain

Ref.	Study design (PEV PAM) <sup>†</sup>	Type of pain (Baseline pain intensity)	N, Efficacy analysis [Sex, RRA patients]	Age, mean ± SD [median], (range)	DPP ± APAP preparation and dosage regimen <sup>‡</sup>	Comparator(s) and dose(s)	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE, SoR]				(years)	[HCl equivalent (mg/day)]	[mg/day]	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
<b>DPP ± APAP inferior to NSAID or APAP combination in terms of analgesic efficacy (p &lt; 0.05)</b>									
Anderson (1978) <sup>50</sup> [I, B]	DBCO (SGA)	Primary dysmenorrhea (NR)	30 [0 M / 30 F]	(<16 to 34)	DPP+APAP 65 + 650 mg q8h [195 + 1950]	Mefenamic acid (MA) 500 mg q8h until symptoms gone or menses ended [1500] <sup>§</sup>	3.5 <sup>  ††</sup>	Lost to follow-up: 13 of 56 enrolled patients (23.2%) General assessment by patient at the final visit: More patients chose MA as the most effective treatment vs. DPP+APAP (12 vs. 3) and fewer patients chose MA as the least effective treatment (2 vs. 15). MA > DPP+APAP* for general patient preference using +1, 0, and -1 scores for best, second best, and worst treatments, respectively (total scores 10.5 vs. -12.5; p < 0.001) MA > DPP+APAP* for total symptom score with 3 indicating greatest severity for any symptom, 315 vs. 440 (p < 0.01) MA = DPP+APAP for absence from work or school (10.5 d vs. 15.25 d; p > 0.05) MA = DPP+APAP for number of capsules taken (548 vs. 633; p > 0.05) Fewer doses of additional analgesics taken in MA vs. DPP+APAP group (mean for 3 cycles, 2.6 vs. 6.8; p < 0.01)	AEs, seriousness / intensity not reported: 2 MA (1 DVT, 3 wk after taking MA; 1 extremely dizzy and nauseated); 1 DPP+APAP (extremely dizzy and nauseated; completed trial) WDAE: 2 MA (1 headaches, 2 DVT)

Ref.	Study design (PEV PAM) <sup>†</sup>	Type of pain (Baseline pain intensity)	N, Efficacy analysis [Sex, RRA patients]	Age, mean ± SD [median], (range)	DPP ± APAP preparation and dosage regimen <sup>‡</sup>	Comparator(s) and dose(s)	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE, SoR]				(years)	[HCl equivalent (mg/day)]	[mg/day]	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
Evans (1980) <sup>†</sup> [I, B]	SBCO (4PIRS)	Low back pain (Moderate)	60 (30 per treatment group) [20 M / 40 F]	47.0 ± 9.2	DPP+APAP 65 + 650 mg q.i.d. [260 + 2600]	Mefenamic acid (MA) 500 mg t.i.d. [1500]  Aspirin (ASA) 900 mg q.i.d. [3600]	7	Spinal anterior flexion: MA = DPP+APAP (mean, 5.7 vs. 5.6 cm; p > 0.05). ASA = DPP+APAP (mean, 5.7 vs. 5.6; p > 0.05). Mean daily pain index with 0–nil, 3–severe: MA > DPP+APAP* (1.4 vs. 1.7; p < 0.05). ASA > DPP+APAP* for mean daily pain index with 0–nil, 3–severe (1.4 vs. 1.7; p < 0.05). MA > DPP+APAP* for radiating pain not brought on by sneezing (p < 0.05). Higher percentage of recommended dose taken in MA vs. DPP+APAP group (91.8% vs. 71.7%; p < 0.01). Fewer defaults from full regimen in MA vs. DPP+APAP group (8 vs. 17, out of 30 possible). MA = DPP+APAP: patients' preference with 1–best, 3–worst (mean ranks, 1.75 vs. 2.07; p > 0.05).	Intensity of AEs not recorded. Fewer defaults from full regimen due to AE in MA vs. DPP+APAP group (2 vs. 13; p < 0.001). Larger proportion of MA patients with no AEs but treatment difference not statistically significant (60% vs. 37%, p > 0.05). Smaller proportion of MA patients with neurologic AEs but treatment difference not statistically significant (8 vs. 15; p > 0.05). Number of patients with any AE: 12 MA vs. 19 DPP+APAP.

Ref.	Study design (PEV PAM) <sup>†</sup>	Type of pain (Baseline pain intensity)	N, Efficacy analysis [Sex, RRA patients]	Age, mean ± SD [median], (range)	DPP ± APAP preparation and dosage regimen <sup>‡</sup>	Comparator(s) and dose(s)	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE, SoR]				(years)	[HCl equivalent (mg/day)]	[mg/day]	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
Langrick (1982) <sup>51</sup> [I, B]	SBPG (5PIRS)	Primary dysmenorrhea (Mild to severe)	39 [0 M / 39 F]	[21] (16 to 34)	DPPN+APAP 100 + 650 mg at onset of pain then t.i.d. [195 + 1950]	Naproxen (NAP) 275 mg at onset of pain then q.i.d. [1100]	3 <sup>  </sup>	Lost to follow-up: 3 (2 NAP, 1 DPPN+APAP) 9 of 12 hourly mean pain scores on day 2 were lower on NAP vs. DPPN+APAP (p < 0.05) Patients' daily assessments of pain severity was lower on NAP vs. DPPN+APAP on day 2 (1.7 vs. 2.1; p < 0.05) and day 3 (0.4 vs. 0.8; p < 0.05) with 0=none, 4=very severe. Symptom control higher on NAP vs. DPPN+APAP on day 1 (3.9 vs. 3.4; p < 0.05) and day 2 (4.3 vs. 3.7; p < 0.01) on scale of excellent to worse (values not specified). Lower degree of disturbance of concentration or ability to go about normal routine on NAP vs. DPPN+APAP based on 4-point rating scale for Episode 1 (0.67 vs. 1.37; p < 0.05), Episode 2 (0.62 vs. 1.33; p < 0.05), and Episode 3 (0.50 vs. 1.43; p < 0.01)	WDAE: 1 NAP (nausea) AE, seriousness not reported: 6 NAP, 9 DPPN+APAP
Cantor (1968) <sup>52</sup> [I, B]	DBPG (4PRS)	Gingivectomy (NR)	100 [26 M / 74 F]	(19 to 56)	DPP 64 mg q4h or prn [384 or prn]	Percogesic (PERC) 2 cap q4h or prn [APAP 3900, phenyltoxamine 360, homatropine methyrbromide 30, caffeine 360 or prn]	1 to 2	PERC > DPP* using ridit analysis for time of onset (0.58; p < 0.05) and degree of pain relief (0.60; p < 0.05) <sup>   </sup> PERC = DPP, ridit analysis: duration of pain relief (0.47; p > 0.05) <sup>   </sup> PERC = DPP, for onset (1.50 vs. 1.32), duration (0.66 vs. 0.62), and pain relief (2.14 vs. 1.86) (p > 0.05 for each analysis) by distribution analysis (using 3-point scoring system where the number of points assigned were 3 for excellent pain relief; 2 for onset < 30 min, duration 4 to 6 h, or good pain relief; 1 for onset 30 to 60 min, duration 2 to 4 h, or poor pain relief; and no points for others)	AEs minimal in both groups. 11 cases PERC (4 nausea, 5 drowsiness, 2 heartburn) 4 cases DPP (3 drowsiness, 1 nausea)



Ref.	Study design (PEV PAM) <sup>†</sup>	Type of pain (Baseline pain intensity)	N, Efficacy analysis [Sex, RRA patients]	Age, mean ± SD [median], (range)	DPP ± APAP preparation and dosage regimen <sup>‡</sup>	Comparator(s) and dose(s)	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE, SoR]				(years)	[HCl equivalent (mg/day)]	[mg/day]	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
<b>No difference between DPP+ APAP and NSAID in terms of analgesic efficacy (p &gt; 0.05)</b>									
Giles (1981) <sup>56</sup> [I, B]	DBPG (5PIRS)	Dental extraction (NR)	38 [16 M / 23 F]	25 ± NR	DPP+APAP up to 65 + 650 mg q6h [260 + 2600]	Ibuprofen (IBU) 400 mg q6h [1600 (max)]	7	Withdrawal due to lack of efficacy: 2 DPP+APAP IBU = DPP+APAP for degree of pain at day 3 (mean score with 0–none, 4–very severe: 1.8 vs. 2.1; p > 0.10) and day 7 (1.0 vs. 0.9; p > 0.10). IBU = DPP+APAP for degree of pain relief at day 3 (mean score with 0–no relief, 4–complete: 3.0 vs. 3.0; p > 0.10) and day 7 (3.3 vs. 3.3; p > 0.10). Less trismus on IBU with mean mouth opening greater on POD 3 (83.5% vs. 73.8%; p < 0.025) but no difference on POD 7 (91.8% vs. 91.9%; p > 0.10).	WDAE, severe: 5 DPP+APAP (excluded from efficacy analyses). AEs, seriousness not reported: 3 infected sockets (1 IBU, 2 DPP+APAP). Number of reports by severity (IBU vs. DPP+APAP; severity scores of 1 to 3 were not defined): 1 12 vs. 17 2 6 vs. 8 3 4 vs. 15 Number of reports by organ system (IBU vs. DPP+APAP): GI 1 vs. 10 CNS 21 vs. 30 Total 22 vs. 40 Fewer patients on IBU reported AEs during early post-op period (no data; p < 0.05)
Buck (1978) <sup>53</sup> [I, C]	DBPG DD Preliminary (4PIRS)	Episiotomy (NR)	57 [0 M / 57 F]	NR	DPP+APAP 65 + 650 mg t.i.d. [195 + 1950]	Diflunisal (DIF) 500 mg b.i.d. [1000] Placebo (PL) control	2	All 3 treatments produced the same effect in relieving pain at night. DIF = DPP+APAP = PL for spontaneous pain at 2, 4, 6, and 8 h after start of therapy (no data; p-value NR) All 3 treatments equally beneficial in patients' opinion (no data). DIF better than DPP+APAP, and both better than PL according to investigator's opinion of response (no data).	AEs: 1 DIF (tiredness) 4 DPP+APAP (tiredness and dizziness) 2 PL (tiredness)

Ref.	Study design (PEV PAM) <sup>†</sup>	Type of pain (Baseline pain intensity)	N, Efficacy analysis [Sex, RRA patients]	Age, mean ± SD [median], (range)	DPP ± APAP preparation and dosage regimen <sup>‡</sup>	Comparator(s) and dose(s)	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE, SoR]				(years)	[HCl equivalent (mg/day)]	[mg/day]	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
Jaffé (1978) <sup>57</sup> [I, B]	DBPG DD Ongoing (4PIRS)	Sprains and strains (Moderate)	51 [29 M / 20 F]	(16 to 62)	DPP+APAP 65 + 650 mg t.i.d. [195 + 1950]	Diflunisal (DIF) 500 mg b.i.d. [1000]	3	DIF = DPP+APAP for patients' assessment of relief of spontaneous pain (complete, partial, no relief, and no answer) on day 1 (2, 6, 17, 1 vs. 1, 13, 11, 0) and day 3 (8, 11, 7, 0 vs. 8, 14, 2, 1) (p-values NR). DIF = DPP+APAP for pain on movement on day 1 (1, 14, 10, 1 vs. 0, 12, 13, 0) and day 3 (2, 18, 6, 0 vs. 1, 18, 5, 1) (p-values NR). DIF = DPP+APAP for patients' and physicians' overall evaluations of treatment (p-values NR).	3 DPP+APAP complained of the quantity of tablets and found them difficult to take (1 withdrew, omitted from analysis; 1 withdrew after 24 h, results from first 24 h included; 1 completed trial). 1 DIF (headache, considered by clinician to be causally related) 1 DPP+APAP (nausea on 2 occasions, considered by clinician to be causally related).

Ref.	Study design (PEV PAM) <sup>†</sup>	Type of pain (Baseline pain intensity)	N, Efficacy analysis [Sex, RRA patients]	Age, mean ± SD [median], (range)	DPP ± APAP preparation and dosage regimen <sup>‡</sup>	Comparator(s) and dose(s)	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE, SoR]				(years)	[HCl equivalent (mg/day)]	[mg/day]	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
Rao (1982) <sup>58</sup> [I, B]	SBPG (5PIRS)	Traumatic injury (Moderate)	40 [7 M / 33 F]	80 to 81 (70 to 93)	DPP+APAP 65 + 650 mg q.i.d. [260 + 2600]	Diflunisal (DIF) 500 mg b.i.d. [1000]	5	<p>Lost to follow-up: 1 1 DPP+APAP obtained no relief after 4 d and did not return on day 5.</p> <p>DIF = DPP+APAP for spontaneous pain in terms of ratio of number of patients who were much better (M) or better (B) to same (S) or worse (W). M/B:S/W for DIF vs. DPP+APAP, results for day 5 only shown here, 15:1 vs. 15:1.</p> <p>DIF = DPP+APAP for night pain; results for day 5 only shown here, 17:1 vs. 11:2.</p> <p>DIF &gt; DPP+APAP* for pain on passive movement on day 3, 13:2 vs. 4:8 (p &lt; 0.007); day 4, 13:2 vs. 6:6 (p &lt; 0.049); and day 5, 14:1 vs. 6:5 (p &lt; 0.032).</p> <p>DIF &gt; DPP+APAP* for tenderness on day 2, 16:4 vs. 8:11 (p = 0.01); and day 3, 17:1 vs. 12:7 (p = 0.05).</p> <p>DIF = DPP+APAP for patient's evaluation of overall response based on success:failure ratio (success—excellent and good; failure—fair, poor, and none), results for day 5 only shown here, 13:7 (65%) vs. 8:11 (40%) (p-value NR).</p> <p>DIF = DPP+APAP for clinician's assessment of overall response, 14:6 (70%) vs. 11:9 (56%) (p-value NR).</p>	NSAEs: 1 DIF (nausea and vomiting of moderate intensity thought to be probably related to DIF). 1 DPP+APAP (nausea of moderate intensity thought to be possibly related to DPP+APAP).

Ref.	Study design (PEV PAM) <sup>†</sup>	Type of pain (Baseline pain intensity)	N, Efficacy analysis [Sex, RRA patients]	Age, mean ± SD [median], (range)	DPP ± APAP preparation and dosage regimen <sup>‡</sup>	Comparator(s) and dose(s)	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE, SoR]				(years)	[HCl equivalent (mg/day)]	[mg/day]	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
Joki (1989) <sup>63</sup> [I, B]	OLPG (11PIRS)	Arthroscopic knee surgery (Mild to moderate)	26 [20 M, 6 F]	36.5 ± 11.0 Diflunisal 35.1 ± 10.0 DPPN+APAP	DPPN+APAP 100 + 650 mg q4h prn [600 + 3900 prn]	Diflunisal (DIF) 500 mg q12h prn [1000 prn] (following 1000 mg loading dose)	15 (max.)	DIF = DPPN+APAP for mean self-rating pain scores (0=no pain, 1 to 3=mild pain, 4 to 7=moderate pain, 8 to 10=severe pain) during 8 to 16 h, 17 to 24 h, 25 to 48 h, and 8 to 48 h (overall rating) (p-values ≥ 0.32). Overall rating only shown here, 4.1 vs. 4.6 (p = 0.59). DIF = DPPN+APAP for patients' global assessment of efficacy; 9 of 12 (75%) vs. 10 of 14 (71%) patients rated treatment good or excellent (p = 0.84); and 4 (33%) vs. 3 (21%) rated treatment excellent (p = 0.50).	No patients reported AEs.
Sleet (1980) <sup>59</sup> [I, B]	DBPG DD (100VAS)	Traumatic injury or soft tissue infection (NR)	87 [50 M / 37 F]	37.0 ± 17.1 (15 to 80)	DPP+APAP (32.5 + 325 mg/cap) 2 cap to total of 3 doses in first 24 h, followed by 1 or 2 cap q6h prn [130 to 260 + 1300 to 2600 prn]	Mefenamic acid (MA) (250 mg/cap) same dosing regimen as DPP+APAP [1000 to 2000 prn]	5	MA => DPP+APAP* for mean pain relief on retiring adjusted for regression on initial pain (calculated pain scores from 0.00 to 1.57 corresponding to original analgesic VAS from 0 to 100); no treatment differences except on day 3 (0.25 vs. 0.02, p < 0.05 for the difference). MA = DPP+APAP for mean number of capsules / dummy placebo tablets taken per day, adjusted for regression on initial pain score, on days 1 to 5; results for day 5 only shown here, 6.3 vs. 7.3 (p > 0.05 for each analysis). MA = DPP+APAP for pain, if disturbing sleep, adjusted for regression on pain before retiring on days 1 to 5; results for day 5 only shown here, 0.43 vs. 0.40 (p > 0.05 for each analysis).	1 Severe AE: DPP+APAP (nausea) 4 WDAEs: 0 MA, 4 DPP+APAP (1 severe nausea, 1 headache, 1 rash/fever/backache, 1 nausea) 27 AEs: 6 MA, 21 DPP+APAP (no statistics reported). Vomiting and nausea associated with DPP+APAP (0 vs. 7; p < 0.05).

Ref.	Study design (PEV PAM) <sup>†</sup>	Type of pain (Baseline pain intensity)	N, Efficacy analysis [Sex, RRA patients]	Age, mean ± SD [median], (range)	DPP ± APAP preparation and dosage regimen <sup>‡</sup>	Comparator(s) and dose(s)	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE, SoR]				(years)	[HCl equivalent (mg/day)]	[mg/day]	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
Stableforth (1977) <sup>60</sup> [I, B]	DBPG (4PIRS)	Soft tissue injury (NR)	48 34 M / 14 F	NR	DPP+APAP 65 + 650 mg up to t.i.d. prn [195 + 1950 prn (max)]	Mefenamic acid (MA) 500 mg up to t.i.d. prn [1500 prn (max)]	3	MA = DPP+APAP for all the following assessments (p > 0.05 for each) (0=no change, 3=good improvement), day 7 values only shown here: –Pain 2.21 vs. 1.87 –Swelling 1.79 vs. 1.93 –Tenderness 2.00 vs. 1.80 –Joint mobility 1.67 vs. 1.72 –Overall assessment 1.67 vs. 1.65 2 Study treatment ineffective: 1 MA and 1 DPP+APAP; both took alternative or additional analgesic.	4 WDAE: 2 MA, 2 DPP+APAP (all GI intolerance) 8 AE, no further details: 4 MA, 4 DPP+APAP
Williams (1982) <sup>61</sup> [I, B]	OLPG (5PIRS)	Primary dysmenorrhea (NR)	59 [0 M / 59 F]	19.2 to 20.3 (15 to 36)	DPP+APAP 65 + 650 mg t.i.d. [195 + 1950]	Naproxen (NAP) 275 mg q.i.d. [1100]	3 <sup>  </sup>	Lost to follow-up: 9 (15%), 7 NAP and 2 DPP+APAP Hourly scores of pain showed similar changes in the two treatment groups (no statistics). NAP = DPP+APAP for pain severity (0=none, 4=very severe) on day 1 (1.52 vs. 1.65), day 2 (1.25 vs. 1.72), and day 3 (0.67 vs. 0.81) (p > 0.05 for each analysis). NAP > DPP+APAP* for symptom control (1=worst, 2=no change, 3=mild, 4=moderate, 5=excellent) on day 2 (4.04 vs. 3.58) and day 3 (4.43 vs. 4.06) (p < 0.05 for both analyses).	6 Severe AEs (all DPP+APAP, no details). 2 WDAEs (both DPP+APAP, CNS AEs) Smaller proportion of patients reported AEs with NAP (6 of 24, 25%) than with DPP+APAP (14 of 24, 58%) (p = 0.03). Most frequently reported AEs for NAP vs. DPP+APAP were nausea (2 vs. 6), dizzy/giddy (1 vs. 6), and sleepy/drowsy (2 vs. 6), and these AEs were more frequent in the DPP+APAP group. 2 NAP reported gastric upset.

Ref.	Study design (PEV PAM) <sup>†</sup>	Type of pain (Baseline pain intensity)	N, Efficacy analysis [Sex, RRA patients]	Age, mean ± SD [median], (range)	DPP ± APAP preparation and dosage regimen <sup>‡</sup>	Comparator(s) and dose(s)	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE, SoR]				(years)	[HCl equivalent (mg/day)]	[mg/day]	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
Beveridge (1985) <sup>62</sup> [II-1, B]	SBPG (4PIRS)	Soft-tissue injury (Moderate)	63 [68 M, 0 F]	21.5 ± 4.2	DPPN 100 mg initially, then q.i.d. [260]	Naproxen (NAP) 550 mg initially, then 275 mg q.i.d. [2200]	5 to 14 <sup>\$5</sup>	Lost to follow-up: 1 A greater proportion of patients were instructed to perform rehabilitation exercises in the NAP group (10 of 31, 32%) than in the DPPN group (3 of 32, 9%). Cumulative total number of patients requiring no further treatment was greater with NAP than with DPPN on day 8 (~11 vs. 5), day 9 (~13 vs. ~6), and day 10 (~17 vs. 9) (p < 0.05 for each analysis). NAP ≥ DPPN* for mean number of days for patients to return to training: 7.0 vs. 7.8 d; to be available for selection: 8.3 vs. 9.6 d (no statistics). NAP = DPPN for mean daily symptom scores (4–none, 1–severe) for pain on passive movement (2.00 vs. 2.03) and tenderness (1.77 vs. 1.75) (p > 0.05 for each analysis). NAP ≥ DPPN* for swelling on days 2 to 6 (~3.5 to 3.8 vs. ~3.5 to 3.6) (p < 0.05). 1 Study treatment ineffective: (DPPN, withdrew from trial)	1 WDAE (NAP, epigastric pain and heartburn).

Ref.	Study design (PEV PAM) <sup>†</sup>	Type of pain (Baseline pain intensity)	N, Efficacy analysis [Sex, RRA patients]	Age, mean ± SD [median], (range)	DPP ± APAP preparation and dosage regimen <sup>‡</sup>	Comparator(s) and dose(s)	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE, SoR]				(years)	[HCl equivalent (mg/day)]	[mg/day]	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
Evans (1980) <sup>†</sup> [I, B]	SBCO (4PIRS)	Low back pain (Moderate)	60 (30 per treatment group) [20 M / 40 F]	47.0 ± 9.2	DPP+APAP 65 + 650 mg q.i.d. [260 + 2600]	Indomethacin (INDO) 50 mg t.i.d. [150] Phenylbutazone (PBZ) 100 mg t.i.d. [300] APAP 1000 mg q.i.d. [4000]	7	INDO = PBZ = APAP = DPP+APAP for spinal anterior flexion. INDO = PBZ = APAP = DPP+APAP for mean daily pain index with 0–nil, 3–severe (1.5 vs. 1.4 vs. 1.7 vs. 1.7; p > 0.05 for all analyses). PBZ > DPP+APAP* for percentage of recommended dose taken (96.5% vs. 71.7%; p < 0.01). APAP > DPP+APAP* for percentage of recommended dose taken (89.8% vs. 71.7%; p < 0.05). Fewer defaults from full regimen in INDO, PBZ, and APAP groups (14, 6, and 9, respectively) vs. DPP+APAP (17, out of 30 possible). INDO = PBZ = APAP = DPP+APAP for patients' preference with 1–best, 3–worst (mean ranks, 1.98 vs. 1.68 vs. 2.15 vs. 2.07; p > 0.05 for all analyses).	Fewer defaults from full regimen due to AE on PBZ and on APAP vs. DPP+APAP (1 and 4 vs. 13; p < 0.001). A larger proportion of PBZ and APAP patients had no AEs but the treatment differences were not statistically significant (37%, 53% and 57% vs. 37%; p > 0.05). A smaller proportion of PBZ and APAP patients (27% and 27%) than DPP+APAP and INDO patients (50% and 53%) had neurologic AEs but treatment differences were not statistically significant (p > 0.05). Number of patients with any AE: 4 PBZ, 13 APAP, 19 INDO, 19 DPP+APAP.

Results presented for agents available in the U.S. (See <sup>§</sup> below.)

AE = Adverse event; APAP = Acetaminophen; DPP = *d*-Propoxyphene; F = Females; M = Males; NR = Not reported; POD = Post-operative day; Prn = Pro re nata (as needed); QE = Quality of evidence; RRA = Recruited, randomized, or analyzed (patient sex was reported for different study populations among the various trials); SoR = Strength of recommendation regarding treatment comparisons for analgesic efficacy; WDAE = Withdrawal from study or discontinuation of medication due to adverse event. Abbreviations for drugs are shown under the columns for either age or dosage regimens in the relevant table row.

<sup>†</sup> Study design: DBPG = Double-blind, parallel group; DD = Double-dummy; OLPG = Open-label parallel group; SBCO = Single-blind, crossover; SBPG = Single-blind, parallel group. PEV (Primary efficacy variable); PAM (Pain assessment method): 4PIRS = 4-point Pain intensity scale; 5PIRS = 5-point Pain intensity scale; 4PRS = 4-point pain relief scale; SGA = Subjective general assessment (most/least effective); 100VAS = 100-mm Visual analog scale.

<sup>‡</sup> DPP + APAP = *D*-propoxyphene + acetaminophen. Daily DPP doses (shown in brackets) are expressed in terms of DPP HCl equivalent (100 mg DPP napsylate equivalent to 65 mg DPP HCl).

<sup>§</sup> Flufenamic acid not included (not available in U.S.); flufenamic acid was statistically significantly superior to DPP in terms of the patient's subjective general assessment of symptom relief.

<sup>||</sup> Number of days for each of 3 consecutive menstrual cycles

<sup>††</sup> Duration of DPP + APAP therapy; value was estimated by calculating the number of days of treatment per patient per month based on a total of 633 DPP + APAP capsules taken.

<sup>§§</sup> About 21 (66%) of 32 DPP patients and about 14 (45%) of 31 naproxen patients required more than 10 days' treatment (values obtained from graphical presentation of results).

<sup>|||</sup> Comparisons were based on mean ridit score for PERC with DPP as the reference population. The ridit analysis is a "distribution free" method and allows a scoring system to be determined by the distribution of the reference population.

Appendix Table 3 RCTs comparing multiple doses of DPP ± APAP with opioids in treatment of acute pain

Ref.	Study design (PEV PAM) <sup>†</sup>	Type of pain (Baseline pain intensity)	N, Efficacy analysis [Sex, RRA patients]	Age, mean ± SD [median], (range) <sup>‡</sup>	DPP(N) ± APAP preparation and dosage regimen	Comparator(s) and dose(s) <sup>‡</sup>	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; < means inferior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE, SoR]				(years)	[HCl equivalent <sup>‡</sup> (mg/day)]	(mg/day)	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
<b>Opioid superior to DPP + APAP in terms of analgesic efficacy (p &lt; 0.05)</b>									
Sagne (1987) <sup>64</sup> [I, B]	DBPG (100VAS) The evaluation of analgesic efficacy was based on the extent of pain reduction and pain reduction index (PRIX) after dose 1, and doses 1 and 2.	Dental extraction (mean, 64 mm DPP+APAP, 65 mm Codeine+APAP)	180 [93 M / 87 F]	28.4 to 30.8	DPP+APAP 65 + 650 mg at least 2 h apart prn, up to 3 doses [65 to 195 + 650 to 1950 prn]	Codeine+APAP (COD+APAP) 60 + 1000 mg at least 2 h apart prn, up to 3 doses [60 to 180 + 1000 to 3000 prn]	0.4	COD+APAP > DPP+APAP* for duration of effect after first dose (6.6 h vs. 5.7 h; p < 0.05). Fewer doses taken in COD+APAP than DPP+APAP group in terms of proportion of patients who took 1 dose (~30% vs. ~25%), 2 doses (~50% vs. ~45%), or 3 doses (~25% vs. ~35%) but not statistically significant; (p > 0.05 for each analysis). COD+APAP > DPP+APAP* for mean percentage pain reduction after dose 1 for men (65.8% vs. 50.1%) and whole group (63.8% vs. 53.3%); and after doses 1 and 2 for whole group (67.3% vs. 59.4%) (0.01 < p < 0.05 for each analysis). COD+APAP > DPP+APAP* for mean PRIX after dose 1 for males (476.9 vs. 317.0; 0.01 < p < 0.05) and for whole group (442.3 vs. 330.5; 0.001 < p < 0.01); and after doses 1 and 2 for males (480.1 vs. 367.0) and for whole group (461.5 vs. 376.9) (0.01 < p < 0.05 for both analyses). No significant differences for females in percentage pain reduction or PRIX.	Dizziness, tiredness and nausea were most frequent AEs. A greater proportion of females experienced AEs on COD+APAP (55%) than on DPP+APAP (31%; p < 0.05); no significant difference for males (18% vs. 23%).



Ref.	Study design (PEV PAM) <sup>†</sup>	Type of pain (Baseline pain intensity)	N, Efficacy analysis [Sex, RRA patients]	Age, mean ± SD [median], (range) <sup>‡</sup>	DPP(N) ± APAP preparation and dosage regimen	Comparator(s) and dose(s) <sup>‡</sup>	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; < means inferior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE, SoR]				(years)	[HCl equivalent <sup>‡</sup> (mg/day)]	(mg/day)	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
<b>No difference between opioid and DPP + APAP in terms of analgesic efficacy (p &gt; 0.05)</b>									
Boissier (1992) <sup>49</sup> [I, B]	DBPG DD (VAS/4VPS <sup>§</sup> ) A priori estimate of sample size Principal trial criterion (success–failure) was defined from overall assessment of acceptability by patient classified into the following 4 categories: treatment very poorly and poorly tolerated (failure); treatment well and very well tolerated (success). WDAEs were also classified as failures.	Osteoarthritis (NR)	141 [38 M / 103 F]	66 ± NR	DPP+APAP (DI-Antalvic) 60 + 800 mg t.i.d. [180 + 2400]	Codeine+APAP (COD+APAP, Efferalgan-Codeine) 60 + 1000 mg t.i.d. [180 + 3000]	5	COD+APAP = DPP+APAP for visual pain scale (3.7 cm vs. 3.3 cm); verbal pain scale (pain severity nil : moderate : severe or very severe, 7 : 40 : 14 vs. 7 : 48 : 13); overall efficacy assessment by physician (no change or worse : improved : greatly improved, 19 : 30 : 11 vs. 12 : 45 : 11) and by patient (16 : 32 : 12 vs. 14 : 38 : 15) (p > 0.05 for each analysis).	1 SAE: Codeine+APAP (acute pulmonary edema; association confounded by beta-blocker treatment). Failure rate was higher with COD+APAP (36 of 68, 53%) than with DPP+APAP (20 of 68, 29%; p = 0.005). No significant difference in success rate (32, 47% vs. 48, 71%). COD+APAP < DPP+APAP* for overall acceptability assessment by patient in terms of treatment well tolerated (success) (17 vs. 25; p = 0.013). WDAEs were three times more frequent with COD+APAP (27) than with DPP+APAP (9; p = 0.001). Reasons were GI, neurologic, or other types of intolerance (p ≤ 0.03 for each analysis). None of these AEs were serious enough to require hospitalization.

Ref.	Study design (PEV PAM) <sup>†</sup>	Type of pain (Baseline pain intensity)	N, Efficacy analysis [Sex, RRA patients]	Age, mean ± SD [median], (range) <sup>‡</sup>	DPP(N) ± APAP preparation and dosage regimen	Comparator(s) and dose(s) <sup>‡</sup>	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; < means inferior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE, SoR]				(years)	[HCl equivalent <sup>‡</sup> (mg/day)]	(mg/day)	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
Edmondson (1983) <sup>55</sup> [I, B]	SBPG (VAS)	Dental extraction (NR)	83 [32 M / 51 F]	NR (17 to 49)	DPPN+APAP 100+650 mg q.i.d. [260 + 2600]	Codeine+APAP+Caffeine (Solpadeine effervescent, SOL) <sup>  </sup> 16 + 1000 + 60 mg q.i.d. [64 + 4000 + 240]	3	SOL = DPP+APAP for pain intensity (no data), mean interval between doses (6.91 vs. 7.53 h), or overall pain relief (very good or good, 63.4% vs. 50%) (p > 0.05 for each analysis). SOL > DPP+APAP* for medication easier to take (90.5% vs. 65%; p < 0.01). A smaller proportion of SOL than DPP+APAP patients described their medication as having an unpleasant taste (14% vs. 39%; p < 0.025); and a smaller proportion of SOL patients commented that their tablets didn't dissolve well (7.1% vs. 26.8%). At 1-wk follow-up visit, more DPP+APAP (13 of 41, 32%) than SOL (2 of 42, 5%) patients described their pain as sharp. More SOL (32, 76%) than DPP+APAP (24, 58%) patients described their pain as dull.	No SAEs. NSAEs: 11 (26.2%) SOL vs. 12 (29.3%) DPP+APAP. More patients on SOL (n = 8) than DPPN+APAP (n = 3) reported nausea.

Ref.	Study design (PEV PAM) <sup>†</sup>	Type of pain (Baseline pain intensity)	N, Efficacy analysis [Sex, RRA patients]	Age, mean ± SD [median], (range) <sup>‡</sup>	DPP(N) ± APAP preparation and dosage regimen	Comparator(s) and dose(s) <sup>‡</sup>	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; < means inferior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE, SoR]				(years)	[HCl equivalent <sup>‡</sup> (mg/day)]	(mg/day)	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
MacKay (1982) <sup>65</sup> [II-1, B]	SBPG (VAS)	Tonsillectomy (NR)	74 [21 M / 53 F]	25.7 DPPN+APAP; 23.9 Solpadeine (SOL)	DPPN+APAP 100 + 650 mg q6h [260 + 2600 ]	Codeine+APAP+CAF (SOL) <sup>  </sup> 16+1000+60 mg q6h [32 + 2000 + 120]	3	Female DPPN+APAP patients older than SOL patients (mean age, 26.0 vs. 22.2 yr; p < 0.05). SOL = DPPN+APAP for clinician's assessment of pain relief (1-poor, 4-excellent); mean score 2.8 vs. 2.6 (p > 0.05). A greater proportion of SOL patients (8, 20%) than DPPN+APAP (3, 8.8%) had excellent pain relief (no statistics). SOL = DPPN+APAP for patient's assessment of pain severity on day 1, number of times awoken during night, severity of pain on eating, severity of pain on waking, daytime pain relief, and severity of pain on retiring (p > 0.05 for each analysis).	1 SAE: SOL (post-operative hemorrhage; code broken). 3 WDAEs: 2 SOL, 1 DPPN+APAP (all 3 because of upset stomach). AEs, seriousness or intensity not reported: 1 SOL (nausea, vomiting), 2 DPPN+APAP (1 pins and needles in the jaw; 1 nausea, dizziness, and extreme drowsiness).

Ref.	Study design (PEV PAM) <sup>†</sup>	Type of pain (Baseline pain intensity)	N, Efficacy analysis [Sex, RRA patients]	Age, mean ± SD [median], (range) <sup>‡</sup>	DPP(N) ± APAP preparation and dosage regimen	Comparator(s) and dose(s) <sup>‡</sup>	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; < means inferior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE, SoR]				(years)	[HCl equivalent <sup>‡</sup> (mg/day)]	(mg/day)	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
Young (1978) <sup>48</sup> [I, A]	DBPG (5PIRS)	Major surgery (Mild to moderate)	151 [68 M / 83 F]	47.5 M; 44.6 F (18 to 88)	DPPN 100 mg at 0 and 4 h (DPPN2) DPPN 100 mg at 0 h (DPPN1) [130 and 65]	Codeine 60 mg at 0 and 4 h (COD2) Codeine 60 mg at 0 h (COD1) [120 and 60] Placebo at 4 h	< 1	Single-dose regimen of either drug did not produce satisfactory 8-h analgesia (did not exceed 50% of maximum) in the majority of patients (COD 24 of 31, 77% and DPPN 23 of 30, 77%). Proportion of patients who obtained satisfactory analgesia scores (> 50% of maximum): DPPN2 > DPPN1*: 70% vs. 23% (p = 0.001). COD2 > COD1*: 77% vs. 23% (p < 0.001). COD2 = DPPN2: 74% vs. 70% (p > 0.50).	No SAEs. No severe AEs. NSAEs: 4 reports among 60 DPPN patients (3 nausea, 1 itching) vs. 7 reports among 61 COD patients (5 nausea, 1 weakness, 1 abdominal pain). All slight or moderate in intensity.

Ref.	Study design (PEV PAM) <sup>†</sup>	Type of pain (Baseline pain intensity)	N, Efficacy analysis [Sex, RRA patients]	Age, mean ± SD [median], (range) <sup>‡</sup>	DPP(N) ± APAP preparation and dosage regimen	Comparator(s) and dose(s) <sup>‡</sup>	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; < means inferior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE, SoR]				(years)	[HCl equivalent <sup>‡</sup> (mg/day)]	(mg/day)	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
Crighton (1997) <sup>54</sup> [I, B]	DBPG (4VPS/VAS) A priori estimation of sample size.	Laparoscopic sterilization (Mild)	68 [0 M / 75 F]	(33.1 to 34)	DPP+APAP 65 + 650 mg after emergence from anesthesia, then 32.5 to 65 mg + 325 to 650 mg q 4 to 6 h prn, up to 260 + 2600 mg/24 h [114 + 1140] (mean; doses given prn)	Tramadol (TRAM) 100 mg after emergence from anesthesia, then 50 to 100 mg q 4 to 6 h prn, up to 400 mg/24 h [400 (max)] Codeine+APAP (COD+APAP) 60 + 1000 mg after emergence from anesthesia, then 30 to 60 mg + 500 to 1000 mg q 4 to 6 h prn, up to 240 + 4000 mg/24 h [240 + 4000 (max)]	1	TRAM = COD+APAP = DPP+APAP for pain intensity for average pain and worst pain, sleep disturbed by pain, mobility, pain relief, satisfaction, and number of tablets taken (p > 0.05 for each analysis).	No differences between TRAM, COD+APAP, and DPP+APAP in proportion of patients who experienced at least one AE (57% vs. 78% vs. 61%; p = 0.37), nausea and/or vomiting (39% vs. 44% vs. 38%; p = 0.93), or CNS AEs (drowsiness, dizziness, headache) (72% vs. 39% vs. 52%; p = 0.11). Proportion of patients who experienced itching were similar (6% vs. 4% vs. 5%; no p-value reported). Proportion of patients experiencing CNS AEs was lower with COD+APAP than with TRAM, 39% vs. 72% (p = 0.035).

NSAE = Nonserious adverse event; SAE = Serious adverse event; WDAE = Withdrawal from study or discontinuation of medication due to adverse event

<sup>†</sup> Study design: DBPG = Double-blind, parallel group; DD = Double-dummy; MC = Multicenter; 5PIRS = 5-point Pain intensity rating scale; RRA = Recruited, randomized, or analyzed (patient sex was reported for different study populations among the various trials); SBPG = Single-blind, parallel group; WDAE = Withdrawal from study or discontinuation of medication due to adverse event.  
PEV (Primary efficacy variable) PAM (Pain assessment method): 100VAS = 100 mm (10 cm) Visual analog scale; VAS = Visual analog scale (parameters not stated); 4VPS = 4-item verbal pain scale (categorical, non-numerical)

<sup>‡</sup> DPP + APAP = *D*-propoxyphene hydrochloride in combination with acetaminophen; DPPN+A = *D*-propoxyphene napsylate in combination with acetaminophen; F = Females M = Males; NR = Not reported; QE = Quality of evidence; SoR = Strength of recommendation regarding treatment comparisons for analgesic efficacy; Tx = Treatment (group).

<sup>§</sup> Secondary efficacy variable

<sup>||</sup> Combination product not available in U.S.

Appendix Table 4 RCTs comparing multiple doses of DPP with NSAIDs or opioids in treatment of chronic pain

Ref.	Study design (PEV PAM)†	Type of pain (Baseline pain intensity)	N (Efficacy) [Sex, RRA patients]	Age, mean ± SD [median], (range)	DPP preparation and dosage regimen	Comparator(s) and dosage regimen	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE]				(years)	[HCl equivalent (mg/day) ‡	[mg/day]]	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
<b>DPP inferior to NSAID in terms of analgesic efficacy (p &lt; 0.05)</b>									
Parr (1989) <sup>67</sup> [I, B]	DBPG DD, QoL (100VAS)	Arthralgia (NR)	752 [355 M, 400 F]	55.0 Diclofenac SR (DSR) 54.6 DPP+APAP	DPP+APAP 60 + 650 mg t.i.d. (and dummy placebo diclofenac 1 tablet qam) [180 + 1950]	DSR 100 mg qam (and dummy placebo DPP+APAP 2 tablets t.i.d.) [100]	28	DSR > DPP+APAP* for pain relief as measured by reduction on VAS; p < 0.05. DSR resulted in 8% greater relative (%) pain reduction from baseline in terms of VAS scores relative to DPP+APAP and a 13% greater relative (%) improvement in physical mobility (p < 0.05 for both analyses). The difference between mean absolute changes, however, was small (-4.3 mm on 100-mm VAS; 95% CI for the difference between changes for diclofenac and DPP-A: -7.7 to -0.9 mm). DSR = DPP+APAP for pain relief as measured by Nottingham Health Profile (NHP) (p = 0.13). DSR > DPP+APAP* for limitation on movement. The numbers of patients whose mobility improved, did not change, and deteriorated were better on DSR (120, 222, and 7, respectively) than on DPP+APAP (86, 258, and 8; p < 0.05). DSR > DPP+APAP* for Improvement (change) in mobility as measured by NHP; p < 0.01). Certain health related problems were less frequent on DSR; developed problems with work (1% of 373 vs. 5% of 382; p < 0.05); time lost from work (1% and 6%; p < 0.05). 13 Withdrawals due to inefficacy: 5 DSR, 8 DPP+APAP.	1 Death (DSR, myocardial infarction). 81 WDAEs: 39 of 373 (10%) DSR, 42 of 382 (11%) DPP+APAP (mostly GI and CNS AEs in both groups). CNS AEs more common on DPP+APAP (24.3%) than on DSR (12.8%; p < 0.01). CNS AEs that were more common on DPP+APAP than DSR were dizziness / lightheadedness (7.8% vs. 3.8%; p < 0.05) and tiredness / sleep disturbance (13.1% vs. 5.6%; p < 0.01). GI AEs that were more common on DSR than DPP+APAP were abdominal/epigastric pain or indigestion (10.7% vs. 4.7%; p < 0.01) and diarrhea (3.8% vs. 0.5%; p < 0.01).

Ref.	Study design (PEV PAM)†	Type of pain (Baseline pain intensity)	N (Efficacy) [Sex, RRA patients]	Age, mean ± SD [median], (range)	DPP preparation and dosage regimen	Comparator(s) and dosage regimen	Treatment duration	Efficacy results	Safety results
								(For treatment comparisons: > means superior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	
[QE]				(years)	[HCl equivalent (mg/day) ‡	[mg/day]]	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
No difference between DPP and NSAID in terms of analgesic efficacy (p > 0.05)									
Saarialho-Kere (1988) <sup>68</sup> [I, B]	DBCO (100VAS)	Rheumatoid arthritis (mean, 42.3 mm)	15 [2 M / 14 F]	(21 to 67)	Days 1 to 3: (Tx 3 and 4) APAP 500 mg b.i.d. Days 4 to 5: (Tx 3) DPP 65 mg t.i.d. (Tx 4) DPP 65 mg b.i.d. + amitriptyline (AMI) 25 mg qhs Day 6: (Tx 3) DPP 130 mg (Tx 4) DPP 65 mg + AMI 25 mg [Tx 3: DPP 130 to 195] [Tx 4: DPP 65 to 130 + AMI 25]‡	Days 1 to 3: (Tx 1 and 2) APAP 500 mg b.i.d. Days 4 to 5: (Tx 1) Placebo (PL) (Tx 2) Indomethacin (INDO) 25 mg t.i.d. Day 6: (Tx 1) Placebo (Tx 2) INDO 50 mg [Tx 2: INDO 50 to 75]	3	INDO = DPP for pain intensity (0=no pain, 100 mm=very severe pain), at 2 h (42 mm vs. 36 mm) and 4 h (36 mm vs. 34 mm) (p > 0.05). DPP > DPP+AMI* for pain intensity at 4 h, 34 vs. 44 mm. INDO and DPP > PL*: Pain intensity at 2 h (p < 0.05) but not at 4 h. INDO and DPP > baseline* for pain intensity at 4 h.	1 Severe AE: INDO (nausea and dizziness). DPP tended to cause vertigo and DPP+AMI tended to cause dry mouth. No statistically significant differences in AEs between treatment groups because of small number of subjects and high frequency of AEs on PL. All treatments caused relatively mild alterations in psychomotor skills that coincided with peak drug concentrations.

Ref.	Study design (PEV PAM)†	Type of pain (Baseline pain intensity)	N (Efficacy) [Sex, RRA patients]	Age, mean ± SD [median], (range)	DPP preparation and dosage regimen	Comparator(s) and dosage regimen	Treatment duration	Efficacy results (For treatment comparisons: > means superior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	Safety results
[QE]				(years)	[HCl equivalent (mg/day) ‡	[mg/day]]	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
<b>No difference between DPP and opioid agent in terms of analgesic efficacy (p &gt; 0.05)</b>									
Lloyd (1992) <sup>69</sup> [I, B]	DBPG (100-mm VAS) A priori power calculation.	Osteoarthritis (NR)	65 [28 M, 58 F]	66 (33 to 85)	DPP + APAP 65 + 650 mg t.i.d. to q.i.d. Lower dose was given to dihydrocodeine (DHC)-naive patients or patients who had been on ≤ 6 tab of DPP+APAP (32.5 + 325 mg/tab). Higher dose was given to patients who had been on DHC at any dose ≤ 240 mg/d or DPP+APAP > 6 tab/d. [97.5 to 130 + 975 to 1300]	DHC CR 60 mg to 120 mg b.i.d. Determination of dosage regimen as described under DPP+APAP dosage regimen. [120 to 240]	14	Lost to follow-up: 5 of 86 (5.8%). DHC = DPP+APAP for maximum average daily VAS pain scores for week 1 (58.3 mm vs. 48.6 mm) or week 2 (49.8 mm vs. 49.2 mm) (p > 0.05 for both analyses). DHC = DPP+APAP for mean average daily VAS pain scores for week 1 (50.1 mm vs. 38.2 mm) and week 2 (39.2 mm vs. 39.8 mm) (p > 0.05 for both analyses). DHC = DPP+APAP for number of waking nights due to pain (p > 0.05). DHC > DPP+APAP* for pain on passive movement at visit 3; number of patients with no, mild, moderate, or severe pain, 2, 15, 7, 0 for DHC vs. 1, 15, 15, 5 for DPP+APAP (p = 0.02). However, there was no data for 19 (44%) DHC patients and 7 (16%) DPP+APAP patients. 3 Withdrawals due to inefficacy: 1 DHC, 2 DPP.	21 WDAEs: 17 of 43 (39.5%) DHC, 4 of 43 (9.3%) DPP+APA (no statistics). No difference between lower and higher dosage regimens. Severity of nausea and of vomiting was significantly greater on DHC than DPP+APAP at visit 2 but not at visit 3. Number of patients with none, mild, moderate, or severe nausea at visit 2: 21, 6, 3, 9 on DHC vs. 31, 6, 2, 2 on DPP+APAP (p = 0.02). For vomiting, 29, 2, 3, 5 vs. 38, 1, 2, 0 (p = 0.02). Missing data 19 (44%) for DHC and 7 (16%) for DPP+APAP for both AEs. No significant treatment differences in severity of constipation, and drowsiness, difficulty in concentrating (p > 0.05 for each analysis). No significant differences between treatment groups and between lower and higher dosage groups in other AEs.



Ref.	Study design (PEV PAM)†	Type of pain (Baseline pain intensity)	N (Efficacy) [Sex, RRA patients]	Age, mean ± SD [median], (range)	DPP preparation and dosage regimen	Comparator(s) and dosage regimen	Treatment duration	Efficacy results	Safety results
								(For treatment comparisons: > means superior to; = means not different from [p > 0.05]) * indicates statistically significant (p < 0.05)	
[QE]				(years)	[HCl equivalent (mg/day) ‡	[mg/day]]	(days)	(n, unless otherwise stated)	(n, unless otherwise stated)
Mercadante (1998) <sup>14</sup> [II-1, B]	OLPG (100 VAS)	Cancer (Moderate)	32 [16 M, 16 F]	69.0 DPP 67.7 Morphine SR (MSR) (47 to 87)	DPP dose adjusted according to clinical situation; 120 to 240 mg/d. [60 ± 22.5 (mean ± SD)]	MSR 10 mg b.i.d. [20.1 ± 6.0 (mean ± SD)] Step 1 agents (mainly diclofenac 100 mg orally or 75 mg intramuscularly twice daily) were continued upon addition of opioid treatment.	10 (46 DPP; 68 Morphine SR) §	The overall mean duration of therapy was 46 days for DPP and 68 days for morphine. Days on MSR were longer in MSR group (68 d) than in DPP group (29 d; p < 0.01). Median daily doses of morphine equivalents in the last 4 weeks were higher in MSR group (42 mg) than DPP group (30 mg; p < 0.01). In the DPP group, 3 of 16 (19%) patients maintained DPP until death (range, 25 to 131 d) and 13 (81%) were switched to MSR. Reasons for switching to MSR were the need to increase analgesia in 11 patients and inability to swallow in 2 patients. Mean equianalgesic doses in the first 10 d of therapy were lower with DPP (14 mg) than MSR (20.1 mg; p < 0.01) without difference in pain relief. MSR = DPP for pain intensity (10-cm VAS) in first 10 d, assessed by patient when possible or by home physician; median (range), 3 cm (2 to 5 cm) vs. 3 cm (2 to 5 cm) (p > 0.05).	There were statistically significant differences in the intensity of drowsiness, nausea / vomiting, xerostomia, and symptom distress score (sum of the symptom intensity) between treatment groups (worse with MSR; p < 0.01 for each analysis); however, clinical differences were slight (scores were 0 with DPP and 1 with MSR, where 0 was not at all, 1 was slight, 2 was a lot, and 3 was awful). 3 MSR patients switched to DPP after 5 to 7 d because of intolerable AEs, principally vomiting and drowsiness. These patients continued DPP until death with adequate pain relief.

CR = Controlled release; DPP = *D*-propoxyphene HCl (or unspecified salt); DPP + APAP = *D*-propoxyphene HCl (or unspecified salt) in combination with acetaminophen; F = Females M = Males; NR = Not reported; Prn = Pro re nata (as needed); QE = Quality of evidence; RRA = Recruited, randomized, or analyzed (patient sex was reported for different study populations among the various trials); SoR = Strength of recommendation (in regards to comparative analgesic efficacies of treatments); SR = Slow- or sustained release;

† Pain scores were statistically significantly lower (less pain) on DPP alone than on DPP + amitriptyline (p < 0.05)

§ Assessments of pain intensity reported for the first 10 days of treatment at the doses shown; mean total duration of treatment was 46 days for DPP (120 to 240 mg/day, titrated) and 68 days for morphine (20 mg/day). DPP patients were switched to morphine sulfate sustained release when pain was no longer controlled at daily DPP doses of 240 mg. For further explanation, see text.

Appendix Table 5 Summary of safety RCTs

Ref.	Study design	Type of subjects	N (Safety) [Sex, RRA patients]	Age, mean $\pm$ SD [median], (range)	DPP preparation and dosage regimen	Comparator(s) and dose(s)	Treatment duration	Safety results
[QE, SoR]				(years)	[HCl equivalent (mg/day) †]	[mg/day]	(days)	(n, unless otherwise stated)
O'Neill (1995) <sup>155</sup> [I, A]	DBCO	Healthy	12 [3 M, 9 F]	36 (30 to 50)	(Tx 1) DPPN 100 mg [65] (Tx 2) DPPN 200 mg [130]	(Tx 3) Lorazepam (LOR) (Tx 4) Placebo (PL)	Single dose treatments separated by 1 wk	DPPN did not produce significant impairment of cognitive and psychomotor function. A dose related effect in critical flicker fusion threshold (CFFT) was detected with DPPN 200 mg ( $p < .05$ ). DPPN 200 mg significantly increased word recognition sensitivity at 4 h ( $p < 0.05$ ). in contrast, LOR produced marked slowing on simple reaction time task and choice reaction time task, caused disruption of word recall, word recognition task, and picture recognition tasks, and decreased CFFT in comparison with PL ( $p < 0.05$ for each analysis). LOR significantly decreased subjective alertness compared with PL ( $p < 0.05$ ); no differences were seen in any subjective assessments (alertness, contentment, calmness) with DPPN.
O'Neill (2000) <sup>157</sup> [I, A]	DBCO	Healthy	10 [4 M, 6 F]	31 (25 to 40)	(Tx 1) DPPN 100 mg q4h $\times$ 4 doses [260]	(Tx 2) Morphine sulfate (MS) 10 mg q4h $\times$ 4 doses [40] (Tx 3) Lorazepam (LOR) 0.5 mg q4h $\times$ 4 doses [2] (Tx 4) Placebo (PL)	1	DPPN impaired choice reaction time and picture recognition at some time points ( $p < 0.05$ ). MS increased accuracy of responding on choice reaction time task at every assessment ( $p < 0.05$ ), had sporadic effects on other tests, and increased subjective calmness. LOR impaired the speed of responding on all tasks in which speed was recorded ( $p < 0.05$ ) except digit vigilance, and increased subjective calmness. 2 Non-minor AEs: Both DPPN (severe nausea / vomiting and troublesome headache). No remarkable differences in frequency of any AEs between treatment groups.

Ref.	Study design	Type of subjects	N (Safety) [Sex, RRA patients]	Age, mean $\pm$ SD [median], (range)	DPP preparation and dosage regimen	Comparator(s) and dose(s)	Treatment duration	Safety results
[QE, SoR]				(years)	[HCl equivalent (mg/day) †]	[mg/day]	(days)	(n, unless otherwise stated)
Woody (1980) <sup>44</sup> [I, A]	DB, 2-center	Heroin addicts	227 [NR]	NR	DPPN 200 to 400 mg b.i.d. initially, then increasing by as much as 200 mg/d until a maximum of 500 mg b.i.d. [650, max]	Methadone (METH) 12 to 24 mg/d initially, then increasing to 32 mg/d	Up to 180	At one center, of 79 patients who began DPPN, 57 dropped out before 1 mo and were excluded from analyses, leaving 22 patients who received 2 mo of treatment. Of these, 17 received 4 mo of treatment, and 14 completed 6 mo of treatment. At the other center, 36 remained in treatment for a month. 2 SAEs on DPPN: 1 TIA in 52 yr old male with mild diabetes. 1 obtundation in patient with history of alcohol, sedative, benzodiazepine, and narcotic abuse; SAE occurred on third day of treatment apparently due to ingestion of DPPN 300 mg b.i.d. with sedative drugs (two 30-mg flurazepam capsules and five "pills" of unknown content). CNS irritability (anxiety, restlessness, or confusion) seen in 12% of patients who took DPPN for more than 1 mo. Otherwise no symptoms resembling those seen in DPP(N) overdoses. No significant changes in mean values of laboratory tests for DPPN or METH. Among DPPN patients, the frequency of abnormal values for SGOT and total bilirubin decreased over 6 mo ( $p < 0.05$ ). ECGs of DPPN patients were normal or were initially slightly abnormal then became normal during the study. No seizure activity was noted clinically or on EEG in any DPPN patients.

#### **Appendix 4 Summary of a national assessment of propoxyphene in postmortem medicolegal investigation (1972–1975)**

In 1976 the main manufacturer of DPP, Lilly Research Laboratories, sponsored an extensive survey of 1022 DPP-related deaths that occurred in the U.S. and Toronto and the Province of Ontario, Canada between 1972 and 1975.<sup>4</sup> The results of this survey formed the foundation for what is currently known about DPP-related deaths and supports the black-box warnings for DPP.

##### **Terminal signs and symptoms**

Terminal signs and symptoms were clearly described by a witness and officially documented in the case report in 180 cases (17.6% of total). Respiratory depression (~ 50%) was the most common final event, followed by cardiac arrest (~ 40%), coma (~ 40%), seizures (~ 20%), intoxication (~ 18%), and syncope (~ 10%). Seizures were slightly more frequent among cases involving only DPP (about 12%) than among those involving DPP and other drugs (about 10%). The typical findings on autopsy consisted of pulmonary and cerebral edema and visceral congestion. It is noteworthy that signs of intoxication (ataxia, disorientation, or slurred speech) apparently did not always precede the subject's collapse.

##### **Characteristics of fatal cases**

Finkle, *et al.* identified the following characteristics of the deceased or the nature of DPP exposure that are now considered to be reasons for avoiding DPP use:

- History of prescription drug misuse, such as excessive self-medication (17.1%), alcohol abuse (17.0%), or either alcohol or drug abuse, or both (34.3%). A minority of the deceased had a history of heroin abuse (3.3%) or DPP abuse (1.6%).
- Emotional problems (82%).
- Self-destructive behavior (death classified as suicide or documented history of suicide attempts; 50.7%).
- Co-ingestion of alcohol (42.0% of total cases, 40.8% of suicides, 42.7% of accidental deaths, and 43.2% of undetermined cases).
- Involvement of another drug (76.1%), excluding aspirin, phenacetin, and caffeine. Diazepam was the most frequently mentioned agent (44%), and about three fourths of all the cases involved psychotropic/tranquilizer agents (40.1%), sedative/hypnotics (21.2%), or analgesics (12.1%).

The manner of death was most frequently classified as suicide (468 cases, 45.8%). Death was accidental in 267 cases (26.1%), and undetermined in 213 cases (20.8%). A small number of cases listed natural causes, homicide, and unknown manner of death.

Death was rapid with 20% of 769 cases having a survival time (interval from the time the deceased was last seen alive until death) of less than 1 hour. More than half (52%) of the victims died in 5 hours or less, and 81% died within 10 hours. There was a small group (n = 52) who had sudden unexplained deaths (survival times less than 15 minutes), of which 84.6% were preceded by respiratory arrest, 30.8% by cardiac arrest, and 30.8% by syncope.

**Appendix 5 Medical outcomes associated with exposure to selected analgesics:  
1999 AAPCC TESS data**

An expanded summary of medical outcomes associated with exposure to selected analgesics is presented in Appendix Table 6. This table includes none, minor, and moderate outcomes, and complements Table 9 in Section 9.1.1.5.1.1.

**Appendix Table 6 Medical outcomes associated with exposure to selected analgesics by drug or drug combination class: 1999 AAPCC TESS data**

Agent implicated in exposure	No. of Exposures	% of all analgesic exposures (N = 214,066)	Outcome									
			None		Minor		Moderate		Major		Death	
			No.	%	No.	%	No.	%	No.	%	No.	%
<b>Opioids</b>												
Codeine	1258	0.6%	311	24.7%	210	16.7%	50	4.0%	16	1.3%	3	0.2%
D-propoxyphene	560	0.3%	99	17.7%	113	20.2%	83	14.8%	33	5.9%	12	2.1%
Meperidine	600	0.3%	96	16.0%	134	22.3%	72	12.0%	25	4.2%	2	0.3%
Methadone	1047	0.5%	87	8.3%	190	18.1%	204	19.5%	117	1.7%	17	1.6%
Morphine	1218	0.6%	189	15.5%	245	20.1%	169	13.9%	61	5.0%	10	0.8%
Oxycodone	1632	0.8%	268	16.4%	324	19.9%	181	11.1%	71	4.4%	12	0.7%
Pentazocine	204	0.1%	25	12.3%	57	27.9%	14	6.9%	7	3.4%	0	0.0%
Other/unknown narcotic	3267	1.5%	503	15.4%	702	21.5%	419	12.8%	159	4.9%	44	1.3%
<b>Acetaminophen + opioid combinations</b>												
Acetaminophen + codeine	5741	2.7%	1364	23.8%	1349	23.5%	439	7.6%	98	1.7%	3	0.1%
Acetaminophen + <i>α</i> -propoxyphene	5120	2.4%	1162	22.7%	1338	26.1%	519	10.1%	193	3.8%	18	0.4%
Acetaminophen + oxycodone	3553	1.7%	678	19.1%	850	23.9%	265	7.5%	81	2.3%	15	0.4%
Acetaminophen + other narcotics	11626	5.4%	2211	19.0%	2741	23.6%	979	8.4%	320	2.8%	40	0.3%
<b>Aspirin + opioid combinations</b>												
Aspirin + codeine	353	0.2%	67	19.0%	94	26.6%	36	10.2%	18	5.1%	1	0.3%
Aspirin + <i>α</i> -propoxyphene	41	0.0%	8	19.5%	11	26.8%	3	7.3%	2	4.9%	0	0.0%
Aspirin + oxycodone	234	0.1%	43	18.4%	45	19.2%	27	11.5%	5	2.1%	2	0.9%
Aspirin + other narcotics	33	0.0%	9	27.3%	7	21.2%	1	3.0%	1	3.0%	1	3.0%
<b>NSAIDs / Acetaminophen</b>												
Acetaminophen alone, adult formulations	25978	12.1%	8258	31.8%	3531	13.6%	1451	5.6%	457	1.8%	38	0.1%
Acetaminophen alone, unknown formulations	8963	4.2%	2413	26.9%	1390	15.5%	662	7.4%	261	2.9%	47	0.5%
Aspirin alone, adult formulations	4022	1.9%	1202	29.9%	619	15.4%	317	7.9%	38	0.9%	7	0.2%
Aspirin alone, unknown formulations	9350	4.4%	2490	26.6%	1949	20.8%	1276	13.6%	213	2.3%	38	0.4%
Ibuprofen	54643	25.5%	17073	31.2%	4149	7.6%	854	1.6%	105	0.2%	3	0.0%
Indomethacin	682	0.3%	180	26.4%	120	17.6%	30	4.4%	4	0.6%	0	0.0%
Nonaspirin salicylates	1065	0.5%	342	32.1%	146	13.7%	63	5.9%	5	0.5%	0	0.0%
Other NSAID	18181	8.5%	5174	28.5%	2532	13.9%	738	4.1%	115	0.6%	3	0.0%

cont'd

Agent implicated in exposure	No. of Exposures	% of all analgesic exposures (N = 214,066)	Outcome									
			None		Minor		Moderate		Major		Death	
			No.	%	No.	%	No.	%	No.	%	No.	%
<b>Combined totals</b>												
All <i>d</i> -propoxyphene-containing agents	31131	14.5%	9429	30.3%	4876	15.7%	1971	6.3%	651	2.1%	57	0.2%
All codeine-containing agents	13891	6.5%	2487	17.9%	3176	22.9%	1352	9.7%	498	3.6%	67	0.5%
All oxycodone-containing agents	55678	26.0%	17320	31.1%	4363	7.8%	920	1.7%	127	0.2%	4	0.0%

Adapted from Litovitz, *et al.*<sup>124</sup> AAPCC TESS = American Association of Poison Control Centers Toxic Exposure Surveillance System. Medical outcome categories were defined as follows: *None*—The patient developed no signs or symptoms as a result of the exposure. *Minor*—The patient developed some signs or symptoms as a result of the exposure, but they were minimally bothersome and generally resolved rapidly with no residual disability or disfigurement. *Moderate*—The patient exhibited signs or symptoms as a result of the exposure that were more pronounced, more prolonged, or more systemic in nature than minor symptoms. Usually some form of treatment was indicated. Symptoms were not life-threatening and the patient had no residual disability or disfigurement. *Major*—The patient exhibited signs or symptoms as a result of the exposure that were life-threatening or resulted in significant residual disability or disfigurement. *Death*—The patient died as a result of the exposure or as a direct complication of the exposure. Only those deaths that were probably or undoubtedly related to the exposure were coded here.

## Appendix 5 Prevalence of mental disorders including alcohol abuse among veterans

The 1999 Large Health Survey of Veterans found the national prevalence of certain mental conditions, including alcohol abuse, to be 15% or less.<sup>71</sup>

**Appendix Table 7 Prevalence of mental conditions among veterans**

Mental condition	Prevalence (%)
Depression	15.1
Alcohol abuse	11.0
Anxiety	8.8
Post-traumatic stress disorder	6.8
Schizophrenia	4.6
Bipolar disorder	4.0

Data collected from 1 Oct 1996 to 30 Jun 1999. Values based on the number of survey respondents (887,775), weighted to represent the population of veteran enrollees (3,421,388).

A higher rate of alcohol use, either current (46.2%) or past (58.1%), was seen among 117 veterans followed at the pain clinic of the Madison VAMC (GD Greany-Hudson, written communication, November 2000; see Section 9.2.3). In addition, 10.3% of this cohort met criteria for (current) substance abuse, and 53% had a history of substance abuse.